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Abstract 
Introduction: 
Alloimmunity is a major contributor to chronic allograft injury. There are currently no routine 
clinical cell-based assays that allow quantification of the recipients’ alloimmune  response 
towards a graft. Previous work from our group identified indirect alloimmune responses to 
non-polymorphic regions of HLA Class 1. The aim of this thesis was to assess the 
alloimmune response in renal transplant recipients (RTRs) by using synthetic peptides to non-
polymorphic regions of HLA Class 2.  
Methods: 
Responses to newly synthesized HLA Class 2 peptides were tested in RTRs via an γ-
interferon ELISPOT assay. Cell surface staining techniques and Luminex technology were 
used to identify the T-cell subsets driving the immune responses and subsequent cytokine 
production respectively.  
Results: 
Increased responses to HLA Class 2 derived peptides were detected in renal transplant 
recipients compared to healthy controls. The activated effector memory subset of T-cells was 
expanded in RTRs compared to healthy controls and generated these responses. T effector 
memory cell dependent TNF-α and IL-2 and T regulatory dependent IL-10 synthesis in the 
presence of specific peptide antigen was detected.  
Conclusion: 
A potential reproducible assay of T cell alloreactivity has been identified to help stratify 
RTRs at risk of an ongoing alloimmune response but needs further testing in a larger 
multicentre study.  
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1 Background and Literature Review 
1.1 Introduction 
Transplantation is the optimal form of renal replacement therapy in many patients with end 
stage renal failure bringing improved survival and quality of life (Fiebiger et al., 2004). In a 
landmark study (Wolfe et al., 1999) comparing mortality between patients on dialysis 
awaiting a transplant, patients receiving a transplant and patients deemed not fit for transplant 
and continuing on dialysis, mortality was 68% lower in transplanted patients. These data have 
been replicated in a more recent smaller study from Scotland (Oniscu et al., 2005). In 
addition, transplantation is more cost effective than long-term dialysis (Sharif and Baboolal, 
2011). Deceased donor one year graft survival in the UK has increased from 83% for the 
period of 2000-2002 to 93% for the period 2009-2013 (NHSBT, September 2014) which may 
be attributed to antimicrobial prophylaxis, better diagnosis and treatment of post-operative 
complications and increasing potency of immunosuppressive drugs preventing acute rejection. 
There have been significant effects on 1-year graft survival but, long term kidney allograft 
attrition rates have remained relatively constant and 10-year survival is approximately 75% 
(Lodhi and Meier-Kriesche, 2011).  
 
Life expectancy beyond 10 years post renal transplantation is still considerably less than in 
the general population (Briggs, 2001). An analysis of the United States Renal Data System 
(USRDS) of 7040 deaths in renal transplant recipients from 1988-97 revealed the 3 main 
categories of causes of death were from cardiovascular disease (42%), malignancy (9%) and 
infection (18%) (Ojo et al., 2000). 31% of deaths were from unknown causes (Ojo et al., 
2000). Unpublished data from 6 European Registries revealed similar statistics (Briggs, 
2001). Sellares et al studied 315 allograft recipients who underwent indication biopsies 
ranging from 6 days to 32 years post-transplant. The findings of the study showed that 60 
kidneys progressed to failure in the follow-up period (median 31.4 months). The researchers 
concluded that biopsies of many failures manifest features of antibody-mediated or mixed 
rejection (Sellares et al., 2012). Several other large retrospective studies have concluded that 
alloimmunity remains the most common mechanism leading to graft failure in renal transplant 
recipients (Gomez et al., 2013, El-Zoghby et al., 2009). El-Zoghby & colleagues 
histologically studied graft loss in 1317 allografts over 50.3 +/- 32.6 months of follow up. 
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Transplant glomerulopathy was the single most specific histological diagnosis in grafts that 
failed (El-Zoghby et al., 2009). Interstitial fibrosis & Tubular Atrophy (IFTA) was attributed 
to immunological processes in 8.5% of all graft losses. Gomez & colleagues studied 487 
grafts over 114 months follow up and concluded that in 37% of the grafts that survived over 
15 years, chronic allograft injury (CAI) was the main cause of failure in 66% of those cases 
however no differentiation between the causes of CAI was presented (Gomez et al., 2013).  
 
1.2 Chronic allograft injury 
Despite improvements in immunosuppressive protocols CAI remains a major barrier for long-
term graft survival. Its pathogenesis is multifactorial and clinically characterized by a slow, 
often discontinuous loss of graft function associated with proteinuria and hypertension (Paul, 
1999). Histological changes in CAI usually precede functional deterioration and include 
interstitial fibrosis/tubular atrophy accompanied by vascular changes and glomerulosclerosis. 
In 2003 Nankivell et al published data on the natural history of CAI by studying 961 kidney 
transplant biopsy specimens from 120 renal transplant recipients (Nankivell et al., 2003). 
They observed two distinctive phases of injury. An initial phase, within 1 year of 
transplantation, with early tubulointerstitial damage associated with and attributed to 
ischaemic injury, prior severe rejection and subclinical rejection and a later phase, beyond one 
year, characterized by microvascular and glomerular injury. Use of Calcineurin inhibitor 
(CNI) exacerbated arteriolar hyalinosis, glomerulosclerosis and tubulointerstitial damage. 
Stegall and colleagues showed a similar progression of CAI but encouragingly fewer, less 
severe and less progressive chronic histologic changes in the first 5 years after transplantation 
(Stegall et al., 2011) 
 
The non-specific histological changes and the association of CAI with immunologically 
relevant and non-immunological variables limit its clinical utility. The role of the immune 
system and immune mediated risk factors are discussed further in section 1.4. There are 
several non-immune mediated risk factors associated with the development of CAI. 
Increasing donor age has been linked with an increased risk of CAI. This was previously 
thought to be due to reduced renal mass leading to secondary hyperperfusion and 
glomerulosclerosis. However, pathological lesions observed in CAI correlate with changes 
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seen in ageing kidneys (Melk et al., 2000) leading to suggestions that accelerated senescence 
of renal cells might lead to deterioration of graft function (Melk and Halloran, 2001). Human 
Cytomegalovirus (CMV) infection is also an established risk factor for developing CAI. 
Animal studies found that CMV infection intensified the inflammatory response and 
expression of Intracellular adhesion molecule-1 (ICAM-1), vascular cellular adhesion 
molecule-1 (VCAM-1), tissue growth factor (TGF)-beta, platelet derived growth factor 
(PDGF) and connective tissue growth factor resulting in rapid progression of collagen 
production and subsequently accelerated chronic rejection compared to uninfected animals 
(Lautenschlager et al., 1999). Delayed graft function (DGF) confers an increased risk of acute 
rejection and subsequently a higher prevalence of earlier onset CAI (Troppmann et al., 1995). 
The results observed with living-unrelated donors are better than with cadaveric Human 
Leukocyte Antigen (HLA) matched donors (Gjertson and Cecka, 2000). Donor brain death is 
an independent risk factor for graft failure associated with increased levels of for example 
endothelial E-selectin, ICAM-1 and VCAM-1(Pratschke et al., 2001). The contribution of 
Calcineurin inhibitors (CNIs) to the development of CAI is also well established. Large 
studies show that the pathological features of CNI nephrotoxicity are almost universal by 10 
years post transplant (Solez et al., 1998). The role of CNI toxicity is thought to be mediated 
via endothelial dysfunction (Oflaz et al., 2003). Additionally, CNIs induce hyperlipidaemia 
and hypertension in recipients- other potential CAI contributors (Satterthwaite et al., 1998). 
Figure 1.1 below shows alloantigen dependent/independent factors in relation to CAI.
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Figure 1.1.Alloantigen Independent/Dependent Factors leading to CAI 
(Heemann0and0Lutz,02013)0
 
The presence of CAI is inferred from chronic allograft dysfunction on the evaluation of 
clinical parameters such as renal function (changes in serum creatinine or glomerular filtration 
rate (GFR) and proteinuria), plasma levels of immunosuppressive drugs, and non-specific 
histological findings in the graft. The primary barrier to successful transplantation at all stages 
is alloimmunity. This requires lifelong maintenance of immunosuppression, which 
paradoxically may contribute to allograft loss through various other mechanisms. The role of 
alloantigen dependent factors in the development of CAI is suggested by various risk factors 
which include (Yates and Nicholson, 2006) 
10 A history of acute rejection. 
20 The detection of anti-HLA antibody. 
30 The effect of prior sensitization through transplantation on long-term graft 
outcome. 
40 Increased levels of HLA incompatibility associated with worse graft outcome. 
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The assessment of pre-transplant immunological risk is a critical part of improving renal 
transplant outcome and currently involves HLA matching between donor and recipient and 
routine screening for Panel Reactive Antibodies (PRA) which predict worse outcome. 
However, these measures are focused on humoral immunity. T-cell mediated immunity as 
described in section 1.4 is a critical mediator of CAI and is currently not routinely assessed. 
Prognostic immune makers sensitive and specific enough to allow us to know the functional 
state of the alloimmune response at different stages during renal transplantation may allow 
reprogramming of the immune system to achieve a state of donor hyporesponsiveness or 
tolerance in order to reduced or even eliminate immunosuppression safely- eventually leading 
to improved graft outcome.  
 
1.3 Histopathology of CAI 
CAI is not a specific histological appearance. It may include arteriosclerosis, glomerular 
lesions and sclerosis, multilayering of the peritubular capillaries (PTC) and IFTA.  In 1964, 
the term “transplant glomerulopathy” (TG) was used to describe the glomerular changes in 
CAI involving enlargement of the glomeruli, swelling of the endothelial and mesangial cells, 
mesangial matrix expansion and widening of the subendothelial zone with interposition of 
mesangial cells and matrix (Hamburger et al., 1964).  Immunofluorescent studies of grafts 
with CAI show in most cases a non-diagnostic pattern of immunoglobulin deposition, 
although some show linear IgG deposits along the glomerular basement membrane or 
granular deposits of IgG and IgA in peripheral capillary loops (Habib et al., 1987). On 
electron microscopy examination circumferential multilamellation was found on the majority 
of CAI specimens and more than 7 layers of the basement membrane was found to be specific 
for a large number of CAI specimens (Paul, 1999). This is now recognized as a feature of 
chronic antibody mediated rejection.  
.  
1.3.1 Banff Classification 
In attempts to improve the reproducibility of renal transplant histology, particularly when 
reporting clinical studies, in 1991 a group of pathologists, nephrologists and transplant 
surgeons developed a scheme for the standardization of nomenclature and criteria reporting. 
This was finally published in 1993 after a series of revision meetings (Solez et al., 1993). 
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Since then, the Banff group meet every 2 years and the Banff criteria has undergone 
considerable revision over the years the latest being in 2013 (Haas et al., 2014). The principal 
diagnostic categories were: normal, antibody mediated rejection (immediate or delayed), 
borderline changes (suspicious for acute rejection with no intimal arteritis), acute rejection- T-
cell mediated (Grades IA, IB, IIA, IIB, III), chronic allograft nephropathy (CAN-Grade I-III) 
and other (Racusen et al., 1999).  
 
In 2005, the term CAN was eliminated from the diagnostic categories as it was felt the term 
did not encompass other potential causes of late scarring such as chronic hypertension, CNI 
toxicity, chronic obstruction, bacterial pyelonephritis and viral infection (Solez et al., 2007). 
Banff classification was further updated recognizing separate pathology of antibody mediated 
rejection and T-cell mediated rejection and incorporated C4d staining- a marker of antibody 
mediated rejection (Solez et al., 2008).  Antibody mediated rejection (Category 2) was 
classified into acute antibody mediated rejection with C4d positivity, presence of circulating 
anti-donor antibodies and evidence of acute tissue injury and chronic antibody mediated 
rejection was defined similarly with evidence of chronic tissue injury such as double contours 
of the glomerular basement membrane (GBM), multi-layering of the PTC, IFTA or intimal 
thickening of the arteries. T-cell mediated rejection was classified into Acute T-cell mediated 
(similar to grades above) and chronic T-cell mediated rejection (or chronic allograft 
arteriopathy) with arterial intimal fibrosis with mononuclear cell infiltration and formation of 
neo-intima.  
 
In 2007 PTC grading was introduced and C4d staining of the peritubular capillaries was 
graded based on the percentage of stained tissue on immunofluorescence and 
immunohistochemistry staining that has linear, circumferential staining pattern in PTC (Solez 
et al., 2008). C4d deposition without morphological evidence of rejection was added to the 
antibody mediated category (Solez et al., 2008).  This was based on findings that C4d 
deposition occurs in 2-26% of histologically normal ABO-compatible grafts with the higher 
frequency in HLA- sensitized patients (Mengel et al., 2005, Haas et al., 2006). In addition 
these studies along with others showed C4d staining along the PTC in 25-80% of ABO-
incompatible transplants but with evidence of antibody-mediated rejection (ABMR) in only 4-
12% (Haas et al., 2006, Dickenmann et al., 2006).  
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The most recent revision in 2013 has included the C4d negative ABMR in its criteria as 
multiple subsequent studies supported the existence of ABMR with negative or minimal C4d 
deposition (Haas, 2011, Haas, 2013).  
 
1.4  Role of the immune system in CAI 
1.4.1 Innate Immunity 
The innate immune system provides first line of defense against tissue damage and invading 
pathogens (Matzinger, 2014). Activation of vascular endothelium and the induction of various 
pro-inflammatory cytokines such as interleukin (IL)-1, IL-6 and Tumour Necrosis Factor 
(TNF)-α can be demonstrated early post-transplantation. The up-regulation of pro-
inflammatory cytokines combined with increased expression of adhesion molecules (Koo et 
al., 1998) results in an early infiltrate of inflammatory cells, including macrophages (McLean 
et al., 1997). This early inflammatory response also triggers the egress of graft tissue-resident, 
bone marrow–derived dendritic cells (DCs) (Larsen et al., 1990a, Larsen et al., 1990b). Cells 
of the innate immune system including dendritic cells bear receptors (pattern recognition 
receptors-PRRs) that recognize and respond to molecules expressed by both pathogens 
(pathogen-associated molecular patterns (PAMP)) and also damaged tissue- damage/danger 
associated molecular patterns (DAMPS). All forms of graft injury can result in the expression 
of DAMPs, engagement of these patterns by PRRs and thus innate immune system activation 
(Cucchiari et al., 2016). A number of factors influence innate immune system activation in 
kidney transplantation. In donation before cardiac death; upregulation of the complement 
system, sympathetic overactivity and intracranial hypertension induced cytokine surges all 
contribute to activation of cell-adhesion molecules and leukocyte infiltration to the grafted 
kidney (Cucchiari et al., 2016). The most potent and best-studied activator of the innate 
immune system in the context of renal allotransplantation is ischaemia-reperfusion injury. 
Clinically, ischaemia-reperfusion injury is associated with delayed graft function, graft 
rejection, chronic rejection and chronic allograft dysfunction (Schroppel and Legendre, 2014, 
Yarlagadda et al., 2009). Ischaemia-reperfusion affects many regulatory systems that drive an 
inflammatory reaction within the kidney graft (Kalogeris et al., 2012). Chemokines and 
cytokines together with other factors promote the inflammatory response leading to activation 
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of the innate immune system as well as the adaptive immune system (Salvadori et al., 2015, 
Satpute et al., 2009). Amelioration of ischaemia-reperfusion injury may be one way in which 
extracorporeal machine perfusion improves outcomes such as delayed graft function 
(Nicholson and Hosgood, 2013) 
 
Antigen presenting cells (APCs) bridge the gap between innate and adaptive immunity. DCs 
are key cells in this regard. In the absence of noxious stimuli DCs express low levels of 
proteins of the B7 family, CD80 and CD86. The T-cell receptor CD28 engages proteins of the 
B7 family, which provide a T-cell co-stimulatory signal. Co-stimulation is essential for T-cell 
activation (Cucchiari et al., 2016). It follows that absence of B7 protein expression results in 
reduced T-cell activation and proliferation. Thus, in an inflamed or acutely damaged kidney 
DAMPs such as toll like receptors engage PRRs on DCs resulting in enhanced B7 protein 
expression on the surface of DCs. Engagement of CD28 by B7 proteins provides the 
necessary co-stimulation that T-cells need to proliferate upon antigen recognition (Cucchiari 
et al., 2016). Cytotoxic T lymphocyte antigen 4 (CTLA-4) is structurally similar to CD28 and 
is an important negative regulator of T-cell activation (Ville et al., 2015). In contrast to CD28, 
which is constitutively present on T-cells, CTLA-4 is only expressed transiently following T-
cell activation (except on FoxP3+ cells where it is present constitutively) (Wing et al., 2008). 
CTLA-4 is thought to raise the threshold for T-Cell Receptor (TCR) signaling thereby 
preventing response to self-antigens. Although the precise mechanism is unclear, Qureshi and 
colleagues propose that CTLA-4 mediated trans-endocytosis and hence removal of B7 
proteins reduces availability of these ligands to the stimulatory CD28 molecule (Qureshi et 
al., 2011). CD28 and CTLA-4 work together and the balance between them is critical in 
determining the outcome of T-cell responses; agents to modulate both pathways are in use. 
Blocking CD28 activation favours immunosuppression as would be desirable after organ 
transplantation (Lenschow et al., 1996) whilst on the other hand abrogating CTLA-4 mediated 
signaling enhances T-cell responsiveness (Leach et al., 1996).  
 
Further regulation of DC activation is provided for by natural Killer (NK) cells (Raulet, 
2004). NK cells interact with DCs through various cell surface receptors that are activating or 
inhibitory thus “quantifying danger” (Martin-Fontecha et al., 2004). Lastly the complement 
system (another component of the innate immune system) produces C3a and C5a which 
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directly activate intragraft T-cells and APCs (Zhou et al., 2007, Strainic et al., 2008). Early 
graft inflammation, especially that due to ischaemia-reperfusion thus sets in play a sequence 
of events including innate immune system activation that eventually contribute to the 
development of CAI (Hauet et al., 2001, Land, 2013). 
 
1.4.2 Adaptive Immunity 
Recipient adaptive immune response to an allograft can be divided up into humoral (antibody 
mediated) and cellular (lymphocyte mediated) mechanisms. Histocompatibility antigens play 
a central role in both pathways.  
 
1.4.2.1 Major histocompatibility complex (MHC) 
Histocompatibility antigens differ between members of the same species and are therefore 
targets of the immune response in allogeneic transplantation. In all vertebrate species, 
histocompatibility antigens (termed Human Leukocyte antigens (HLA) in humans) can be 
divided into a single albeit multigenic, major histocompatibility complex (MHC) and 
numerous minor histocompatibility (miH) systems. Incompatibility between donor and 
recipient for either MHC or miH leads to an immune response against the graft, more 
vigorous for MHC than miH mismatches. HLA matching significantly reduces the risk of 
graft rejection and failure in solid organ transplantation (Dunn et al., 2011, Rizzari et al., 
2011).  
 
The highly polymorphic HLA system can be subdivided into two major classes: MHC Class 1 
and MHC Class 2. In general, MHC Class 1 molecules (HLA-A, -B, and -C) present 
endogenous peptides of 8–11 amino acids in length that can be recognized by CD8+ T-cells, 
while MHC Class 2 molecules (HLA-DR, -DQ, and -DP) present exogenous peptides of 13–
18 amino acids in length that can be recognized by CD4+ T-cells. MHC Class 1 molecules 
consist of a polymorphic α chain and a non-polymorphic β2-microglobulin and have a closed 
peptide-binding groove. On the other hand, MHC Class 2 molecules are rather more open but 
similar to their Class 2 counterparts have polymorphic and non-polymorphic regions. 
Crystallography reveals MHC Class 2 molecules consist of 2 chains (α and β), each with 
distal and proximal domains. The highly polymorphic α-1 and β-1 regions are distal, whilst 
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the proximal α-2 and β-2 regions and well conserved and relatively non-polymorphic 
(Fairchild and SpringerLink (Online service), 2013). 
 
A combination of MHC and peptide forms a compound epitope that is engaged by the antigen 
specific TCR. The peptide-binding groove is usually occupied by many different peptides, 
often derived from MHC proteins, or other self-proteins which are replaced by those derived 
from pathogens during infection (Chicz et al., 1992). It is the specific role of MHC Class 1 
and Class 2 molecules in presenting antigenic peptide to the TCR that underlies their 
significance as barriers to transplantation. The highly polymorphic nature of MHC antigens is 
an important driver to humoral sensitisation stimulated by pregnancy, blood transfusion and 
prior transplantation but the immune mechanisms involved in these responses are not 
fundamentally different to any other antigen. The cellular immune response to alloantigen is 
however fundamentally different at least in magnitude, because MHC molecules bind a 
diverse range of endogenous peptides, which are therefore normally presented at the cell 
surface. Allogeneic MHC generates a correspondingly wide range of compound epitopes 
distinct from the repertoire generated by syngeneic MHC. These are therefore recognised as 
foreign and engaged by the TCR in the so-called ‘direct alloimmune response’. The cellular 
immune response to MHC alloantigens is consequently unique in its diversity and therefore 
the number of T-cells that can be recruited to an immune response (Felix et al., 2007, Ely et 
al., 2008). 
 
1.4.2.2 Humoral Immunity 
The humoral (or antibody mediated) response involves B-Cells that recognize target antigen. 
In the case of renal transplantation target antigens are primarily MHC Class 1, MHC Class 2, 
MICA and the ABO blood group antigens. Antibody dependent cellular cytotoxicity (ADCC) 
is where antibody acts as a bridge between target tissue and effector cells resulting in tissue 
damage (Miltenburg et al., 1989). Alternatively, antibody can activate the classical 
complement pathway and deposit complement traces to cause endothelial damage via 
macrophage and neutrophil recruitment (Flowers et al., 2011). B cells and plasma cells 
differentiated from naïve B cell proliferation has also recently been shown to occur via the 
indirect pathway of allorecognition (Lanzavecchia et al., 2006). Grafts have been shown to be 
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infiltrated by B cells and present graft-derived antigens to alloreactive T cells (Alegre et al., 
2007). 
 
Several investigators have detected an association of circulating HLA-antibodies with an 
increased risk of long-term graft loss (Terasaki et al., 2007, Worthington et al., 2003). These 
antibodies may be donor specific (DSA) or non-donor specific (NDSA) (Hourmant et al., 
2005). Although, the relative roles DSAs and NDSAs play in graft rejection is yet to be 
comprehensively established, it is clear that the presence of either significantly correlates with 
lower graft survival, poor transplant function, and proteinuria (Hourmant et al., 2005). Using 
HLA Class 2 single antigen beads Cai and colleagues determined that the majority of non-
donor HLA antibody specificities detected in transplant recipients were due to sharing of the 
same epitope with donor antigen (Cai et al., 2006). 
 
A major discovery has been the detection of complement fragment C4d in PTCs of patients 
with acute rejection and is linked to DSAs (Mauiyyedi et al., 2002). C4d deposition reflects 
complement activation via the classical pathway and represents traces of remaining 
alloantibodies (Regele et al., 2002). A positive correlation has been found between acute 
rejection episodes and the presence of CD20+ B cells and plasma cells infiltrating allografts 
(Hippen et al., 2005). Depletion of CD20+ Bells using a chimeric anti-CD20 monoclonal 
antibody (Rituximab) has been effective in treating some but not all cases of acute humoral 
rejection (Becker et al., 2006). 
 
1.4.2.3 Cellular Adaptive Immunity 
The antigen-specific or adaptive cellular immune response to a graft occurs in two main 
stages. In the afferent arm donor antigens stimulate recipient lymphocytes, which become 
activated, proliferate, and differentiate while sending signals for growth and differentiation to 
a variety of other cell types. In the efferent arm effector leukocytes migrate into the organ and 
donor specific alloantibodies synthesised causing tissue damage. The principle targets of 
immune response to allogeneic tissue are the MHC molecules, which are present on donor 
cells. 
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1.4.2.3.1 Cellular Allorecognition 
Cellular allorecognition refers to T-cell recognition of genetically encoded polymorphisms 
between members of the same species. The principal targets of the immune response to 
allogeneic tissues are the MHC molecules, which are present on donor cells. This recognition 
of allograft MHC antigen is the primary event that ultimately leads to graft rejection. T-cells 
involved in allorecognition can be sensitized against alloantigens via one of 2 distinct (but not 
mutually exclusive) pathways first described by Lechler and Batchelor in the 1980s (Lechler 
and Batchelor, 1982), 
•0 Direct pathway where the recipient T-cells recognize intact donor MHC molecules 
complexed with peptide on donor stimulator cells. 
•0 Indirect pathway where recipient APC processes the donor-MHC antigen prior to 
presentation to recipient T-cells in a self- restricted manner. 
 
In the last ten years, a number of publications have shown that intact donor cell-surface 
molecules, including MHC, can be transferred to recipient APCs leading to activation of T-
cells which can directly recognize allograft cells- termed semi-direct allorecognition (Jiang et 
al., 2004, Afzali et al., 2008).  
 
Direct Pathway 
In order for recipient T-cells to directly bind to intact allogeneic peptide-MHC complexes, 
donor APC must migrate out of the graft to make direct contact with recipient T-cells within 
secondary lymphoid tissue. The importance of donor APC in causing graft rejection was 
demonstrated by prolonged survival of donor-derived APC- depleted allogeneic thyroid grafts 
in the absence of immunosuppression in causing graft rejection (Lafferty et al., 1976). 
Furthermore, MHC Class 2 deficient mice also rejected grafts when reconstituted with CD4+ 
T-cells (Pietra et al., 2000). It is believed that the direct pathway is responsible for early 
rejection because of the high frequency of T-cells capable of recognizing allogeneic MHC on 
donor dendritic cells (Caballero et al., 2006) Also,  donor DCs are depleted rapidly after 
engraftment due to apoptosis and eliminated by the recipient immune system (Caballero et al., 
2006). Allogeneic MHC on DCs derived from the graft will be occupied by a wide range of 
different endogenous peptides derived from donor tissue, both from non-polymorphic proteins 
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but also from MHC proteins themselves (Daniel et al., 1998). These combinations of peptide 
and MHC generate a range of compound epitopes that can be engaged by recipient TCR 
 
Indirect Pathway 
The indirect pathway describes the presentation of foreign MHC molecules on recipient APCs 
to recipient T lymphocytes. All proteins in a donor graft different to the recipient can 
potentially induce an antigraft response via this pathway. Antigen delivery may occur via 3 
mechanisms: 
a.0 Recipient DCs resident in secondary lymphoid tissue engulf antigens from the 
graft that are present in the circulation. 
b.0 Recipient DCs resident in secondary lymphoid tissue engulf donor cells that 
migrate there. 
c.0 Recipient APCs can migrate into grafts where they pick up antigen and then 
migrate to secondary lymphoid tissue.  
 
Benichou et al showed that donor derived peptides were dissolved from the groove of 
recipient MHC molecules supporting this pathway (Benichou et al., 1992). In addition, skin 
graft mouse models where APC from the graft were incapable of activating CD4 T-cells, 
rejection still occurred involving recipient CD4 T-cells (Auchincloss et al., 1993).  
 
Lechler & colleagues made a direct comparison of both the direct and indirect pathways in the 
same group of longstanding renal transplant recipients, some with good graft function and 
some with a diagnosis of CAI (Baker et al., 2001). Frequencies of alloreactive CD4+ T-cells 
stimulated through the direct pathway were conducted by performing limiting dilution assays 
that permitted the enumeration of donor and third party specific T-cells. CD4+ T-cells from all 
patients (irrespective of CAI or not) demonstrated donor- specific hyporesponsiveness by the 
direct pathway. However, patients with CAI had significantly higher responses of CD4+ T-
cells indirectly activated by allogeneic peptides implicating its importance in the pathogenesis 
of CAI. Subsequent studies however suggest that both pathways may persist and be of 
relevance for the pathological changes of CAI. Mouse studies demonstrated priming of T-
cells by both pathways when recipient dendritic cells were co-cultured with allogeneic 
dendritic cells or endothelial cells (Suciu-Foca et al., 1999). Bestard et al tested alloresponses 
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by both pathways in 34 long standing renal transplant recipients (>2 years post transplant) via 
γ-interferon (Bestard et al., 2008). Directly primed alloreactive T-cell frequencies positively 
correlated with serum creatinine but no correlation was found with indirect alloresponses. The 
longer the patient had a transplant, the higher the donor-specific alloresponse by the indirect 
pathway possibly as with time donor-derived APC are replaced by recipient APC. This study 
concluded that both pathways were detectable and may have a role in affecting long-standing 
transplant function.  
 
Semidirect pathway 
The semidirect pathway allows the activation of both CD4+ and CD8+ cells by the same 
APC. There is evidence that this occurs via the direct transfer of MHC-peptide complexes 
from donor to recipient APC as shown in Figure 1.2C. This mode of transfer can be via the 
release and uptake of exosomes, or via direct cell-to-cell contact (Afzali et al., 2008).  
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Figure 1.2. Pathways of Allorecognition. 
A.Direct0pathway,0B.0Inirect0Pathway,0C.SemiEdirect0Pathway0
(LiconaELimon0et0al.,02013)0
0
0
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1.4.3 Epitope spreading/mapping 
In the indirect pathway of T-cell activation, since a continuous supply of donor allopeptides is 
processed and presented by host APCs, self- MHC restricted T helper cells may perpetuate 
the alloimmune response causing chronic rejection (Sayegh et al., 1994, Benichou and 
Fedoseyeva, 1996, Bradley, 1996). There is evidence in T-cell responses that intramolecular 
and intermolecular epitope spreading occurs during the course of autoimmune disease 
(Goebels et al., 2000, McRae et al., 1995, Chan et al., 1998), and indeed chronic infections. It 
is therefore possible that epitope spreading could be a feature of chronicity of T-cell reactivity 
and inflammation in (chronic) allograft rejection. In which case rejection is initiated by T cell 
recognition of immunodominant epitopes. Further enhancement of this acute rejection 
pathway is through a larger more diversified repertoire of T cells that are able to recognize 
and thus react to subdominant or cryptic epitopes. Peripheral lymph node APCs including 
antigen specific B cells and macrophages are critical to processing tissue debris and then 
presenting such epitopes to T cells.  
 
 
1.4.4 Transplantation Tolerance 
Transplant tolerance is defined as the maintenance of stable graft function without the clinical 
evidence of immunosuppression. This can include true tolerance defined as “the absence of 
any detectable detrimental immune response and no immune-suppression”, and operational 
tolerance defined as “the gross phenotype of tolerance with an immune response or deficit 
that has no significant clinical impact” (Girlanda and Kirk, 2007). An essential part of T-cell 
mediated immunity is to develop non-responsiveness to naturally occurring self-antigens 
whilst mounting an effective immune response to “foreign” antigens (Nashan et al., 1997). 
Initial tolerance is through a process of negative selection in the thymus during development 
of T-cells (Alessiani et al., 1996). High-affinity interactions of the TCR on immature 
thymocytes with self-antigen on thymic stromal cells results in apoptosis and elimination of 
such T-cells. Only T-cells with TCR of low affinity to self-antigens are released to the 
periphery. In the periphery, thymus derived CD25+ nTregs suppress other types of cell 
activation by complex mechanisms. Adaptive (antigen-induced) Tregs are generated in the 
periphery and act through various mechanisms including the secretion of cytokines such as 
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IL-10 and TGF-β. Given the presence of donor-reactive (non-self reactive) cytopathic T-cells, 
alloimmunity may in some circumstances be subject to the action of CD4+FOXP3+Tregs to 
effector T-cells that inhibit the action of donor reactive effector T-cells. This is one potential 
mechanism of peripheral tolerance. In these circumstances rejection or tolerance depends on 
the balance between donor-reactive cytopathic effector and cytoprotective Tregs.  
The immune tolerance network (www.immunetolerance.org) has been set up to establish 
collaboration amongst research groups conducting clinical research trials looking at immune 
tolerance in areas of autoimmune disease, allergies and more. It also collects data on rare 
cases of RTRs who have become tolerant of their grafts (Matthews et al., 2003). Their focus 
in transplantation medicine is thus on biomarkers of tolerance and interventional trials to 
achieve complete and planned withdrawal of all immunosuppression whilst maintaining graft 
function.  
 
1.5 T-cells in transplantation 
T-cell mediated immunity is the central element of the adaptive immune system and includes 
a primary response by naïve T-cells, effector functions by activated T-cells and persistence of 
antigen-specific memory T-cells. The process is more complex however and includes other 
coordinated responses with other effector cells such as macrophages, natural killer cells, mast 
cells, basophils, eosinophils and neutrophils (Winearls, 1995). T Lymphocytes develop and 
mature in the thymus and express a unique TCR as part of this process (Alessiani et al., 1996). 
Mature T Lymphocytes (naïve T-cells) circulate though the blood and lymphatic system and 
reside in secondary lymphoid organs. Naïve T-cells have not been activated until they 
encounter foreign antigen presented to them on DCs also known as APCs in this context. DCs 
acquire antigen in non-lymphoid tissues and migrate into secondary lymphoid organs guided 
by inflammatory stimuli and cytokines. APCs generate antigenic peptides from a pathogenic 
agent of self-antigen by antigen processing and display then on the cell surface in the context 
of MHC molecules via TCR engagement, which triggers a cascade of intracellular signaling 
events resulting in activation of the naïve T-cell.   
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1.6 T-cell subsets 
Thymic selection results in the appearance of T-cells with two types of TCR.  1.0 The!majority!of!TNcells,!which!are!disulfideNlinked!heterodimers!of!Ig!superfamily!proteins,!express!αβ!chains!in!the!TCR. αβTCR T-cells represent mature T-cells that 
circulate through secondary lymphoid organs and have a wide range of antigen 
recognition.  2.0 γδ chains are expressed by a small fraction of T-cells and are less heterogenic than αβTCR T-cells. They are not fully understood and reside in skin and other mucosal 
surfaces.  
 αβTCR T-cells are subdivided into groups based on lineage markers or functional activities. 
Based on lineage markers 2 groups exist: 
1. CD4+ T-cells- these express the co-receptor molecule CD4 and recognize antigen in 
the context of MHC Class 2 molecules expressed on B cells, macrophages and DCs. 
They produce cytokines as effector T helper cells. 
2. CD8+ T-cells- express the co-receptor CD8 and activated by antigenic peptides 
presented by MHC Class 1 and form effector cytotoxic T lymphocytes (CTL).  
 
There are various ways to further characterize and group T-cells. Cell surface markers can be 
used to identify T-cells subsets, which correlate with function. This includes the identification 
of naïve, effector memory and regulatory cells. Activated T-cells may be differentiated on the 
basis of cytokine production, for example CD4 derived Th cells into IFN-γ (Th1) vs. IL4/IL5 
(Th2) or CD8 T-cells into Tc1 or Tc2 subsets, yields another method of classifying these 
lymphocytes. These are also associated with particular patterns of transcription factor 
expression. Advancing knowledge about T-cell biology reveals that groups of T-cells that 
were initially thought to exclusively derive from one lineage may have contributions from 
other lineage derived cells. CD8 T regulatory cells were first described in 1970 but 
subsequently we have realized that a substantial contribution to T-cell mediated suppression 
comes from CD4 cells specifically the CD4+CD25+ compartment (Wang et al., 2009). 
Allowing for this complexity, it is still useful to divide T-cells by cell surface markers or 
cytokine profile. These are presented below. 
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1.6.1 Effector T-cells 
1.6.1.1 CD4+ Helper cells  
CD4+ T-cells can differentiate from pluripotent naïve cells to various different committed T 
helper (Th) cells: 
 
Th1 cells 
The defining features of Th1 cells are the expression of IFN-γ and differentiation mediated 
through signal transducers and activators of transcription STAT1 and STAT4 proteins 
(Weaver et al., 2007, Safinia et al., 2010). Th1 cells enhance pro-cell-mediated immunity, are 
of critical importance to delayed type hypersensitivity reactions and mediate the response to 
intracellular pathogens such as mycobacteria(Safinia et al., 2010). 
Th2 cells 
IL-4 and IL-2 are critical for Th2 differentiation. IL-4 induced STAT6 upregulates GATA3, 
the master regulator which through various mechanisms drives Th2 differentiation 
(Luckheeram et al., 2012). Key effector cytokines that Th2 cells produce include IL-4, IL-5, 
IL-6, IL-10 and IL-13. Th2 cells significantly contribute to the immune response to 
extracellular parasites such as helminthes and play a major role in the pathogenesis of allergic 
diseases such as asthma. Th2 produced IL-4 is involved in allergic inflammation, mediating 
IgE class switching and secretion by B cells (Steinke and Borish, 2001). 
 
Th17 cells 
IL-6, IL-21, IL-23, and TGF-β are the major signaling cytokines involved in Th17 cell 
differentiation, and retinoic acid receptor-related orphan receptor gamma-T (RORt) is the 
their regulator (Luckheeram et al., 2012). Th17 cells produce the highly pro-inflammatory IL-
17 and are central in the response to invading pathogens. Other cytokines expressed by Th17 
cells include IL-21 and IL-22. IL-22 is known to both mediate inflammation and exhibit 
tissue protective properties. It works synergistically with IL-17 to enhance expression of 
antimicrobial peptides thus amplifying innate responses to infections (Liang et al., 2006). 
These cells are significant contributors to human autoimmune diseases (Afzali et al., 2007). 
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T regulatory cells (Tregs) 
Tregs play a critical role in the maintenance of tolerance, down-regulation in the amplitude of 
productive immunity and prevention of autoimmune disease. A number of early studies have 
shown a positive correlation between Treg function and allograft survival in solid organ 
transplants (Demirkiran et al., 2006, Salama et al., 2003) The mechanisms by which they 
exert their function are still not fully known but immunosuppressive cytokines such as IL-10, 
IL-35 and TGF-β play a role (Roth et al., 2011). There is enough evidence to say Tregs 
participate in all cell-mediated responses affecting Th1, Th2, Th17, CTL and B cell reactions 
against self and non-self antigens (Corthay, 2009). The majority of Tregs appear within the 
CD4+ T-cell subset and are characterized by the expression of the α-chain of the IL-2 receptor 
(CD25) and transcription factor Foxp3 that is essential for the development of naïve Tregs 
(nTregs) (Guerra et al., 2011). Activation of Tregs via stimulation of the TCR mediates 
function via direct cell contact through inhibitory molecules such as CTLA-4 or via secretion 
of IL-10 and TGF- β. IL-10 can reduce T-cell activation by suppressing differentiation of Th1 
and Th2 cells therefore reducing cytokine production of IL-2, IL-5 and TNF-α (Roth et al., 
2011). They can also indirectly inhibit T-cell activation by down-regulating MHC and co-
stimulatory molecules on APC (Roth et al., 2011). Foxp3+ Tregs may arise from the thymus 
(nTregs) of may be induced in the periphery (iTregs). One important question is the extent to 
which these phenotypes are stable, a question that has particularly arisen for iTregs.  
 
Th9 cells 
This recently described Th cell subset preferentially produces IL-9. Th9 cell development is 
IL-2 dependent and strongly enhanced by TGF-β and IL-4. These cells have been shown to 
drive autoimmunity in experimental models of encephalitis and allergic asthma but also have 
beneficial effects by inhibiting melanoma cell growth (Schmitt et al., 2014) and enhancing 
host immunity during parasitic infections (Licona-Limon et al., 2013). 
 
Tfh 
Tfh or T follicular helper cells specialize in providing cognate help to B cells and are thus of 
fundamental importance in the generation of T-cell dependent B cell responses (Ma et al., 
2012). These cells depend on the expression of the master regulator transcription factor Bcl6.  
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Th22 cells 
IL-22 production was initially thought to be restricted to Th17 cells (Fujita, 2013). Recently 
however a unique subset of T helper cells which produce IL-22 but unlike Th17 cells lack the 
ability to produce IL-17 and IFN-γ have been described (Eyerich et al., 2009). Th22 cells, 
which express the skin homing chemokine receptors CCR4 and CCR10, reside in the normal 
skin but are enriched in and thought to drive inflammatory skin diseases (Fujita, 2013, Akdis 
et al., 2012). 
1.6.1.2 CD8 T-cells 
Until relatively recently, effector CD8+ T-cells were thought to exist only as cytotoxic cells 
that secrete γ-interferon and TNF. Given the broad range of Th cells that derive from CD4+ 
cells researchers have sought to establish whether CD8 T-cells could differentiate in a similar 
manner in response to environmental cues. Initially in vitro experiments revealed that CD8+ 
T-cells could be induced to produce other cytokines. Thus after activation in the presence of 
IL-4, CD8+ T-cells acquire secretion of IL-4 and IL-5, while production of γ-interferon and 
cytotoxic ability are decreased. Two CD8+ T-cell subpopulations were defined on the basis of 
their Type 1 or Type 2 cytokine secretion profiles, and were termed Tc1 and Tc2, respectively 
(Kemp et al., 2005, Sad et al., 1995). Subsequently Tc9, Tc17 and CD8 T memory cell 
subsets have been described (Mittrucker et al., 2014). An overview of the different CD8 T-
cell subsets is provided in Table 1.1. 
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Table 1.1. Overview of effector CD8+ T-cell subpopulations 
(Mittrucker*et*al.,*2014)*
Type 
Polarizing 
cytokines in vitro 
Important 
transcription factors 
Effector molecules Function 
Tc1 IL-2, IL-12 T-bet, Blimp-1, 
Id2, IRF4 
IFN-γ, TNF-α, 
granzymes, perforin 
Immunity against intracellular pathogens and tumors 
Tc2 IL-4 GATA3 IL-5, IL-13, IL-4, 
granzymes, perforin 
Propagation of Th2-mediated allergy, contribution to 
arthritis 
Tc9 TGF-β, IL-4 ?/IRF4 IL-9, IL-10 Inhibition of CD4+ T-cell-mediated colitis, 
propagation of Th2-mediated allergy, anti-tumor 
response 
Tc17 TGF-β, IL-6, 
IL-21 
RORγt, RORα, 
IRF4 
IL-17, IL-21 Propagation of autoimmunity, immunity to viral 
infections, contribution to anti-tumor response 
CD8+ 
Treg 
TGF-β ?/Foxp3 TGF-β, IL-10, 
granzymes, perforin 
Regulation of T-cell-mediated responses 
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1.6.2 Memory T-cells 
Compared to naïve T-cells, memory cells are highly sensitive to antigen and function rapidly 
producing effector cytokines (Rogers et al., 2000) and thus allograft damage. In clinical 
transplantation, and in experimental settings in which animals are maintained outside of a 
pathogen-free environment T-cells specific for directly presented alloantigen are 
predominantly memory cells. This is assumed to be consequent upon heterologous immunity 
that is to say cross reactivity between allogeneic MHC and self- restricted responses to 
pathogen associated antigen. This situation differs from the generation of memory cells 
specific for extrinsic antigen including indirectly presented alloantigen. In this situation the 
generation of T-cell memory reflects exposure to alloantigen following blood transfusion, 
pregnancy and previous transplantation.  
 
As we age, the proportion of memory phenotype T-cells increases, and it is established that 
memory T-cells pose a significant barrier to inducing tolerance to allografts (Adams et al., 
2003). When a previous antigen is encountered, memory T lymphocytes are rapidly mobilized 
to deliver a recall response. This enhanced memory response is often beneficial and provides 
immunity against recurrent pathogens. However, in transplant recipients this poses a 
formidable hurdle to tolerance induction. Alloantigenic stimulation of naïve T-cells provides 
the most direct source of alloreactive memory T-cells (Lin et al., 2015). 
 
Memory cells (CD3CD45RAneg) can be divided on the basis of cell surface markers into 
central memory (Tcm; CD45RAnegCCR7posCD62Lpos) or effector memory (Tem; 
CD45RAnegCCR7neg/CD62Lneg) subsets. These subsets exhibit differing pathways of 
trafficking and mobilization on antigen re-exposure. The latter population becomes the 
dominant population after T-cell depletion (Surh and Sprent, 2008). Although T-cell 
depletion, a component of induction therapy prior to renal allotransplantation is considered to 
favor the induction of immunological tolerance (Le Moine et al., 2009), the emergence of 
effector memory cells in this context can have deleterious effects on the graft inducing 
putative ‘lymphopaenic rejection’ (Le Moine et al., 2009, Monti et al., 2008). T memory cell 
proliferation under conditions of lymphopaenia is termed homeostatic proliferation and yields 
a population of T memory cells that exhibit resistance to the suppressive effects of Tregs 
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(Yang et al., 2007), costimulatory blockade (Le Moine et al., 2009, Wu et al., 2004) and a 
variety of immunosuppressive agents (Le Moine et al., 2009). This may be relevant to 
autoimmune phenomena following lymphocyte depletion with alemtuzumab and to the 
pathogenesis of chronic graft versus host disease.  
 
T-cells with features of memory cells can also be generated in the absence of antigen 
exposure and homeostatic proliferation, via heterologous immunity. Memory T-cells are 
generated during heterologous immunity due to infectious or environmental stimuli and have 
the potential to cross react with allogeneic MHCs on donor organ cells (Lin et al., 2015). Rat 
models demonstrate that viruses can induce the heterologous generation of alloreactive 
memory T-cells, which markedly hinder the response to tolerance induction regimes 
(Williams et al., 2002, Adams et al., 2003). Thus heterologous immunity or T-cell cross-
reactivity between viral epitopes and “alloantigen” ensures a continued stimulus for memory 
T-cells and highlights another mechanism via which memory T-cells can contribute to chronic 
graft rejection (Selin and Brehm, 2007). 
1.7 T-cell subset markers 
1.7.1 Naïve T-cell markers 
Naïve T-cells circulating in the blood express L-selectin (CD62L), CC chemokine receptor 7 
(CCR7) and leucocyte function antigen-1 (LFA-1). These mediate the rolling, adhesion and 
extravasation of cells through the high endothelial venules (HEVs) in peripheral lymph nodes 
and mucosal lymphoid organs.  
 
1.7.2 Effector T-cell markers 
Once T-cells are activated phenotypic changes occur-CD69 and CD25 (IL-2Ra) are expressed 
very early upon activation. Other important surface receptors are CD40 and CD28 the latter 
being a co-stimulatory signal binding to CD80 and CD86 enhancing IL-2 production and 
increasing T-cell activation. TNF receptor family molecules OX-40, CD27 and 4-1BB are 
also found on primary activated T-cells.  
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1.7.3 Memory T-cell markers 
CD45RO is an activation marker exhibited on memory T-cells. Additionally, adhesion 
molecules such as CD44 and CD11a promote efficient interactions with APCs. Sallusto et al 
(Sallusto et al., 1999a) showed that the expression of CCR7 a chemokine receptor that 
controls homing to secondary lymphoid organs divides human memory T-cells in 2 subsets: 
1.! CCR7- memory cells express receptors for migration to inflamed tissue and have 
immediate effector function and are termed effector memory T-cells (Tems). 
2.! CCR7+ memory cells express lymph node homing receptors and lack immediate 
effector function, these are termed T central memory cells (Tcms). CCR7+ cells 
however efficiently stimulate dendritic cells and differentiate into CCR7- effector 
cells upon secondary stimulation (Sallusto et al., 1999b). 
1.7.4 Regulatory T-cell markers 
Many studies indicate CD25 is a crucial cell surface marker for the T regulatory subset 
(Kasiske et al., 2000b, Szenohradszky et al., 1999). In 2003, several elegant studies 
discovered a marker and functional regulator of Treg cell development and function, 
transcription factor Foxp3 (Hollander et al., 1997, Kasiske et al., 2000a). However, as Foxp3 
is an intracellular protein, it cannot be used to separate human Treg cells for functional studies 
or in vivo expansion during cellular therapy, thereby limiting its use in the human setting.  Liu 
et al demonstrated that CD127 is an excellent cell surface biomarker of human Tregs 
especially when used in combination with CD25 (Jiang et al., 2004). CD127 expression 
inversely correlated with Foxp3 expression and is expressed at low levels on a majority of 
Treg cells (Jiang et al., 2004).  
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Figure 1.3. Overview of Naïve, Memory and Effector T-cell markers 
(Sakaguchi et al., 2010) 
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1.8 Immunosuppression in renal transplant recipients (RTRs) 
Maintenance immunosuppression in RTRs generally consists of steroids, a Calcineurin 
inhibitor (CNI) agent (cyclosporin or tacrolimus) and an antiproliferative agent (azathioprine 
or mycophenolate mofetil). The introduction of CNIs in the 1980s vastly improved short-term 
allograft outcome. Experts in the field of renal transplantation have varying views on the use 
of induction agents at the time of transplantation and to this date no consensus on this topic 
has been reached. The long-term side effects of steroids and CNIs are well known and 
currently the aim of most research on immunosuppression on RTRs is the effect of steroid 
and/or CNI avoidance or withdrawal.  
 
1.8.1  Immunosuppressive Agents 
Available Immunosuppressive agents can be divided into 5 categories 
a.! corticosteroids 
b.! immunophilin-binding agests: ciclosporin, tacrolimus 
c.! mammalian target of rapamycin (mTOR) inhibitors: sirolimus, everolimus 
d.! antiproliferative agents: azathioprine, mycophenolate mofetil (MMF) 
e.! antibodies : basiliximab, alemtuzamab, daclizumab (antilymphocyte  and 
antithymocyte globulins) 
 
These agents and their use in significant clinical trials in renal transplantation are discussed in 
further detail below.  
 
1.8.1.1 Induction agents 
Currently, 2 induction agents, both IL-2 receptor antagonists (basiliximab and daclizumab) 
have been FDA approved for use in kidney transplantation. The underlying idea behind using 
these agents is to decrease the risk of acute allograft rejection and to allow the use of a lower 
intensity maintenance regime. However, the benefit of this is still debated within the 
transplantation community and the use of induction agents is center specific. Both antibodies 
block the IL2 receptor a-chain (CD25) thus preventing the formation of high affinity IL2 
(Martin, 2012). A pooled analysis of two trials that compared daclizumab with placebo 
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showed significantly fewer acute rejection episodes in patients treated with daclizumab 
(Ekberg et al., 2000) however no difference in graft survival, patient survival or serum 
creatinine concentration at 3 years (Bumgardner et al., 2001). Three similar trials using 
basiliximab as the induction agent showed similar results versus placebo. (Nashan et al., 
1997, Kahan et al., 1999, Ponticelli et al., 2001). 
 
A 3rd induction agent, alemtuzamab- an anti-CD52 T-cell and B-cell depleting antibody has 
been tested clinically in renal transplantation in a number of randomized trials. The “3C” 
multicenter study, compared induction with alemtuzamab followed by low dose tacrolimus 
and MMF versus basiliximab induction followed by tacrolimus and MMF and steroids 
maintenance in over 800 RTRs (Group et al., 2014). Early results of this study have shown a 
reduced risk of biopsy proven acute rejection in the alemtuzamab group (Group et al., 2014). 
A further study compared alemtuzamab induction followed by tacrolimus monotherapy versus 
basiliximab induction followed by tactrolimus and MMF maintenance in over 100 RTRs and 
found no major difference in 1-year transplant outcome between the 2 groups (Welberry 
Smith et al., 2013). 
 
1.8.1.2 Corticosteroids 
Early data from the Collaborative Transplant Study database showed better 5-year graft 
survival in patients who had been switched to a steroid free regime suggesting their 
detrimental effects exceeded the benefits over long term graft outcome (Opelz, 1994). 
Contradicting this, a Canadian multicenter steroid withdrawal study found better 5-year graft 
survival in patients who continued on “standard” dose prednisolone versus “ultra-low” dose 
(Sinclair, 1992). A study from Leiden showed increased acute rejection episodes in patients 
where steroids were withdrawn one-year post transplantation (Hollander et al., 1997).  In a 
meta-analysis of nine corticosteroid withdrawal trials, the risk of acute rejection and risk of 
graft failure was increased (Kasiske et al., 2000a). Since this was published several other 
trials have also demonstrated this. Long term data to determine the appropriate timing of 
corticosteroid withdrawal, and the patient population for whom this is acceptable practice is 
lacking. The potential for earlier graft loss to acute rejection may negate any benefit of 
avoiding adverse effects with withdrawal or avoidance. 
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1.8.1.3 Azathioprine 
Azathioprine is a thiopurine; it is metabolized into 6-mercaptopurine (6-MP) through 
reduction by glutathione. It is next enzymatically converted to 6 thioguanine (6-TG) 
ultimately ending up being incorporated into replicating DNA and blocking de novo purine 
synthesis (Nielsen et al., 2001). Data from the Collaborative Transplant Study Registry 
suggested that azathioprine does not improve long term outcome when used in conjunction 
with Ciclosporin A (CsA) and steroids (Opelz, 1994). Similar results were found in a meta-
analysis of five trials comparing the same regimes as above (Kunz and Neumayer, 1997). A 
UK based trial found no difference in graft survival between patients on triple therapy, dual 
therapy with CsA and azathioprine, or monotherapy with CsA only (Griffin and Salaman, 
1991). 
 
1.8.1.4 Mycophenoloic Acid (MPA) 
Mycophenolic acid works by depleting guanosine nucleotides preferentially in T and B 
lymphocytes thus inhibiting their proliferation (Allison, 2005). MPA when used in 
conjunction with cyclosporin A (CsA) decrease the incidence of acute rejection in the first 6 
months after transplantation by approximately 50% compared with placebo or azathioprine 
(Group, 1995, Group, 1996). 
 
1.8.1.5 Calcineurin inhibitors (CNIs) 
CsA and tacrolimus (FK506) are both calcineurin inhibitors. Both drugs block T-cell 
proliferation by inhibiting calcineurin phosphatase thus blocking activation of the 
transcription factor NFAT (Nuclear factor of activated T-cells) (Reynolds and Al-Daraji, 
2002). The subtle difference in mechanism of action between the two drugs involves the 
cytoplasmic immunophilin they each bind to prior to inhibiting calcineurin phosphatase. CsA 
binds to cyclophilin, a cytoplasmic propyl peptidyl isomerase whilst tacrolimus binds to the 
cytoplasmic immunophilin, FK binding protein 12 (FKBP12) (Hoorn et al., 2012). Concerns 
over CsA’s nephrotoxicity and other side effects have instigated several trials of CsA 
withdrawal studies over the years. One report found that virtually all recipients of kidney-
pancreas transplants who had received ciclosporin based immunosuppression had 
nephrotoxicity 10 years after transplantation (Nankivell et al., 2004). Analysis of over 12,000 
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transplant recipients from the Collaborative Transplant Study showed better outcome at 5 
years in those who remained on CsAs versus those that remained on azathioprine and 
corticosteroids only after 1 year post transplantation (Opelz, 1994).  
 
Comparing tacrolimus to CsA, several early studies showed a significant decrease in the rate 
of acute rejection in the tacrolimus group in the first year post transplantation in a meta-
analysis comparing tacrolimus with ciclosporin (in 3 studies both patient groups received 
azathioprine and steroids) (Knoll and Bell, 1999, Solez et al., 1993, Vincenti et al., 2002, 
Johnson et al., 2000, Margreiter and European Tacrolimus vs Ciclosporin Microemulsion 
Renal Transplantation Study, 2002). Margreiter’s European study showed no difference in 
patient or graft survival at 6 months (Margreiter and European Tacrolimus vs Ciclosporin 
Microemulsion Renal Transplantation Study, 2002). Similarly Johnson’s trial when analyzed 
at 3 years showed no significant difference in renal function, patient or graft survival between 
the 2 tacrolimus groups (tacrolimus with azathioprine and tacrolimus with MMF) and 
ciclosporin (+MMF) group (Irish et al., 2003). A study published in 2007 collaborating with 
the ELITE-Symphony trial compared standard dose ciclosporin, MMF and steroids versus 
daclizumab induction, MMF and steroids in combination with low dose ciclosporin, or low-
dose tacrolimus or low-dose sirolimus. They found that at 12 months post transplantation, 
there was better allograft survival, better mean eGFR and less episodes of acute rejection in 
those patients who had the low-dose ciclosporin regime (Ekberg et al., 2007). 
 
Studies looking at the long-term outcomes of tacrolimus versus ciclosporin have been less 
straightforward. A Study from Miami Florida looked at the 8-year survival of 150 kidney 
transplant recipients randomized to receive tacrolimus/sirolimus, tacrolimus/MMF or 
ciclosporin/sirolimus. Overall patients who had tac/MMF maintenance therapy had 
significantly lowers rates of acute rejection, renal dysfunction, and dyslipidaemia and 
protocol violation. However graft survival did not significantly differ in the 3 groups at 8 
years post transplantation (Guerra et al., 2011). To date, clinical trials of ciclosporin versus 
tacrolimus have not determined which regime is better for chronic immunosuppression in 
renal transplant recipients.  
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1.8.1.6 Sirolimus 
Sirolimus and everolimus are both mammalian target of rapamycin (mTOR) inhibitors. 
mTOR is a protein kinase that controls cell growth, proliferation, and survival. mTOR 
inhibitors bind to this kinase thus inhibiting its function (Ballou and Lin, 2008). Initial trials 
with sirolimus included its use in combination with ciclosporin: one included sirolimus or 
azathioprine and the other sirolimus or placebo in combination with steroids and ciclosporin. 
Both trials showed significantly reduced acute rejection rates within the first 6-12 months post 
transplantation, similar patient and graft survival at 12 months, but worse creatinine clearance 
in the sirolimus groups at 12 months (Kahan, 2003, MacDonald and Group, 2001). Further 
trials with sirolimus then compared its use versus ciclosporin. Both studies and a further 
analysis pool showed no difference in acute rejection rates, no difference in patient or graft 
survival at 12 months, but a better creatinine clearance at 12 months in the sirolimus group 
(Groth et al., 1999, Kreis et al., 2000, Morales et al., 2002).  Early post transplantation 
complications of sirolimus (poor wound healing, lymphoceles and delayed graft function) 
seen in these studies have limited the use of sirolimus de novo. Instead an important 
multicenter study evaluated the use of Sirolimus in an early CNI withdrawal regimen where 
patients were randomized to either CNI withdrawal or conversion to Sirolimus or CNI 
continuation 3 months post transplantation (Johnson et al., 2001, Oberbauer et al., 2003).  
There was a significantly increase rate of acute rejection in the CNI withdrawal group (9.8% 
Vs. 5.1%). There was no difference in patient or graft survival at 24 months, but the CNI 
withdrawal group had improved eGFR, lower serum creatinine level at 12 months, which 
persisted at 24 months.  This data suggests that sirolimus may have a favourable role in CNI 
free maintenance therapy however the potential long term effects are unknown. Current 
studies are also evaluating the role of sirolimus conversion for CNI-induced nephrotoxicity.  
 
1.8.1.7 Other immunosuppressive agents in kidney transplantation 
Everolimus similar to sirolimus is a mammalian target of rapamycin (mTOR) inhibitor. Its 
benefit over CNI based treatment was assessed in a 2-year multicentre study (Holdaas et al.) 
where patients with a kidney transplant of over 6 months was converted to everolimus with 
CNI withdrawal or minimization or remained on CNI. As with sirolimus, there was no overall 
renal benefit with conversion to everolimus but more adverse events and discontinuation 
(Holdaas et al., 2011).  
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Belatacept is a second-generation variant of abatacept. It differs from its parent molecule by 
two amino acids within the region that binds CD28-B7 (CD80, CD86), the co-stimulatory 
molecules required for full T-cell activation. The US FDA approved Belatacept in 2011 based 
on 3-year results of 2 open labeled multicenter trials (BENEFIT and BENEFIT-EXT) that 
demonstrated comparable survival between belatacept and CsA (Vincenti et al., 2012, 
Durrbach et al., 2010). At 5 years follow up patients on belatacept had a significantly better 
eGFR but there was no difference in graft loss or patient death between the 2 groups 
(Rostaing et al., 2013). 
 
1.8.2 Individualized immunosuppression 
The use of immunosuppression to prevent allograft rejection is problematic, because these 
agents not only have a narrow therapeutic index, they have predictable side effects even 
within a therapeutic window. In the case of CNIs in particular, the narrow therapeutic index is 
exacerbated by significant pharmacokinetic variability, which can in part be addressed using 
therapeutic drug monitoring. These side effects may be a consequence of non-specific 
immunosuppression or other “off-target” effects by potent inhibitors of pleiotropic signaling 
pathways. There is good evidence that reduced exposure to immunosuppression is associated 
with acute rejection and in all probability chronic rejection, although it may be difficult to 
separate the latter from the former. Conversely, immunosuppression may lead directly to 
infections, including those such as BK virus that impacts directly on allograft function or 
contribute to malignancy. A range of “off-target” effects include diabetes mellitus, 
hyperlipidaemia and nephrotoxicity. There are therefore potential benefits and costs 
associated with different exposure to immunosuppression. The evidence for risk of acute 
rejection in patients who undergo immunosuppression tapering post transplantation is 
conflicting, positive results are often reported over short periods of follow-up but may be 
subject to publication bias. Johnson and colleagues (Johnson et al., 2001) found a minimal 
risk of acute rejection upon withdrawal of ciclosporin and maintenance on a sirolimus/steroid 
regime 3 months post transplantation. There was no difference in patient and graft survival 
between the groups and instead renal function and blood pressure improved when ciclosporin 
was withdrawn. In contrast, a more recent ciclosporin withdrawal trial was aborted due to 
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high rates of acute rejection albeit maintenance regime included a different treatment regime 
(MMF/prednisolone rather than sirolimus) (Asberg et al., 2013). Recently published data on 
15 year follow up after CNI withdrawal showed a significantly increased number of acute 
rejection episodes within 18 months of CNI withdrawal and no difference in patient or graft 
survival (Roodnat et al., 2014).   
 
Improved outcomes in renal transplantation over the course of the last two decades have 
arguably been due to increased exposure to immunosuppression in the general transplant 
population, this suggests caution when interpreting the literature on the withdrawal of 
immunosuppression. This caution is also supported by growing literature on outcomes in the 
setting of reduced concordance or simply increasing variability of exposure to CNIs. In many 
studies of immunosuppression withdrawal in renal transplantation, the selection of subjects is 
based on clinical criteria along with the contemporaneous histology, the role of which is 
primarily to rule out acute rejection. Indeed, in such populations the predicted rate of many 
“hard outcome measures” is low making any extrapolation into higher risk populations 
difficult. A reasonable question may be to ask whether it would be possible to stratify 
transplant recipients not only on the basis of prognosis but also likely or at least hypothesized 
response to treatment. A theoretical ideal would be to quantify not only the concentration of 
particular immune-suppressive drugs as currently done, but their effects on the responses of 
specific mediators of cellular and humoral immunity primarily responsible for rejection. This 
ideal would be further benefited if a distinction were possible between alloimmunity and 
immunity of infectious organisms. If a measure of donor reactive immune response could 
predict which patients could tolerate immunosuppressive drug reduction with minimal risk of 
allograft injury and which could not, it could be possible to tailor therapy for an individual 
patient in a truly scientific manner. This would be true stratified medicine applied to 
transplantation.  
 
1.9 Immune Monitoring to predict CAI 
A critical feature in many cases of CAI is believed to be an ongoing alloimmune response 
either via the cellular or antibody mediated pathways as described extensively above. 
Currently in clinical practice, immune reactivity can be estimated by measuring anti-HLA 
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antibodies present in the circulation, monitoring immunosuppression drug levels, or by 
histological evaluation of the graft. More recently, attempts have been made to evaluate renal 
allograft tissue injury using transcriptomic or proteomic technologies however the principle of 
measuring tissue injury and its mechanism at a given time-point is highly analogous to the 
way in which histology is currently used.  
 
Cellular immune assays can either be donor antigen specific or antigen nonspecific. A 
combination of assays may allow us to identify a cohort of RTRs at risk of immune mediated 
CAI. Table 1.2 summarizes immune monitoring assays currently available or under 
investigation and a few are reviewed in greater detail below. 
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Table 1.2. A summary of   peripheral blood based immune monitoring assays to predict CAI 
MLR: Mixed Lymphocyte Reaction, PBMC: Peripheral Blood Mononuclear cells, LDA: Limiting Dilution Assays, ELISPOT; Enzyme 
Linked Immunosorbent Assay. Modified from (Cravedi and Mannon, 2009) 
 
Assays Material 
Needed 
Technique Advantages Disadvantages 
Cell based assays 
MLRs PBMCs Recipient PBMCs are cultured with irradiated donor cells. 
Proliferation of recipient PBMCs is assessed by titrated thymidine 
uptake 
Relatively 
easy to 
perform 
Inexpensive 
Time consuming 
Poor 
reproducibility 
Radioactive 
material 
LDAs PBMCs Frequency of alloreactive T-cell precursors is estimated through 
mixing serial dilutions of recipient cells with donor cells and 
measuring cytokine secretion, proliferation or cytotoxicity 
Sensitive Complex technique 
Time consuming 
ELISPOT PBMCs Recipient PBMCs are cultured with donor cells in culture wells coated 
with a capture antibody specific for the cytokine of interest. Each cell 
primed to the stimulating antigen(s) can be detected by the "spots", 
resulting from the binding of secreted cytokine with a labelled 
secondary antibody 
 
Reproducible 
Relatively 
easy to 
perform 
 
Relatively 
expensive on a 
large scale 
 46 
Assays Material 
Needed 
Technique Advantages Disadvantages 
Direct 
cytotoxicity 
assays 
PBMCs The lytic activity of recipient cytotoxic lymphocytes toward donor 
cells that have been loaded with 51Cr is measured 
 Radioactive 
material 
Complex assay 
Time consuming 
Immune 
phenotyping 
PBMCs Surface and intracellular staining with antibodies Easy to 
perform 
Sensitive 
Difficult to 
standardize 
Cylex TM 
ImmunKnow® 
assay 
PBMCs T-cell activation after mitogen Phytohemagglutinin-L stimulation is 
measured. This activity is quantified by measuring the ATP produced 
by the activated cells 
Low cost 
Reproducible 
 
Not effective post 
CD4 T-cell 
depletion therapy 
Genotyping PBMCs 
Graft 
biopsy 
Analysis of gene expression  Expensive 
Serum based assays 
Alloantibody Serum Lymphocyte crossmatch (via CDC or flow cytometry) 
Solid phase assays with recombinant HLA proteins (ELISA, flow 
cytometry, Luminex®) 
Sensitive 
assay 
Potentially 
expensive 
CD30 Serum ELISPOT   
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1.9.1 Measuring humoral responses 
1.9.1.1 Donor specific antibody formation 
The measurement of anti-HLA antibodies pre and post renal transplantation is routinely used 
in clinical practice. The presence of pre-transplant antibodies against HLA encoded antigens 
especially those that are expressed by the donor has been shown to be associated with acute 
rejection. The presence of anti-HLA antibodies is associated with poor graft outcome, delayed 
graft function (DGF) at 3 months and acute rejection at 3months and increased graft loss at 3 
years (Susal et al., 2009). Hence, the monitoring of post transplant development of antibodies 
directed against donor-specific HLA Class 1 and HLA Class 2 is of paramount interest. This 
production of de novo donor specific antibody formation post transplantation often indicates 
the onset of acute antibody- medicated (humoral) rejection. 
 
1.9.1.2 CD30 
CD30 (also known as TNFRSF8) is a cell membrane protein of the TNF Receptor family. It is 
expressed on activated B and/or T lymphocytes and is thought to be a co-stimulatory 
molecule balancing regulation between Th1 and Th2 responses (Cravedi and Mannon, 2009). 
The soluble form- sCD30, can be measured in the serum of most individuals. Studies have 
shown an increase in sCD30 in patients with haematological malignancies, viral infections 
and inflammatory conditions such as SLE and Rheumatoid arthritis (Oflazoglu et al., 2009, 
Gerli et al., 1995) A study in 206 RTRs, showed increased levels of pre-transplant sCD30 was 
predictive of poor graft outcome (Heinemann et al., 2007). A Chinese study in 231 RTRs 
showed that patients who suffered an acute rejection episode had significantly higher serum 
levels of sCD30 at Day 5 post transplantation but the levels diminished to baseline thereafter 
(Dong et al., 2006). It is thus postulated that monitoring of sCD30 pre and post 
transplantation may identify a subgroup of patients at increased risk or acute rejection in the 
early post transplant period.  
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1.9.2 Measuring cellular immune responses 
1.9.2.1 Mixed lymphocyte reactions (MLR) and Limiting Dilution Assays (LDAs) 
A 2-way MLR assay involves mixing peripheral blood lymphocytes from 2 individuals and 
measuring lymphocyte proliferation by thymidine uptake. A 1-way MLR involves 
inactivating donor lymphocytes and only allowing recipient lymphocytes to proliferate. In 
LDAs recipient and donor peripheral blood lymphocyte are mixed in serial dilutions and 
cytokine secretion/proliferation measured as the estimated frequency of alloreactive T cells. 
Although these methods are useful research tools and relatively inexpensive, they are labour 
intensive and of limited reproducibility, limiting their use in the clinical setting.  
 
1.9.2.2 Enzyme-linked Immunosorbent Assay (ELISPOT) 
Figure 1.4 shows a diagrammatic representation of a direct ELISPOT assay, which essentially 
combines an MLR assay with the concept of an ELISA assay. ELISPOT assays consist of 
tissue wells coated with antibody specific to the cytokine of interest e.g γ- interferon where T 
cells are cultured with donor cells or 3rd party cells. Whilst in culture, cytokines secreted 
remain bound using a secondary labeled antibody. Bound antibody is detected at the bottom 
of the wells as a “spot” which signifies a single T cell that has been primed to the stimulating 
antigens in vivo. Cameras on computerized plate readers then enumerate the spots digitally.   
 
It has been hypothesized that measuring direct alloreactivity of T cells primed to donor 
antigens using the ELISPOT technique may identify a cohort of patients at a higher 
immunological risk allowing for tailored immunosuppression. Several studies have 
investigated this hypothesis. A study in 55 RTRs showed that ELISPOT measured 
alloreactivity to donor-derived antigens post transplantation significantly correlated with 
worse graft function (measured as eGFR) 6 to 12 months post transplantation (Hricik et al., 
2003). Nather et al. showed similar results in a cohort of patients in addition to showing that 
pre-transplant donor-reactive ELISPOT frequency was expanded in patients with an acute 
rejection episode post transplantation (Nather et al., 2006). Another group used synthetic 
peptides corresponding to donor HLA-DR molecules and found an increased frequency of 
ELISPOT responses in patients with acute rejection in HLA-DR mismatched recipients 
(Najafian et al., 2002). 
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Poggio et al. were the first group to describe a Panel of T-cell reactivity (PRT) similar to 
Panel reactive antibodies (PRA) routinely used to measure anti-HLA antibodies in proposed 
renal transplant recipients (Poggio et al., 2006). They assessed reactivity of activated 
antidonor T cells in a haemodialysis population to a panel of allogeneic stimulator cells from 
healthy controls and deceased donors via γ-interferon ELISPOT assays. A significant finding 
was that assessment of T cell reactivity based on PRT did not predict humoral sensitization 
based on PRA and vice versa (Poggio et al., 2006). 12% of patients were PRA+/PRT+, 20% 
PRA+/PRT- and 34% PRA-/PRT+ (Poggio et al., 2006). Initial data in 7 of the haemodialysis 
patients who received a renal transplant showed that a low frequency PRT positivity 
correlated with better transplant outcome at 1 year (Poggio et al., 2007). Subsequently, other 
studies have shown a significant correlation with increased PRT mean frequency with 
episodes of acute rejection within 6 to 12 months post transplantation (Kim et al., 2007, 
Koscielska-Kasprzak et al., 2009). Again, these studies suggest that a PRT may identify a 
subgroup of patients at a higher immunological risk (independent of PRA) or cellular-immune 
mediated rejection post transplantation and allow for individualized immunosuppression to 
minimize this risk.  
  
 50 
Figure 1.4. A diagrammatic representation of the ELISPOT assay 
 
 
 
 
1.9.2.3 Phenotyping peripheral lymphocytes 
Monitoring and properly balancing the inflammatory and regulatory sides of the immune 
system are important in transplantation. Effector/memory T-cells associated with acute 
rejection (Pearl et al., 2005) can be detected and differentiated from naïve T-cells by staining 
for CD25, CD45RA, CD45RO, and CD62L (Seddiki et al., 2006). Regulatory T-cells, which 
are thought to be crucial for immunoregulation and transplant tolerance, stain positive for 
CD4, CD25, and FoxP3 (Sakaguchi et al., 2010, Wood and Sakaguchi, 2003). Detection of 
FoxP3 requires intracellular staining, fixation, and permeabilization, which impair cell 
viability. Staining of CD127 (IL-7 receptor) provides an alternative to intracellular FoxP3 
staining. In CD4+CD25+ cells, the CD127 expression was correlated inversely with FoxP3 
expression, and indeed CD4+CD25+CD127lo cells showed suppressive activity (Pelzl et al., 
2003). Furthermore, an increased number of CD4+ CD25+CD127hi-activated T-cells and a 
decreased number of FoxP3+ regulatory T-cells have been associated with chronic humoral 
rejection in renal transplant recipients (Vallotton et al., 2011a, Braudeau et al., 2007) whereas 
tolerant recipients have been found to have normal numbers of regulatory T-cells similar to 
healthy controls. A huge advantage of flow cytometry is the capacity to quantify many 
immune cell subsets with great flexibility however, because flow cytometer configuration and 
setup, and data acquisition and analysis, will be different among centers, standardization is a 
challenge. 
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1.10 Summary of preliminary work 
In this chapter I have explained the cellular responses involved in T lymphocyte activation 
and the justifications for the importance of the indirect allorecognition pathway in long-term 
renal allograft injury. The precise definition of indirect allo-epitopes would benefit the 
assessment of donor-specific responses pre and post transplantation to guide 
immunosuppressive therapy. In transplantation, this application is limited by the diversity of 
donor and recipient HLA combinations. Previous work in our research group and others has 
identified the use of the ELISPOT technique to allow the detection of antigen-specific T 
lymphocytes at relatively low frequencies. By studying peptides derived from the full length 
of HLA-A2 (which is highly polymorphic and present in 50% of the donor population) and 
testing responses in allosensitised haemodialysis patients via γ-interferon ELISPOT assay we 
were able to identify indirect allo-epitopes from conserved sequences shared by range of 
different alloantigens i.e. “public T cell epitopes”. In a further study in RTRs our group 
demonstrated responses to peptide sequences derived from the non-polymorphic α3 domain of 
HLA Class 1. Moreover, responses were generally to autologous sequences, i.e. “cryptic self 
epitopes” and were associated with markers of CAI such as eGFR.  
 
It is based on this work that I investigated responses to non-polymorphic HLA Class 1 and 
Class 2 peptides as markers of an ongoing alloimmune response in RTRs in a cross sectional 
and longitudinal study.  
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1.11 Hypothesis & Aims of this thesis 
T-cell mediated immunity is a critical mediator of acute rejection. It is likely that T-cells also 
contribute to CAI and to chronic antibody mediated rejection. Prognostic immune makers 
sensitive and specific enough to allow us to know the functional state of the alloimmune 
response may allow us to reprogramme the immune system to achieve a state of tolerance in 
order to reduce or even eliminate immunosuppression safely- eventually leading to improved 
graft outcome.  
 
As part of this MD I wish to test two main hypotheses: 
 
1.! Responses to synthetically derived HLA peptides can be used as an additional 
prognostic immune marker to identify a group of renal transplant recipients’ at risk of 
CAI. 
2.! Phenotypic expression of CD4+ T-cell markers can be used as an additional tool to 
identify a group of renal transplant recipients’ at risk of CAI.  
 
My aims are to: 
•! Define peptides derived from the non-polymorphic region of HLA Class 2 that are 
predicted to bind to HLA DR. 
•! Measure responses to these peptides in renal transplant recipients and healthy controls. 
•! Optimize mixes of different HLA peptides for screening in a large number of renal 
transplant recipients. 
•! Optimize ELISPOT assay to improve reproducibility. 
•! Correlate responses to peptides with other markers of chronic graft injury. 
•! Define the subset of lymphocytes responding to HLA derived peptides and examine their 
phenotypic expression in the peripheral blood of renal transplant recipients. 
•! Examine other cytokines produced by responses to HLA derived peptides. 
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CHAPTER 2 
 MATERIALS AND METHODS  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Clinical Material 
All materials used were from patients who had undergone a kidney transplant and were under 
routine follow up at the Queen Elizabeth Hospital Birmingham or their base referring hospital 
if it had a dedicated transplant patient follow up service. Control samples were from normal 
donors at the Centre for Inflammation and Translational Research at Birmingham University. 
Ethical approval was obtained prior to the study from the Warwickshire Research Ethics 
Committee (RRK 3341) and the NRES Committee West Midlands- Solihull (RRK 4148).  
Good practice was adhered to, consisting of informed consent being obtained, the use of 
patient information leaflets and study specific consent forms, anonimisation of specimens 
with a unique identifying number, and, as stated on the application to the Regional Ethics 
Committee, specimens not used immediately were stored anonymously using the unique 
identifying number. Records of the stored specimens were maintained in a secure way by the 
principal investigator. Clinical Details of the participants were stored on a secure password 
protected server where all clinical data of patients are accessible in a clinical research file 
only accessible to the principal investigator and myself.  
2.1.2 Buffers, Media, Solutions and Reagents 
Dimethyl Sulfoxide (DMSO) (Sigma- Aldrich, Dorset, UK) 
Tissue Culture Medium (Complete Medium) 
Roswell Park Memorial institute (RPMI) 1640 (Sigma, Poole, UK)  50ml 
L-glutamine (Sigma, Poole, UK)       2mM 
Penicillin (Sigma, Poole, UK)       100IU/ml 
Streptomycin (Sigma, Poole, UK)       100IU/ml 
Foetal calf serum (PAA labs, Somerset, UK)     5% v/v 
Ficoll Plaque (Sigma- Aldrich, Dorset, UK) 
RPMI 1640 (Sigma, Poole, UK) 
Phosphate Buffered Saline (PBS) 
PBS tablet (Oxoid)         1 tablet 
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Sterile distilled water        100ml  
Magnetic Activated Cell Sorting (MACs) Buffer 
Sterile PBS (pH 7.2)         500ml  
Bovine Serum Albumin        0.5%  
EDTA           2mM 
Lipopolysaccharide (LPS) (Sigma- Aldrich, Dorset, UK)   100ng/ml 
Brefeldin A (Ebioscience, ID 00-4506-51)     1:1000 
 
2.2 Methods 
2.2.1 Patient Recruitment 
2.2.1.1 Cross-Sectional Study 
All renal transplant recipients attend a routine follow up clinic held twice weekly at the Queen 
Elizabeth Hospital Birmingham NHS trust. Potential recruits were screened a week prior to 
them attending the clinic. Inclusion criteria were any patient who had undergone a single 
organ kidney transplant (including ABO incompatible) at least 1 year ago. Patients with 
previous failed transplants were also included if they had a current functioning transplant. 
Exclusion criteria included a last-measured haemoglobin of less that 100g/dl or presence of a 
blood borne virus. Patients were approached at the beginning of clinic and given time to read 
the information leaflet (Appendix 1.1) and ask any questions. After written valid consent, 
samples (50mls of heparinized blood) were taken at the time of routine bleeding. If further 
samples were required these were taken only 3 months after the previous set with written 
valid consent again. Figure 2.1 shows an overview of the clinical and laboratory pathway for 
this study. 
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Figure 2.1. Overview of the study design for measuring responses to HLA derived 
peptides in renal transplant recipients. 
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2.2.1.2!Longitudinal Study 
Patients for the longitudinal study were approached at a pre-transplant appointment (for live 
transplant recipients only) or at the time of admission for a transplant (live and cadaveric 
recipients). Patients were introduced to the study and given a written information leaflet 
detailing the study (Appendix A1.2, page 158). If patients were approached at a pre-transplant 
appointment they were then approached again at the time of admission for transplantation to 
obtain written valid consent. If patients were approached for the first time at time of 
admission they were given at least 1 hour with the information leaflet to formulate any 
questions before written valid consent was obtained. Inclusion criteria were any patient 
receiving a kidney transplant (including ABO incompatible transplants) of consenting age and 
exclusion criteria was last measured haemoglobin of less than 100g/dl. Figure 2.2 shows an 
overview of the study design.  
 
 
Figure 2.2. Overview of the study design measuring responses to HLA derived             
peptides in a longitudinal study 
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2.2.2! Peptide Design and Synthesis 
15 Peptides to the non-polymorphic α3 domain of HLA Class 1 were synthesized using Fmoc 
Chemistry (GL Biochem, Shanghai, China) as previously described and published by our 
laboratory (Hanvesakul et al., 2007, Smith et al., 2011). Putative HLA Class 2 binding 
peptides derived from sequences centered on the non-polymorphic β-2 domain of HLA Class 
2 were assessed using the EPIMATRIX algorithm (www.epivax.com). In brief the 
EPIMATRIX programme analyses overlapping 9-mer frames offset by one amino acid. Each 
frame is then scored for predicted binding to common HLA Class 2 types. The EPIMATRIX 
raw binding score predicted for each 9-mer sequence is normalised to a distribution of scores 
derived from a set of randomly generated 9-mer sequences resulting in a z-score for each 9-
mer. A z-score of 1.64 defines the upper 5% and 2.32 the upper 1% of the distribution. 
Peptides in these regions are increasingly likely to bind to the relevant MHC molecule (De 
Groot et al., 2008) and the majority of published T-cell epitopes fall within this range of 
binding scores. The physicochemical properties of peptides were predicted using the program 
at www.expasy.org and adjustment of their precise length undertaken to optimise solubility, 
stability and chemical synthesis. 9 non-polymorphic HLA Class 2 peptides were also 
synthesized using Fmoc chemistry (GL Biochem, Shanghai, China). 
 
Peptide Preparation 
Peptides are stored at -80°C at 20mg/mL stock solutions dissolved in Dimethyl Sulfoxide 
(DMSO). When required, aliquots were thawed at room temperature for 60 minutes. 20ul of 
peptide was diluted with 20ul of tissue culture medium (to make a concentration of 10mg/ml). 
To make the desired final concentration of 40ug/ml, 4ul of the 10mg/ml diluted peptide was 
added to 996ul of complete medium. 50ul of the final dilution was added to each well. Once 
thawed and diluted peptides were stored at 40C for 1 week only. 
 
2.2.3! Isolation of Peripheral Blood Mononuclear Cells 
PBMCs were isolated from whole blood using standard methodology of density gradient 
centrifuge.  50mls of heparinized blood was collected from patients after valid informed 
consent at the time of their routine follow up blood sampling. Samples were kept at room 
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temperature and processed within 4 hours of collection. 15mls Ficoll Plaque (Sigma-Aldrich, 
Dorset, UK) was placed in 2 separate 50mls capacity AccuspinTM tubes (Sigma- Aldrich, 
Dorset, UK) and centrifuged for 2 minutes at 2500rpm to allow the Ficoll to settle in the 
lower chamber. 25mls of collected whole blood was added to each AccuspinTM tube and made 
up to 50mls with 10mls of RPMI 1640 (Sigma, Poole, UK).   The AccuspinTM tubes are then 
subjected to a 15-minute spin in the centrifuge at 2400rpm. After this time blood is separated 
and a fine disc of PBMCs are identifiable. This layer was carefully isolated and washed 2 
more times with RPMI 1640 before pursuing further experiments. AccuspinTM tubes are fitted 
with a high-density polyethylene barrier, which allows a better yield of PBMCs during whole 
blood separation. Analysis by previous colleagues within our laboratory demonstrated a better 
yield than conventional methods of cell separation in renal transplant recipients. PBMCs were 
used for further study straight away and not frozen or store overnight.  
 
2.2.4! Enzyme-Linked Immunosorbent SPOT assays 
A γ- interferon Enzyme-lined immunosorbent (ELISPOT) assay was used according to 
manufacturer’s instructions (Oxford Immunotec, UK). PBMCs were isolated from peripheral 
blood by Ficoll-density gradient centrifugation as described in 2.2.3. A total of 4x105 PBMCs 
were added to each well in a final volume of 50µl complete medium along with 50µl of 
peptide to give a final concentration of 20µg/ml. Peptides were used either singly or in mixes.  
 
Negative control wells contained responder PBMCs plus medium alone. Positive control 
wells included Purified Protein Derivatives (PPD) (SSI, Copenhagen, Denmark) at a final 
concentration of 10µg/ml, and an anti-CD3 based positive control supplied by Oxford 
Immunotec, the manufacturer of the ELISPOT assay. PBMCs were cultured at 370C, 5% CO2 
for 48 hours, then discarded and washed 4 times with Phosphate Buffered Saline (PBS). 
Plates were then incubated at room temperature for 2 hours with 50µl per well of diluted 
secondary conjugate antibody (Oxford Immunotec). This was then discarded and washed a 
further 4 times with PBS. 50µl per well of substrate (equilibrated to room temperature) was 
then added the plates allowed to develop for 7 minutes. Plates were then washed twice with 
distilled water and allowed to air-dry at room temperature for a further 24 hours. Figure 1.4, 
page 48 shows a diagrammatic representation of the ELISPOT assay. Spot counts were then 
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counted on an AID ELISPOT reader and frequency of positive cells registered. Typical 
examples are shown in Figure 2.3. By previously examining the responses to a wide range of 
HLA derived peptides in healthy controls we are able to define an upper limit of normal of 7 
spots per well (Smith et al., 2010).  
 
 
Figure 2.3. Examples of typical appearance of γ-interferon spots as visualized on a 
developed γ-interferon ELISPOT assay with a positive response.  
 
 
 
 
2.2.5 Optimization studies 
To further develop and evaluate the utility and reproducibility of an ELISPOT assay for the 
assessment of allograft specific cellular immunity, a series of optimization tests were carried 
out to assess optimal temperature and incubation time for plate development and the 
reproducibility of reading plates with the AID ELISPOT reader. These studies were carried 
out at two sites- our laboratory and at Oxford Immunotec to further test reproducibility of the 
assay. 
 
γ-interferon responses to HLA Class 1 derived peptide mixes were tested in RTRs. In the first 
experiment, assays were duplicated on two 96-well bottom plates and cultured at 370C and 
5% CO2 as described in section 2.2.4 (page 42). One plate was developed after 24 hours of 
incubation time and the 2nd plate developed after 48 hours of incubation under the same 
conditions. In a second set of experiments, assays were also duplicated and incubated for 48 
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hours at 370C and 5% CO2. After the addition of conjugate antibody and substrate, plates were 
allowed to develop for 7 minutes and then washed twice with distilled water. One plate was 
then allowed to air-dry at room temperature for a further 24 hours and another plate in a dry 
oven (370C) for 4 hours before spots were enumerated on an AIDS ELISPOT reader.  
 
Incubation Time 
Comparing responses between 24 hours and 48 hours of incubation showed a significant 
difference in ELISPOT counts with a more positive response after 48 hours of incubation 
(Figure 3.5). Responses were compared using a paired t test (Wilcoxon test; p<0.0001). This 
suggests that it was not possible to reduce incubation time below 48 hours without 
compromising sensitivity.  
 
Figure 2.4. Comparing optimal incubation times for plate development in a γ-interferon 
ELISPOT assay.  
ELISPOT!plates!incubated!with!4x105!PBMCs!per!well!(duplicate!plates!from!the!same!
patient)!and!50μl!of!HLA!Class!1!derived!peptide!mixes!were!incubated!for!24!AND!48!hours!
and!developed!as!per!manufactures!instructions.!Spots!were!enumarated!on!an!AID!
ELISPOT!reader.!48!hours!of!incubation!showed!a!significant!increase!in!responses!to!HLA!
derived!peptide!mixes!compared!to!24!hours!of!incubation!(!mean!response!12.65/well!Vs.!
1.753/wellT!p<0.0001).!!
!
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Temperature 
Comparing responses between temperatures for spot formation, there was no significant 
difference in allowing plates to develop either for 4 hours in a dry (370C) oven or at room 
temperature (18-240C) for 24 hours (Figure 3.6).  
 
Figure 2.5. Comparing optimal temperature for plate development in a γ-interferon 
ELSIPOT assay.  
ELISPOT!plates!incubated!with!4x105!PBMCs!per!well!(duplicate!plates!from!the!same!
patient)!and!50μl!of!HLA!Class!1!derived!peptide!mixes!were!incubated!for!48!hours!and!
developed!as!per!manufactures!instructions.!For!the!final!drying!step,!after!the!addition!of!
conjugate!and!substrate,!plates!were!either!developed!for!4!hours!in!a!dry!oven!at!370C!or!
for!24!hours!at!room!temperature!before!being!read!on!an!AID!ELISPOT!reader.!There!was!
no!significant!difference!in!responses!between!the!final!step!for!plate!development!(!mean!
response!12.48/well!Vs!12.36/!wellT!p=0.08).!!
!
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2.2.6 Cell staining and Flow Cytometry 
Monoclonal antibodies used for surface staining included CD4 eFluor450, CD25 PE-Cy7, 
CD45RO APC, CD127-PE and CCR7 FITC  
 
Table 2.1. List of primary antibodies used for flow cytometry.  
Abbreviation!used!Phycoerythrin!(PE),!Cyanine!7!(Cy7),!Allophycocyanin!(APC),!Fluorescein!
isothiocyanate!(FITC).!Dilution!is!expressed!as!volume!of!antibody!used!per!1x105!PBMCs. 
 
Target Conjugate Species Isotype Clone Company Catalogue 
Number 
Dilution 
CD4 eFluor450 Mouse IgG2b OKT4 eBiosciences 48-0048-42 1µl 
CD25 Pe-Cy7 Mouse IgG1 BC96 eBiosciences 25-0259-42 3µl 
CD45RO APC Mouse IgG2a UCHL-1 BD 304210 1.6µl 
CD127 PE Mouse IgG1 eBioRDR5 eBiosciences 12-1278-42 2µl 
CCR7 FITC Mouse IgG2a 150503 R&D FAB197F 5µl 
 
 
1x106 fresh PBMCs were incubated with monoclonal antibodies for 30 minutes at 40C then 
washed in MACS buffer twice after centrifugation at 1800 rpm. Cells were suspended in 
500ul of MACS buffer and flow cytometry was performed immediately on a Beckman 
Coulter (CyanTMADP, High Wycombe, UK) gating on a minimum of 2x105 events on the 
mononuclear cell gate based on forward and side scatter. Data was collected and analysed 
using Summit v4.3 software.  
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Negative Controls 
Unstained cells and isotype controls (Table 2.2) were used for every antibody in every batch 
of experiments to confirm that primary antibody staining was specific and not a result of non-
specific binding to antibody or any other proteins.  
 
Table 2.2. List of Isotype Control Antibodies used fo flow cytometry 
 
Isotype Conjugate Clone Company Catalogue Number 
Mouse IgG2b, kappa eFluor450 eBMG2b eBiosciences 48-4732 
Mouse IgG1, kappa Pe-Cy7 P3.6.2.8.1 eBiosciences 25-4714 
Mouse IgG2a, kappa APC MOPC-173 BD 400219 
Mouse IgG1, kappa PE P3.6.2.8.1 eBiosciences 12-4714 
Mouse IgG2a FITC 20102 R&D IC003F 
 
 
Steps taken to ensure robustness of all flow data included 
•! Preparation of all cell suspensions in a standardized manner 
•! Used of fresh cells and no fixation of cells for analysis later 
•! Use of negative control and isotype stains in all batch experiments 
•! Use of the same antibody clones 
•! Compensation of the cytometer prior to each analysis to avoid spectral overlap and 
measurement artefact 
•! Analysis on a large number of events (10,000 events for single antibody stains, and 
200, 000 events for test samples) 
When using flow cytometry to analyse the expression of cell surface markers that is present in 
a small percentage of cells there is a risk that errors in calibration or compensation could give 
erroneous results. Dead or dying cells could also cause an apparent difference, however the 
use of viability stains and isotype controls to set compensation correctly avoided this.  
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2.2.7 Cell Sorting and peptide stimulation assays with different CD4+CD25Hi Subsets 
Patients previously responsive to HLA Class 1 and Class 2 peptides were used for these 
experiments. PBMCs were isolated as previously described in Section 2.2.3, page 56. 4.8x104 
PBMCs were saved in complete medium at room temperature for use later and 1x107 PBMCs 
were surface stained with antibody using the methods described in Section 2.2.5. The stained 
cells were finally suspended in 500ul MACS and sorted at The Centre for Translational 
Inflammation Research (CTIR) using a MoFLo Legacy cell sorter. Cells were counted and 
sorted into 3 categories 
1. Tems- T effector memory cells (CD4+CD25HiCD45RO+CD127HiCCR7-) 
2. Tcms- T central memory cells (CD4+CD25HiCD45RO+CD127HiCCR7+) 
3. Tregs- T Regulatory cells (CD4+CD25HiCD45RO+CD127Lo) 
 
A 96-well bottom plate (Oxford Immunotec, UK) was prepared containing peptides to which 
the patients were known to be reactive (active) or unreactive (inactive) to (Appendix 3.4). 
Sorted cells were then collected in sterile FACs tubes and 2x103 cells were added into the 
corresponding well (Appendix 3.4) including the saved PBMCs. The cells were cultured at 
370C, 5% CO2 for 48 hours and developed using the techniques mentioned above (Section 
2.2.4). 
 
2.2.8! Cytokine Assays 
Supernatants from transplant recipients and healthy controls used in the peptide stimulation 
assays were saved in 96-well bottom plates and stored at -800C for these experiments. The 
assay was performed according to manufacturer’s instructions using the following human 
Bioplex Custom Premixed Multiplex (Bio-Rad Hertfordshire, UK): IL-10, TNF-α, IL-2, IL-
1Ra and IL-1β. Plates were washed using the Bio-Rad Bioplex Pro plate washer and the assay 
was read using the Bio-plexTM200 system (Bio-Rad, Hertfordshire, UK). One standard was 
used for all 5 cytokines. 500µl of Standard Diluent was resuspended by vortex for 30 seconds 
and incubated on ice for 30 minutes. 60µl of thawed samples was added to the wells on a u-
bottomed ELISA plate as shown in plate plan Appendix 3.5 and incubated on ice.  
A standard dilution series was then carried out to produce an eight-point standard dilution 
curve with a fourfold dilution between each point. 8 polypropylene 1.5ml tubes were labeled 
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S2-S8 and Blank. 150µl of the appropriate diluent was added to tubes S2-S8.  Standard left on 
ice was resuspended and 50µl added to tube S2. This was resuspended by vortex and a further 
50µl added to tube S3 and process was continued until tube S8. Standards were then 
transferred to the appropriate wells on the ELISA plate. 7475µl of assay buffer was added to a 
falcon tube. Beads were resuspended by vortex at medium speeds for 30 seconds and 575µl of 
each bead was added to the buffer. This was covered with aluminum foil to be protected from 
light. 50ul of the coupled beads were added to each well of an assay plate supplied with the 
kit. This was then washed twice using the magnetic plate washer and wash buffer prepared 
earlier. 50ul of the standards and samples were transferred from the ELISA plate to the 
appropriate well of the assay plate. This was then incubated on a horizontal microplate shaker 
at room temperature for 30 seconds at 1000rpm and 30mins at 350rpm.  
 
Detection antibody was prepared 10 minutes before use by adding 2700µl of the detection 
antibody diluent to a falcon tube, vortex for 30 seconds and then adding 300µl of antibody to 
the diluent. After incubation the assay plate was washed 3 times and 25µl of antibody was 
added to each well. The incubation process was then repeated as above. Streptavidin-RPE was 
prepared 10 minutes before use by adding 5950µl of assay buffer in a falcon tube along with 
50ul of Streptavidin-RPE after vortex for 20 seconds.  
 
After incubation with antibody, the assay plate was washed 3 times and 50ul of the diluted 
Streptavidin-RPE was added to each well. This was incubated as above for 10 minutes.  
The plate was washed for a final 3 times and 120µl of assay buffer added to each well. This 
was sealed and protected from light and placed on a microplate shaker for 30 seconds at 
1000rpm. The plates were read immediately on a Bio-plexTM200 system (Bio-Rad, 
Hertfordshire, UK). 
 
2.2.9! Inhibition assays of PBMC responses to HLA derived peptides 
15 patients (10 responsive to HLA Class 1 derived peptides and 5 responsive to HLA class 2 
peptides) were used for these experiments. PBMCs were isolated as described (2.2.3) and 
1x107 were surface stained and sorted using the methods as described (0). A 96-well plate was 
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prepared containing peptides to which the patient was known to be reactive and unreactive to 
as shown in Appendix 3.6. 
 
Inhibitors of T-cell activation used for this experiment included: 
1.! Ciclosporin A (Sigma- Aldrich, Dorset, UK) at concentrations of 100ng/ml and 
200ng/ml  
2.! Sirolimus  (Pfizer) at concentrations of 250ng/ml and 500ng/ml 
3.! Abatacept (Bristol-Myers Squibb) at concentrations of 500ng/ml and 1ug/ml 
4.! ShK (Stichodactyla helianthus Neurotoxin) (Bachem, Germany) at concentrations of 
10nM and 50nm 
 
All inhibitors were diluted according to manufacturer’s instructions. ShK is a Kv1.3 channel 
inhibitor, which targets T effector memory cells. In animal studies Kv1.3 blockers have 
treated and prevented disease in rat models!of multiple sclerosis, type 1 diabetes and 
rheumatoid arthritis (Beeton et al., 2001, Beeton et al., 2006). The inhibitors were added to 
the wells as shown in Appendix 3.6 followed by 2x103 sorted cells and cultured at 370C, 5% 
CO2 for 48 hours. After incubation, cell culture supernatant cytokine concentrations were 
analysed as described in 2.2.8 and γ-interferon spot enumerated via the ELISPOT assay 
(2.2.4).  
 
2.2.10! IL-10 Staining 
50 mls of heparinized blood was taken from two patients used previously for the cytokine 
experiments (2.2.8). PBMCs were isolated and counted using techniques previously described 
(2.2.3). 5x106 cells were diluted in 5mls of PBS and 50ul was added to each well of a 96-well 
plate (Appendix 3.7). This was done for both patients. The remaining cells were incubated 
with monoclonal antibodies at pre-determined concentrations (Table 2.3) for 30 minutes at 
40C and then washed in MACs buffer twice (Centrifuged 1800 RPM). Cells were counted and 
suspended at a final concentration of 1x107 cells per 500ul MACs buffer prior to cell sorting 
(MoFLo High Speed Cell Sorter-Beckman Coulter).  T regulatory cells 
(CD4+CD25HiCD45RO+CD127lo) were isolated and collected in a sterile FACs tube 
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containing 200ul of MACS buffer. Cells were counted, washed again with MACS buffer and 
resuspended in RPMI 1640 with 5% Human A/B serum at 1x104 cells per ml.  
 
Table 2.3. List of primary antibodies used for IL-10 staining experiments  
Abbreviation used Allophycocyanin (APC), Cyanine 7 (Cy7), Phycoerythrin (PE), Peridinin 
chlorophyll (PerCP). Dilution is expressed as volume of antibody used per 1x105 PBMCs 
 
Target Conjugate Species Isotype Clone Company Catalogue 
Number 
Dilution 
CD4 APC-Cy7 Mouse IgG2b OKT4 BioLegend 317417 1µl 
CD25 Pe-Cy7 Mouse IgG1 BC96 eBiosciences 25-0259-42 3µl 
CD45RO APC Mouse IgG2a UCHL-1 BD 340438 1.6µl 
CD127 PerCP 5.5 Mouse IgG1 A019D5 BioLegend 351321 2µl 
IL-10 PE Rat IgG1 JES3-
9D7 
eBiosciences 12-7108-41 5ul 
CD4 V500 Mouse IgG1 RPA-T4 BD 560768 5ul 
!
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Cell Stimulation 
The aim of the experiment was to stain for intracellular IL-10. We have already demonstrated 
the production of extracellular soluble IL-10 (in the supernatant from Tregs stimulated with 
active Peptide).  For this experiment the same active peptides (Tra 33 and Tra 34) were added 
to the testing wells (Appendix 3,7 Rows A, B, C & E) for a 48-hour stimulation.  
 
Controls 
Our Positive control included staining for monocytes and intracellular IL-10 PE after 48 hours 
of stimulation with LPS.  
Our negative control included incubating PBMCs alone with Tregs and no active or inactive 
peptide.  
 
Plate Plan 
Figure A3.7, page 156 shows the plate plan used for this experiments. As mentioned earlier, 
5x105 PBMCs in 50ul were added to each well used. 2x103 sorted Tregs in 200ul was added 
to each well in the testing rows (Row A), negative control row (Row D- this also contained a 
HLA derived peptide the patient had previously known to be unresponsive to), supernatant 
row (Row E- we pooled and collected the supernatant from these wells as in the initial 
experiments to measure IL-10 production if required), and the unstimulated row (Row F).  
100ng/ml LPS (Sigma-Aldrich) was added to each well of the positive control row (Row G).  
Brefeldin (Ebioscience) at 1:1000 was added to all the rows except the FMO and supernatant 
rows (Rows B, C & E) 6 hours before the end of the 48-hour stimulation.  
After a 48-hour stimulation, cells were pooled from the wells of each row and collected in 
labeled standard sterile FACs tubes as shown in Table 2.4. The cells were washed twice in 
PBS. Viability stain eFluor506 (Ebioscience ID 65-0866-14) at a concentration of 2ul per test 
(1:10 diluted with PBS) was added to cells from all rows except the positive control row (row 
G) and incubated for 30 minutes at 40C. Cells were then washed once again in PBS and 
resuspended in 200ul of MACS buffer. Surface stains were then added to the tubes as shown 
in Table 2.4 and again incubated for 30 minutes at 40C. Compensation tubes were 
simultaneously stained using control PBMCs. Cells were then washed once in MACS buffer.  
Rows B & C were used as the FMO (fluorescence minus one) controls for CD45RO and 
CD127. In these experimental tubes all surface stains were added except for the 
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corresponding marker instead of which their isotype was added. 6.2ul of a PerCP Cy5.5 k 
IgG1 isotype (BD) was added and 10ul of APC k IgG2a (BD) was added.  
Cells were then permeabilized and fixed using a Cytofix kit (BD, Catalogue No 554714) as 
per manufacturer recommendations.  
PE IL-10 intracellular stain was then added to all experimental tubes apart from Tube E from 
which the supernatant was collected into a 2ml AccuspinTM tube and frozen at -800C to be 
analysed later. Cells were incubated with the intracellular stain for 30 minutes at 40C, washed 
once with MACs buffer and finally re-suspended in 200ul MACs buffer for FACS analysis 
(Becton Dickinson LSRII).  
 
Table 2.4. List of Experimental tubes and staining used for the IL-10 experiment  
 
Tube Description Viability 
stain 
eFLuor506 
CD4  
APC- Cy7 
CD25 
 Pe Cy7 
CD45RO  
APC 
CD127  
Per CP 
Cy5.5 
CD14  
V500 
IL-10  
PE 
A AP Test 
sample 
✔ ✔ ✔ ✔ ✔ ✖ ✔ 
B CD127 FMO ✔ ✔ ✔ ✔ ✖ ✖ ✔ 
C CD45RO 
FMO 
✔ ✔ ✔ ✖ ✔ ✖ ✔ 
D IP test sample ✔ ✔ ✔ ✔ ✔ ✖ ✔ 
E Supernatent ✔ ✔ ✔ ✔ ✔ ✖ ✔ 
F Negative 
control 
✔ ✔ ✔ ✔ ✔ ✖ ✔ 
G Positive 
Control 
✖ ✔ ✖ ✖ ✖ ✔ ✔ 
!
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2.2.11! Statistical Analysis 
Continuous variables are expressed as median and interquartile range or mean and standard 
deviation for those normally distributed. Normality of distribution was established using a 
Kolmogorov Simonov test. Categorical variables were compared using the χ 2 test. Mean 
ELISPOT counts were compared with negative control using the t test for independent 
samples. The significance of any differences were assessed using a Mann-Whitney U non-
parametric method and of any correlation with Pearson’s rank correlation coefficient for 
nominal terms or Cohen’s kappa statistic for categorical terms. Statistical analyses were 
undertaken using Minitab v16 (Minitab Inc., PA, USA) and IBM SPSS v21.0 and p values of 
0.05 or less reported as significant.
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CHAPTER 3 
RESULTS 
 
The use of HLA derived peptides as tools 
to predict Chronic Allograft Injury 
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3 Results: The use of HLA derived peptides as tools to predict CAI 
In a previous study, indirect allo-epitopes from HLA-A2 were shown to arise not only from 
sequences of high polymorphism but also from relatively conserved sequences shared by a 
range of different alloantigens (Hanvesakul et al., 2007) The existence of such shared or 
‘public’ indirect epitopes had been predicted by others to account for the fact that non-donor 
specific alloantibody is a risk factor for allograft loss (Tambur et al., 2000). Responses to 
peptides identical in sequence to self were also identified, similar to those ‘cryptic self 
antigens’ described in animal models of transplantation(Boisgerault et al., 2000, Lovegrove et 
al., 2001). If the response to these shared epitopes is representative of indirect alloimmunity 
in general, then they could act as surrogates from which to infer a wider relationship between 
clinical outcomes and this route of allorecognition. Furthermore, the small number of alleles 
for each epitope and the relative promiscuity of their binding to different HLA-DR suggested 
that an assay based on responses to such HLA derived peptides might be applied across a 
population using a practical number of different synthetic antigens. 
Using such an assay we tested the responses to synthetic HLA derived peptides in a cross 
sectional and longitudinal study of renal transplant recipients and correlated these responses 
with clinical parameters indicative/suggestive of CAI.  
 
3.1 Cross sectional study of T-cells responses to non-polymorphic (autologous) HLA 
derived peptides 
Previous work undertaken in the laboratory had investigated immune responses to a range of 
peptides derived from HLA Class 1. A novel finding was the identification of γ-interferon 
responses to peptides derived from the regions of Class 1 HLA that exhibit little 
polymorphism in particular from the α3 domain. Furthermore, long term renal transplant 
recipients were significantly more likely to respond to these peptides than healthy controls 
(51/110 Vs. 1/18, 46.4% Vs. 5.5%, p<0.001) (Smith et al., 2011). The!presence!of!responses!to!these!non-polymorphic!HLA!derived!peptides!were!also!associated!with!CAI,!defined!by!a!reduced!and!falling!estimated!glomerular!filtration!rate!(responders!vs.!non-responders;!eGFR!at!recruitment:!39.5!Vs.!48.8ml/min,!p=0.015;!annual!rate!of!deterioration!of!eGFR!-4.1!vs.!-1.3ml/min/year,!p=0.008)!(Smith!et!al.,!2011).!This!
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suggests!that irrespective of the precise mechanism of their acquisition, these responses 
reflected a relevant change in the immune repertoire of renal transplant recipients.  
 
Summary of Aims 
1! Define peptides derived from the non-polymorphic region of HLA Class 2 predicted to 
bind to HLA-DR. 
2! Measure immune responses to these peptides in renal transplant recipients and healthy 
controls. 
3! Optimise mixes of different HLA derived peptides for screening of large numbers of 
renal transplant recipients using small volumes of blood. 
4! Optimise the ELISPOT assay technique to improve reproducibility. !
3.2 In silico definition of HLA Class 2 derived peptides 
Putative HLA Class 2 binding peptides derived from sequences centred on the non-
polymorphic β-2 domain of HLA Class 2 were assessed using the EPIMATRIX algorithm 
(www.epivax.com). The physicochemical properties of peptides were predicted using the 
program at www.expasy.org and adjustment of their precise length undertaken to optimise 
solubility, stability and chemical synthesis. Table 3.1 (page 52, 53) shows the peptides that 
were synthesized using Fmoc chemistry (GL Biochem, Shanghai, China). 
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Table 3.1. Sequences of non-polymorphic HLA Class 2 derived Single Peptides 
These sequences were derived from the non-polymorphic β2 domain of HLA Class 2. GRAVY (grand average hydropathy) denotes the 
solubility of the peptides. EpiMatrix raw scores are normalized with respect to a score distribution derived from a very large set of 
randomly generated peptide sequences. Any peptide scoring above 1.64 on the EpiMatrix “Z” scale (approximately the top 5% of any 
given peptide set) has a significant chance of binding to the MHC molecule for which it was predicted.www.expasy.org. 20 peptides were 
synthesized and 18 (in bold) were used for further study.""
"
"
"
"
"
"
"
"
"
"
"
"
"
"
"
"
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Peptide  Sequence 
residues 
in parent MW Length 
Isoelectric 
point GRAVY 
Instability 
Index 
Hits 
(top 
10%) 
Hits 
(top 
5%) 
High 
(Top 
1%)  
Epi 
score 
DRE1 HFFNGTERVRLLERCIYNQ 45-63 2394.2 19 8.23 -0.642 S 8 7 4 10.6 
DRE1A HFFNGTERVRLLERSIYNQ 45-63 2378.22 19 8.75 -0.816 S 8 8 3 18.1 
DRE2 GEYRAVTELGRPD 74-86 1461.72 13 4.87 -1.085 S 8 6 0 12.5 
DRE2A EYRAVTELGRP 75-85 1289.67 11 6.24 -0.927 S 8 7 0 14.27 
DRE3 ERVRLLERSIY 51-61 1432.82 11 8.84 -0.573 U 7 5 2 7.54 
DRE3A ESFTVQRRVHPKVTV 116-130 1781.99 15 10.84 -0.487 U 7 6 0 13.26 
DRE3B ESFTVQRRVQPKVTV 116-130 1772.99 15 10.84 -0.507 U 8 6 0 13.79 
DRE3C ESFTVQRRVYPKVTV 116-130 1772.99 15 9.99 -0.36 U 7 6 0 11.21 
DRE4 KVTVYPSKTQPLQHH 127-141 1761.95 15 9.7 -1.047 U 7 5 2 3.96 
DRE4A KVTVYPSKTQPLQ 127-139 1487.43 13 9.7 -0.715 U 7 5 2 5.74 
DRE5 SIEVRWFRNGQEEK 155-169 1776.89 14 5.95 -1.5 U 6 5 1 6.96 
DRE6 GDWTFQTLVMLETVPRSGE 180-198 2165.05 19 4.43 -0.211 S 8 8 2 16.99 
DRP6A GDWTFQTLVMLETVPRS 180-196 1978.98 17 4.37 -0.006 U 8 8 2 22.37 
DRE6B WTFQTLVMLETVPRS 182-196 1806.93 15 6 0.253 U 8 8 2 24.15 
DRE6C WTFQTLVMLETVPRSGE 182-198 1994.2 17 4.86 -0.006 S 8 8 2 18.77 
DRE6D 
DRE6E 
QTLVMLETVPRSG 
HFFNGTERVRLLE 
185-197 
45-57 
1429.76 
1616.84 
13 
13 
6 
6.77 
0.169 
-0.492 
U 
S 
8 
7 
7 
6 
2 
1 
16 
5.82 
DRE7 SPLTVEWRARSESAQSK 211-227 1930.99 17 8.46 -1.071 U 8 5 2 5.92 
DRE8 GLFIYFRNQKGHSGLQ 245-260 1863.97 16 9.99 -0.481 S 8 8 5 25.11 
            
 77 
3.3 Interferon-γ responses to HLA Class 2 derived single peptides 
A total of 18 peptides (13-19 amino acids long) derived from the non-polymorphic β2 domain 
of HLA DR were selected for further study (Table 3.1, page 52 & 53). This selection was on 
the basis of EpiMatrix Z score, solubility and ease of synthesis. On the basis of previous 
studies using HLA Class 1 peptides, single Class 2 peptides were incubated with 4x105 
PBMC’s in γ-interferon ELISPOT plates (Oxford Immunotec) for 48 hours at 370C 5% CO2. 
At this time point plates were developed according to the manufacturers instructions and 
enumerated on an AID ELISPOT reader. The methodology is described in detail in section 
2.2.4 page 57. 
 
An irrelevant peptide was used as negative control. Responses to anti-CD3 and to PPD were 
used as positive controls. The definition of a response in this assay was previously defined as 
> 7 spots per well, based upon previous analysis (Smith et al., 2010).  !
The frequency of γ-interferon producing cells in PBMCs was assessed in 80 renal transplant 
recipients more than 1-year post-transplantation. At recruitment they were on stable 
immunosuppression with no treatment for acute rejection within the previous 3 months. The 
demographics and clinical details of this group are shown in Table 3.2. In addition, the 
response in 19 healthy volunteers (mean age 32.2 ± 10.8 years) was determined.  
A response to at least one HLA Class 2 derived peptide was observed in 55 of 80 renal 
transplant recipients compared with 4 of 19 healthy controls (p=0.0002; Fisher’s Exact). All 4 
healthy volunteers had a history of previous antigen exposure via pregnancies. 
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Table 3.2. Patient Demographics for the 80 patients recruited into the cross sectional 
study to test γ-interferon responses to HLA Class 2 derived single peptides.  
Characteristic All patients (n=80) 
Male (%) 51 (63.8) 
Recipient age, mean (SD) 49.7 (13.31) 
Time since transplant, median/yr. (interquartile range) 5.4 (3.8-11.4) 
eGFR on day of study (ml/min/1.73 m2), mean (SD) 36.8 (14.5) 
Urinary albumin:creatinine ratio (mg/mmol), median (interquartile 
range) 
3.95 (1.25-18.5) 
Number of recruits with previous acute rejection (%) 32 
Immunosuppression on day of recruitment, n (%)  
Corticosteroids 70 
MMF 45 
Azathioprine 48 
Calcineurin inhibitors 88 
HLA mismatch, median (interquartile range) 
HLA A 1.0 (0.0-1.0) 
HLA B 1.0 (0.0-1.0) 
HLA DR 0.0 (0.0-1.0) 
Ethnicity (%) 
White 80 
Indo-Asian 6 
Afro-Caribbean 10 
Mixed race 0 
Other 4 
Type of transplant (%) 
ABO compatible living donation 31 
ABO incompatible living donation 15 
Cadaveric 54 
CMV status (%) 
D-/R- 27 
D+/R- 23 
D-/R+ 17 
D+/R+ 33 
Underlying Cause of ESRF (%) 
Glomerular 26 
Hereditary Structural/Cystic Disease 25 
Diabetes Mellitus 10 
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Characteristic All patients (n=80) 
Vascular 19 
 Interstitial 6 
Others 14 
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Figure 3.1. γ-interferon responses to HLA Class 2 derived peptide in 19 healthy 
volunteers 
ELISPOT(plates(incubated(with(4x105(PBMCs(per(well(and(50μl(of(HLA(Class(2(peptide(were(
incubated(for(48(hours(and(developed(as(per(manufactures(instructions.(The(frequency(of(
cells(synthesizing(γOinterferon(was(enumerated(on(an(AID(ELISPOT(reader.(Only(4(of(the(19(
healthy(volunteers(responded(to(Class(2(HLA(derived(peptides((DRE2,(DRE6B,(DRE8,(
DRP6A(but(all(had(previous(antigen(exposure(via(previous(pregnancies.((
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Figure 3.2. γ-interferon responses to HLA Class 2 derived peptide in 80 Renal 
Transplant Recipients 
ELISPOT(plates(incubated(with(4x105(PBMCs(per(well(and(50μl(of(HLA(Class(2(peptide(were(
incubated(for(48(hours(and(developed(as(per(manufactures(instructions.(The(frequency(of(
cells(synthesizing(γOinterferon(was(enumerated(on(an(AID(ELISPOT(reader.(55(of(the(80(
renal(transplant(recipients(responded(to(HLA(Class(2(derived(peptides.(Responses(were(
seen(in(at(least(1(patient(with(all(Class(2(peptides(with(the(most(number(of(responses(seen(in(
response(to(DRE4A,(DRE5,(DRE6,(DRE6E((and(DRE7.((
 
(
Chronic(Renal(Transplant(Patients((55/80(high(responders)(
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3.4 Correlation between responses to HLA Class 1 and Class 2 derived peptides 
54 of the renal transplant recipients recruited had been previously assessed for their response 
to HLA Class 1 derived peptide (Smith et al., 2011). We compared these previous responses 
to HLA Class 1 peptides to the subsequently measured responses to HLA Class 2 peptides in 
the 54 patients who were in both groups. 25 patients responded to both sets of peptides whilst 
20 patients did not respond to either (Chi-squared test; p<10-4). Although tested at different 
time points the 45 patients whose responses correlated had stable graft function over the few 
years between testing. Of the 9 patients who did not correlate in responses 7 had stable graft 
function between the two time points tested. Interestingly, 2 of 7 patients who previously did 
not respond to HLA Class 1 derived peptides but subsequently responded to HLA Class 2 
derived peptides, had deteriorating allograft function with positive DSAs implying a link 
between T-cell alloreactivity and a humoral response with de-novo DSA production. Any 
such speculation must however be moderated by the fact that patients had to survive with a 
functioning graft to be included in the later study.  
 
Table 3.3. Correlation between responses to HLA Class 1 and Class 2 derived peptides 
in 54 Renal Transplant Recipients 
We(compared(the(correlation(between(responses(to(Class(1(and(Class(2(HLA(derived(
peptides.(54(patients(had(been(previously(assessed(for(their(responses(to(HLA(Class(1(
derived(peptide((Smith(et(al.,(2011).(All(patients(had(stable(graft(function(between(testing(
points(and(statistically,(responses(between(Class(1(and(Class(2(HLA(peptides(correlated(
(ChiOsquared(testZ(p<10O4).(
 
 
Response to Class 1 
Peptide 
No Response to Class 1 
Peptide 
Response to Class 2 
Peptide 
25 7 
No Response to Class 
2 peptide 
2 20 
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3.5 γ-interferon responses to peptide mixes 
The screening for responses to HLA derived peptides in these experiments required 45 mls of 
blood on each occasion. This was because responses to large numbers of different peptides 
were measured. Also the frequency of peptide specific response was likely to be low so that 
high numbers of PBMCs per well were used (400,000 PBMC’s per well). On that basis the 
response to mixtures of different peptides derived from the α3 domain of Class 1 and β2 
domain of Class 2 HLA were defined. Some peptides to which specific γ-interferon 
production was found, overlapped and/or were homologues of one another. On that basis the 
inclusion of overlapping or homologous sequences within the same mix was avoided. The 
combination of different peptides was otherwise non-purposeful. Table 3.4 shows the 7 Class 
1 derived peptide mixes and 3 Class 2 derived peptide mixes that were defined.  
 
Table 3.4. HLA Class 1 and Class 2 peptide mixes composition 
Peptide mixes were defined to reduce the volume of patient blood required on each test. 
Frozen peptides were stored in aliquots at 1mg/ml. On the day of experiments they were 
mixed with complete media at the required volumes and stored at 4oC for a further 1 week. 
 
.(( (
Peptide 
Mix 
      
Class 1       
Mix 2 Tra30 Tra39 Tra51 Tra02 Tra14  
Mix 3 Tra31 Tra40 Tra46 Tra49 Tra06 Tra19 
Mix 4 Tra31 Tra40 Tra52 Tra06 Tra19  
Mix 6 Tra33 Tra41 Tra53 Tra08aT
ra24 
  
Mix 7 Tra34 Tra42 Tra10 Tra29   
Mix 8 P1 P20 P45/46    
Mix 9 P2 P21 P45/46a    
       
Class 2       
DR Mix 
1 
DRE6c DRE2 DRE7    
DR Mix 
2 
DRE6d DRE3c     
DR Mix 
3 
DRE6e DRE4a     !
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3.5.1 γ-interferon responses to HLA Class1 derived peptide mixes 
The frequency of γ-interferon producing cells to Class 1 mixes were tested in 70 transplant 
recipients and 17 healthy controls and!showed!a!significantly!increased!number!of!responses!in!transplant!recipients!(35/70!Vs.!4/17,p=0.04).!The!mean!response!across!all!tests!was!significantly!higher!in!transplant!recipients!than!in!healthy!controls!(5.5!±!0.3!Vs.!2.9!±!0.35,!p<0.001).!! !
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Figure 3.3. γ-interferon responses to HLA Class 1 derived peptide mixes in 17 healthy 
controls 
ELISPOT(plates(incubated(with(4x105(PBMCs(per(well(and(50μl(of(HLA(Class(1(derived(
peptide(mixes(were(incubated(for(48(hours(and(developed(as(per(manufactures(instructions.(
The(frequency(of(cells(synthesizing(γOinterferon(was(enumerated(on(an(AID(ELISPOT(
reader.(Only(4(of(the(17(healthy(controls(responded(to(these(peptides.(Reponses(were(tested(
in(triplicate(to(2(different(concentrations.(Responses(were(seen(to(Mix(2(and(Mix(9.(!
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Figure 3.4. γ-interferon responses to HLA Class 1 derived peptide mixes in 70 Renal 
Transplant Recipients 
ELISPOT(plates(incubated(with(4x105(PBMCs(per(well(and(50μl(of(HLA(Class(1(derived(
peptide(mixes(were(incubated(for(48(hours(and(developed(as(per(manufactures(instructions.(
The(frequency(of(cells(synthesizing(γOinterferon(was(enumerated(on(an(AID(ELISPOT(
reader.(35(of(70(Renal(Transplant(responded(to(HLA(Class(1(derived(peptide(mixes.(Mixes(
were(tested(in(triplicate(at(2(concentrations(as(per(healthy(controls.(Responses(to(all(
peptides(by(at(least(1(patient(were(seen.((
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3.6 Correlation between responses to single peptides and peptide mixes 
A total of 35 patients were tested to both the single and mixed peptides derived from HLA 
Class 1. 21 patients responded to both single and mixed peptides whilst 8 patients did not 
correlate in their responses. 7 of 8 of patients responded to at least one of the single peptides 
screened but not to peptide mixes. Table 3.2 shows the significant correlation between 
responses to Class 1 single peptides and peptide mixes (Chi squared test; p=0.01).  
 
Table 3.5. Correlation between responses to HLA Class 1 single peptides and peptide 
mixes in 35 Renal Transplant Recipients 
We(directly(compared(the(correlation(between(γOinterferon(responses(to(HLA(derived(single(
peptides(and(peptide(mixes(in(an(ELISPOT(assay(in(35(renal(transplant(recipients(and(found(
a(significant(correlation((Chi(squared(testZ(p=0.01).(Only(8(of(the(26(patients(did(not(correlate(
in(their(responses.((
(
 
Response to Class 1 
Single Peptide 
No Response to Class 1 
Single Peptide 
Response to Class 1 
Peptide Mix 
21 1 
No Response to Class 
1 Peptide Mix 
7 6 
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3.7 Correlation between γ-interferon responses and circulating Donor specific 
antibodies (DSAs) 
By September 2012, 130 patients had been tested to HLA derived Class 1 or Class 2 peptide 
mixes. These patients were recruited in a number of studies however all were at least 1-year 
post transplantation at the time of testing. For 95 patients we had corresponding circulating 
DSA data at the time of testing. Figure 3.5 shows the correlation between γ-interferon 
responses and the presence of DSAs. Although this did not show a significant correlation 
(Chi-squared test; p=0.09), as this was a cross-sectional study we cannot say how responses 
vary over time. 
 
Table 3.6. Correlation between γ-interferon responses to HLA derived peptide mixes 
and presence of circulating DSAs.  
 
  
 
Response to HLA 
derived peptide mixes 
No Response to HLA 
derived peptide mixes 
Presence of 
circulating DSAs 
18 23 
Absence of 
circulating DSAs 
14 41 
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3.8 2-year follow up data: Correlation with graft loss, graft function and patient 
death 
We collected 2-year follow up data for the 130 RTRs tested to HLA Class 1 or HLA Class 2 
derived peptide mixes. 5 patients were transferred back to their base hospitals so no follow up 
data was available and hence excluded from the analysis. Table 3.7 shows the 2-year follow 
up data for 125 RTRs; 43 RTRs responded to the peptide mixes and 82 RTRs did not. 
Overall, there was no significant difference in graft function (eGFR) between the two groups 
2 years after testing. A small number of patients lost their graft function or died 2 years after 
testing but there was no significant difference between the two groups. 
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Table 3.7. 2-year follow up data for 125 RTRs tested to HLA Class 1 or Class 2 derived 
peptide mixes.  
Clinical data 2 years post testing was collected for 125 RTRs whose responses were tested via 
γ-interferon ELISPOT assays to HLA Class 1 or Class 2 derived peptide mixes. There was no 
significant difference in ΔeGFR (ml/min/year) between RTRs who tested positive or negative 
to the peptide mixes. There was no significant difference in the number of patients who lost 
their graft function or died between the 2 groups. RTRs who tested positive to the mixes had 
an overall higher ACR 2 years post testing which was significantly different to the group with 
negative responses.  
*ACR:(albumin:creatinine(ratio.((
 Positive 
Responses n=43 
Negative 
Responses n=82 
p value 
ΔeGFR  (ml/min/year), 
mean (SD) 
-0.81(3.31) 0.04(0.82) 0.09 
(Student’s t test) 
*ACR (mg/mmol), median 
(interquartile range) 
11.4 (55.7) 3.7 (13.5) 0.02 
(Mann Whitney U test) 
Graft loss (%) 6 (13.9) 13 (15.9) 0.68 
(Chi-squared test) 
Patient death (%) 2 (4.6) 5 (6.1) 0.73 
(Chi-squared test) 
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3.9 Longitudinal study of T-cells responses to non-polymorphic (autologous) HLA 
derived peptides 
As part of a study of CMV responses in 100 consecutive unselected renal transplant 
recipients, the response to HLA derived peptides was also studied using the methodology 
described above (Section 2.2.4, page 57). This group of patients was separate to the ones in 
the cross-sectional study. γ interferon secretion to HLA Class 1 and 2 derived peptides mixes 
were measured pre-transplant, and at 3,12 and 24-months post transplantation. Donor-specific 
antibody samples were collected at these time points as well along with clinical data including 
serum creatinine, urine albumin: creatinine ration (ACR), biopsy results (performed if 
clinically indicated), treatment for acute rejection (presumed or biopsy proven), infection 
episodes including CMV, graft failure, and patient death.  
 
3.9.1 Patient Demographics 
The demographics of a 100 patients recruited from February 2009 and June 2011 are shown in 
Table 3.8. The transplant population was an average 44.9 yrs. with 57% males and the majority 
of Caucasian origin (73%). There was a roughly even split between live and cadaveric donation 
and an overall low levels of HLA mismatch.  
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Table 3.8. Patient Demographics for the 100 patients recruited into the longitudinal 
study  
  
Characteristic All patients (n=100) 
Male (%) 57 
Recipient age, mean (SD) 44.9 (14.3) 
HLA mismatch, median (interquartile 
range) 
 
HLA A 1.0 (1.0-2.0) 
HLA B 1.0 (1.0-1.0) 
HLA DR 1.0 (0.0-1.0) 
Ethnicity (%)  
White 73 
Indo-Asian 16 
Afro-Caribbean 9 
Mixed race 1 
Other 1 
Type of transplant (%)  
ABO compatible living donation 31 
ABO incompatible living donation 21 
Cadaveric 48 
CMV status (%)  
D-/R- 26 
D+/R- 22 
D-/R+ 17 
D+/R+ 35 
Underlying Cause of ESRF (%)  
Glomerular 37 
Hereditary Structural/Cystic Disease 29 
Diabetes Mellitus 8 
Vascular 11 
 Interstitial 4 
Others 11 
Patients withdrawn from study by 24M 
(%) 
 
Withdrew consent 10 
Failed transplants 7 
Patient death 4 
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A total of 10 patients withdrew from the trial at various time points, 7 patients lost their graft 
function and 4 others died by the end of the 24M period. All samples collected before patient 
withdrawals were included in the analysis. Samples at 12M and particularly 24M were hard to 
obtain as a lot of patients were referred back to their parent hospital trust after transplantation. 
 
Table 3.9. A summary of the number of patient samples successfully processed at the 
chosen time points 
10(patients(withdrew(consent,(7(patients(lost(their(graft(function,(and(4(patients(died(during(
the(study.(A(significant(number(of(patients(were(referred(back(to(their(parent(trust(3(months(
post(transplantation.((
(
Time point Total number of samples 
D0 92 
3M 78 
12M 66 
24M 43 
 
3.9.2! Overall ELISPOT Responses 
Table 3.10 summarizes the total number of positive and negative ELISPOT responses in all 
100 patients. Table 3.11 shows the consecutive responses in 36 transplant recipients.  There is 
a consistent overall trend of more negative than positive responses at all time points with an 
increasing number of positive responses at 12 months. By 24 months however, 5% to 9% of 
patients lose their positive responses to the HLA derived peptides. No patients with 
consecutive data lost their responses and gained them back again. All patients in this cohort 
had induction therapy with basiliximab and maintenance therapy with steroids, tacrolimus and 
mycophenolate. 1 patient was converted to sirolimus at18-months post transplant and 2 others 
were converted to azathioprine at 12-months post treatment. None of these patients had a 
change in ELISPOT response after a change in immunosuppression.  
 
Overall, 21% of patients had positive ELISPOT responses at 24-months post transplantation. 
This is comparable to the cross sectional study where 33% of all RTRs tested responded, 
albeit at various times post transplantation.  
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Table 3.10. Overall ELISPOT Responses to HLA derived peptides obtained during the 
2-year study 
Table(summarizing(the(overall(ELISPOT(responses(to(HLA(derived(peptide(mixes(
pretransplant((n=92),(3M(post(transplant((n=78),(12M(post(transplant((n=66)(and(24M(post(
transplant((n=43).(The(definition(of(a(response(in(this(assay(was(previously(defined(as(>(7(
spots(per(well,(based(upon(analysis.((
 
 Positive Responses, n (%) Negative Responses, n (%) 
Pre-transplantation n=92 15 (16%) 77 (84%) 
3M n=78 14 (18%) 64 (82%) 
12M n=66 17 (26%) 49 (74%) 
24M n=43 9 (21%) 34 (79%) 
 
 
Table 3.11. ELISPOT Responses in 36 patients for whom we had consecutive data at 
each time point 
Table(summarizing(consecutive(γOinterferon(responses(to(HLA(derived(peptide(mixes(in(36(
renal(transplant(recipients.(The(definition(of(a(response(in(this(assay(was(previously(defined(
as(>(7(spots(per(well,(based(upon(analysis.((
 
 Positive Responses, n (%) Negative Responses, n (%) 
Pre-transplantation 8 (22%) 28 (78%) 
3M 6 (17%) 30 (83%) 
12M 11 (31%) 25 (69%) 
24M 8 (22%) 28 (78%) 
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3.9.3! ELISPOT Responses and Acute Rejection Episodes 
All acute rejection episodes were confirmed by histology according to the 2007-revised Banff 
classification (Solez et al). Of the 100 patients recruited, 22 patients had 1 or more episodes of 
acute rejection within the first year post transplantation. A total of 4 patients had an acute 
rejection episode between 12 to 24 months post transplantation, 2 of them having had an 
episode of rejection previously.  
 
Statistical analysis using Chi-squared or Fisher’s exact (based on the minimum expected 
count) were used to test if there was a relationship between patients who had 1 more acute 
rejection episodes and their ELISPOT responses. There was no link to say that patients with 
positive ELISPOT responses had subsequently more episodes of acute rejection, or that acute 
rejection episodes lead to positive ELISPOT responses. 
 
3.9.4! ELISPOT Responses and Biopsy proven chronic rejection 
In our cohort of 100 patients there were only a small number of patients with histology proven 
CAI within 2 years of transplantation, hence any association was not possible to conclude. 
None of the 6 patients with biopsy proven chronic rejection had preceding positive ELISPOT 
response within 2 years of transplantation. There was only 1 patient with biopsy proven 
chronic rejection at 8-months post transplantation whom at 3-month was ELISPOT negative 
but at 12 months was ELISPOT positive and remained positive on subsequent testing.  
 
3.9.5! ELISPOT Responses and Episodes of Infection 
A high proportion of patients (57%) had infective episodes within the first 2 years of 
transplantation. A further 2% had culture negative episodes that were treated as infection. 
There were a total of 92 culture positive and 8 culture negative episodes of infection in a 24-
month period post transplantation. For the purpose of statistical analysis, an infective episode 
was defined as a culture positive episode- bacterial, fungal or viral. Episodes of infection were 
grouped into occurring within 3-months post transplantation, between 3 and 12-months post 
transplantation and between 12 and 24-months post transplantation and compared with 
ELISPOT responses before and after these periods. Multiple episodes of infection were 
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counted as a single episode if it occurred within each time period for a single patient. If an 
episode of infection had missing ELSPOT responses either pre of post infective episode, they 
were not included in the analysis.  
 
Table 3.12. Comparisons between episodes of infection and ELISPOT responses before 
and after the episodes 
As(expected(the(number(of(infective(episodes(reduced(with(time(away(from(transplantation.(
Statistical(analyses(did(not(prove(that(ELISPOT(responses(were(either(predictive(of(or(
changed(due(to(infective(episodes(
(
 
 
 
CMV viraemia episodes were analysed separately and considered positive if >200copies/ml 
were isolated in a peripheral blood sample. Only a small number of episodes of CMV 
viraemia occurred in our cohort of 100 patients over a 2-year period post transplantation. 
Statistical analyses using Fisher’s exact did not show any significance between CMV 
viraemia episodes and ELISPOT responses either before or after the viraemia episode. 
Infective Episodes Pre Episode Post Episode 
 ELISPOT + ELISPOT - ELISPOT + ELISPOT - 
Pretransplantation-3M 9 30 8 24 
3M-12M 5 25 8 21 
12M-24M 5 14 5 7 
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Table 3.13 Comparisons between episodes of CMV viraemia and ELISPOT 
responses before and after the episodes 
A(CMV(viraemia(episode(was(defined(as(>200(copies/ml(on(serum(PCR.(There(was(no(
significant(correlation(between(γOinterferon(ELISPOT(responses(to(HLA(peptides(and(a(CMV(
viraemia(episode(albeit(the(very(low(numbers.(
(
(
(
3.9.6! ELISPOT responses and presence of circulating DSAs 
Of the 100 patients recruited onto the longitudinal study, we had pre-transplant circulating 
DSA data for 79 patients. 15 patients had the presence of circulating DSAs pre-transplant but 
all were ELISPOT negative at the time. Of these 15 patients only 3 patients had an episode of 
acute rejection within 3-months post transplantation. 12 other patients were ELISPOT 
positive pre-transplantation with no evidence of circulating DSAs. Of these, 3/12 patients had 
at least one episode of acute rejection within 12-months post transplantation. 2/12 patients 
subsequently developed circulating DSA. We were able to analyse circulating DSA data at 
0,12 or 24 months for only 25 patients. It is interesting to note that the 8 patients we pre-
transplantation DSAs but where ELISPOT, became ELISPOT positive 12-months later.  
CMV Viraemia Episodes Pre Episode Post Episode 
 ELISPOT + ELISPOT - ELISPOT + ELISPOT - 
Pretransplantation-3M 1 4 1 4 
3M-12M 1 10 4 4 
12M-24M 2 1 1 1 
 98 
 
 
CHAPTER 4 
RESULTS 
 
Responses to non-polymorphic 
(autologous) HLA derived peptides are 
mediated through CD4+ T effector 
memory cells 
  
 99 
4 Results: Responses to non-polymorphic (autologous) HLA derived peptides are 
mediated through CD4+ T effector memory cells 
 
The phenotype of cells responding to non-polymorphic HLA derived peptides has previously 
been demonstrated to lie in the CD4+CD25Hi lymphocyte compartment by intracellular 
staining (Smith et al., 2011). This section aims to define with greater acuity the CD4+ T 
lymphocyte subset responsible for the production of γ-interferon and other cytokines.  
 
4.1 Gating Strategy 
In human lymphocytes, CD25 expression is continuously distributed so that there is not a 
clearly defined CD25 positive population, containing Treg cells. For the purpose of functional 
studies this is not necessarily a problem, since in this setting it is often only necessary to 
demonstrate differential effects generated by phenotypically distinct populations, (although 
even this may be complicated by the fact that the CD25Hi population includes activated T 
lymphocytes). On the other hand, for the purposes of correlating the frequency of expression 
of a particular cell surface phenotype in peripheral blood, this imprecision in gate definition is 
problematic, still more so if any such approach is extended beyond a single operator. A 
number of different approaches have been taken in order to indirectly derive such a ‘CD25Hi 
gate’ however they are potentially confounded by circular arguments or dependence upon 
other variables that are also difficult to standardise. 
 
In this chapter I will show that the lymphocyte population responsible for RTRs’ γ-interferon 
production in response to non-polymorphic HLA derived peptides has the cell surface 
phenotype: CD4+CD25HiCD45RO+CD127+CCR7-. The expression of this phenotype in 
peripheral blood as a proportion of CD4+CD25Hi lymphocytes in RTRs (n=35) and HCs 
(n=17) is shown in Fig 4.1 for populations based upon gating strategies for CD25 expression 
that included progressively greater proportions of CD4+ T lymphocytes. There was a highly 
statistically significant difference in the expression of CD25HiCD45RO+CD127+CCR7- 
lymphocytes when the CD25 gate was set to include 5% or less of CD4+ lymphocytes. The 
significance of this difference was greatest between 1.25% and 5%. A CD25 gate of 2.5% of 
CD4+ T lymphocytes was therefore chosen for all subsequent studies.  
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Figure 4.1. The proportion of cells CD45RO+CD127+CCR7- (as a function of 
CD4+CD25Hi lymphocytes) in RTR Vs. HC incorporating different levels of CD25Hi 
expression  
The(proportion(of(cells(CD45RO+CD127+CCR7O((as(a(function(of(CD4+CD25Hi(lymphocytes)(
in(35(RTRs(immunosuppressed(with(a(calcineurin(inhibitor(and(17(HCs.(This(proportion(was(
significantly(higher(in(RTRs(than(in(HCs(up(to(a(gate(incorporating(the(highest(5%(of(CD25(
expression(and(was(most(significant(when(the(gate(was(set(to(the(highest(2.5%(of(CD4+(T(
lymphocytes:(RTR(median(=(8.9(%((IQR(4.2O13.4)(healthy(control(median(=(2.8%((IQR(1.7O
5.2)((p<0.001).(
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Figure 4.2. Gating strategy to sort CD4+ subset  
1x107(PBMCs(were(surface(stained(with(antibody(using(the(methods(above((Section(2.2.5,(
page(40).(The(stained(cells(were(finally(suspended(in(500ul(MACS(and(sorted(at(The(Centre(
for(Translational(Inflammation(Research((CTIR)(using(a(MoFLo(Legacy(cell(sorter.(Cells(
were(counted(and(sorted(into(3(categories(
1.(TemsO(T(effector(memory(cells((CD4+CD25HiCD45RO+CD127HiCCR7O)(
2.(TcmsO(T(central(memory(cells((CD4+CD25HiCD45RO+CD127HiCCR7+)(
3.(TregsO(T(Regulatory(cells((CD4+CD25HiCD45RO+CD127Lo).(Liu(et(al(demonstrated(that(
CD127(is(an(excellent(cell(surface(biomarker(of(human(Tregs(especially(when(used(in(
combination(with(CD25((Jiang(et(al.,(2004).(CD127(expression(inversely(correlated(with(
Foxp3(expression(and(is(expressed(at(low(levels(on(a(majority(of(Treg(cells((Jiang(et(al.,(
2004).(Hence(Foxp3(staining(wasnot(performed(to(identify(Treg(cells.((
CD25Hi(were(defined(as(the(top(2.5%(of(CD4+CD25+(cells(for(reasons(described(in(Section(
4.1.((
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4.2 γ-interferon responses to HLA derived peptides by different 
CD4+CD25HiCD45RO+ subsets 
The strategy used to deduce the CD4+ T lymphocyte subset responsible for cytokine 
production was to purify T-cell subsets by flow cytometry as shown in the section above. 
These subsets were then added to peptide-stimulated PBMC cultures quantified by γ-
interferon ELISPOT. This strategy was used to combine sensitivity with the potential to 
undertake functional studies.  
 
19 patients were studied on the basis of a consistent response to one or more HLA derived 
peptides in earlier studies. This included, 12 patients responsive to Class 1 derived HLA 
peptides (tra30, tra34, tra33, tra02, tra14, tra31) and 7 patients responsive to Class 2 derived 
HLA peptides (DRE3c, DRE6b, DQ1, DRE2, DRE3b, DRE2a, DRE6c, DRE4a) were chosen.  
 
A significant increment in the response to active Class 1 and Class 2 derived peptides was 
only seen when the CD4+CD25HiCD45RO+CD127HiCCR7- subset was added back to the cell 
culture. Mean Response to Class 1 peptides was 136 spots/well and to class 2 peptides was 
121 spots/well as shown in Figures 4.3 and 4.4. The mean frequency when any other subset of 
cells was titrated back to active peptide was under 10 spots/well.
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Figure 4.3. Interferon-γ responses in the presence of Class 1 HLA derived peptides and 
different CD4+CD25HiCD45RO+ subsets. 
Four(flow(sorted(lymphocyte(subsets:(CD4+CD25HiCD45RO+CD127+/OCCR7+/O((Figure(4.2,(
page(76)(were(titrated(back(into(γOinterferon(ELISPOT(wells(containing(4x105(PBMC’s(with(
active((AP)((tra30,(tra34,(tra33,(tra02,tra14,(tra31)(or(control((IP)(HLA(derived(peptide(
(11.4μmol/L)(and(cultured(for(48(hours(at(370C(and(5%CO2.(A(γOinterferon(ELISPOT(
response(was(observed(only(in(the(presence(of(active(peptide(with(the(
CD4+CD25HiCD45RO+CD127+CCR7O((average(136spots/well)(population(but(not(any(of(the(
other(three(subsets(The(control(peptide(wells(all(returned(4(spots(or(less.(Results(from(all(12(
patients(are(shown.((
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Figure 4.4. Interferon-γ responses in the presence of Class 2 HLA derived active peptide 
and different CD4+CD25HiCD45RO+ subset 
Four(flow(sorted(lymphocyte(subsets:(CD4+CD25HiCD45RO+CD127+/OCCR7+/O((Figure(4.2,(
page(76)(were(titrated(back(into(γOinterferon(ELISPOT(wells(containing(4x105(PBMC’s(with(
active((AP)((DRE3c,(DRE6b,(DQ1,(DRE2,(DRE3b,(DRE2a,(DRE6c,(DRE4a)(or(control((IP)(
HLA(derived(peptide((11.4μmol/L)(and(cultured(for(48(hours(at(370C(and(5%CO2.(A(γO
interferon(ELISPOT(response(was(observed(only(in(the(presence(of(active(peptide(with(the(
CD4+CD25HiCD45RO+CD127+CCR7O((average(121spots/well)(population(but(not(any(of(the(
other(three(subsets(The(control(peptide(wells(all(returned(4(spots(or(less.(Results(from(all(7(
patients(are(shown.((
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4.3 Interferon-γ responses to HLA derived peptides by different 
CD4+CD25HiCD45RO+ subsets at different doses 
Dose titration responses in 13 patients to Class 2 peptides showed a progressive increase in γ-
interferon ELISPOT frequency to active peptide when increased numbers of 
CD4+CD25HiCD45RO+CD127HiCCR7- sorted cells were titrated back. Mean responses are 
shown in Figure 4.3. Responses in all other subsets in any amount showed an average 
frequency of less than 10 spots/well. 
 
 Figure 4.5. Interferon-γ responses in the presence of Class 2 HLA derived active peptide 
and different CD4+CD25HiCD45RO+ subsets in increasing number of cell numbers. 
Four(flow(sorted(lymphocyte(subsets:(CD4+CD25HiCD45RO+CD127+/OCCR7+/O((Figure(4.2,(
page(76)(were(titrated(back(into(γOinterferon(ELISPOT(wells(containing(4x105(PBMC’s(with(
active((DRE2,(DRE3b,(DRE3c(and(DRE6c)(or(control(HLA(derived(peptide((11.4μmol/L)(and(
cultured(for(48(hours(at(370C(and(5%CO2.(A(progressive(increase(in(γOinterferon(ELISPOT(
frequency(was(observed(only(in(the(presence(of(active(peptide(with(the(
CD4+CD25HiCD45RO+CD127+CCR7O(population(but(not(any(of(the(other(three(subsets(.The(
control(peptide(wells(all(returned(4(spots(or(less.(Results(from(all(13(patients(are(shown(
below.(
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4.4 Effect of lymphocyte activation inhibitors on γ-interferon responses to HLA 
derived peptides 
15 patients (10 previously responsive to HLA Class 1 derived peptides and 5 previously 
responsive to HLA class 2 peptides) were studied for γ- Interferon responses by T-effector 
memory cells in the presence of active peptide alone and in the presence of different 
inhibitors of lymphocyte activation. 
 
Table 4.1 shows the median number of γ-interferon responses with and without inhibitors and 
their comparisons. All inhibitors reduced the effect of T effector memory cell responses to 
active peptide, however the effect was less marked with Sirolimus and Abatacept. Figure 4.6 
shows median responses in all 15 patients. 3 of 15 patients had less than 50% inhibition with 
ciclosporin at 100mg/ml. Overall Ciclosporin at 100mg/ml and 200mg/ml and ShK at 10nM 
and 50nM have the most profound effect (less than 40% production compared to that in the 
absence of inhibitors) whilst the effect is less progressively marked with Abatacept and 
Sirolimus. There was no significant difference in inhibition between the doses of inhibitors 
used when compared with each other  
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Table 4.1. Table showing the mean γ-interferon responses of 15 patients to active peptide 
alone and in the presence of lymphocyte activation inhibitors at different doses. 
4x105PBMC’s(from(15(RTRs(previously(identified(to(respond(to(HLA(derived(peptides,(were(
enriched(with(103(sorted(autologous(CD4+CD25HiCD45RO+CD127HiCCR7O(T(lymphocytes(
and(cultured(in(the(presence(or(absence(of(‘active’(peptide(and(of(Ciclosporin((200ng/ml(and(
100ng/ml),(Sirolimus((50ng/ml(and(25ng/ml),(Abatacept((1μg/ml),(Shk(peptide((10nM(and(
50nMO(a(Kv1.3(channel(inhibitor(which(targets(T(effector(memory(cells).Cell(culture(
supernatant(cytokine(concentrations(were(analysed(at(24(hours(using(a(multiplex(assay(and(
γOInterferon(ELISPOTs(enumerated(at(48(hours(of(culture.(Results(are(shown(as(the(median(
frequency(of(γOInterferon(responses(per(well.(The(p(values(show(comparisons(of(responses(
between(responses(with(and(without(each(inhibitor((significant(values(in(red).(Responses(
were(tested(in(triplicate.(
 Median  γ-Interferon 
responses/well (IQR) 
 % inhibition 
median (IQR) 
P value 
TEMS + AP 108   
TEMs AP + 100ng/ml CsA 11.5 (15) 70 (33.8) 0.0002 
TEMs AP + 200ng/ml CsA 13.5 (43.5) 82.7 (26.1) 0.0001 
TEMs AP + 250ng/ml Sir 55 (76) 36.7 (41) 0.0953 
TEMs AP + 500ng/ml Sir 61.5 (73) 46 (38) 0.0323 
TEMs AP + 500ng/ml Abat 40.5 (62.5) 40.3 (47.4) 0.0256 
TEMs AP + 1µg/ml Abat 35.5 (23) 73.9 (42.6) 0.0140 
TEMs AP + 10nM ShK 12.5 (19) 85.6 (18.3) <0.0001 
TEMs AP + 50nM ShK 32.5 (29) 87.5 (31.6) 0.0001 
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Figure 4.6. γ-interferon responses to HLA derived peptides in the presence of 
lymphocyte activation inhibitors in 15 RTRs. 
4x105(PBMC’s(from(each(RTR(previously(identified(to(respond(to(HLA(class(1(and(Clss(2(
derived(peptides,(were(enriched(with(103(sorted(autologous(
CD4+CD25HiCD45RO+CD127HiCCR7O(T(lymphocytes(and(cultured(in(the(presence(or(
absence(of(‘active’(peptide(and(of(Ciclosporin((200ng/ml(and(100ng/ml),(Sirolimus((50ng/ml(
and(25ng/ml),(Abatacept((1μg/ml),(Shk(peptide((10nM(and(50nM(O(a(Kv1.3(channel(inhibitor(
which(targets(T(effector(memory(cells).(Cell(culture(supernatant(cytokine(concentrations(were(
analysed(at(24(hours(using(a(multiplex(assay(and(γOinterferon(ELISPOTs(enumerated(at(48(
hours(culture.(Results(are(shown(as(the(median((triplicatewells)(frequency(of(γOInterferon(
responses(per(well.((
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4.5 Peripheral expansion of activated T effector memory cells in renal transplant 
recipients  
4.5.1 Patient Demographics 
Cell surface markers from the peripheral blood of 37 RTRs and 17 HCs were studied. Table 
4.2 shows the demographics of the 37 renal transplant recipients. 26 patients were male and 
11 patients female with a median age of 49.2 years (range 19-70 years). At the time of the 
study, median time from transplantation was 10.5 years (range 2 to 40.1 years).  
All patients received our department’s standardized immunosuppression with basiliximab at 
induction followed by steroids, CNI and MMF/azathioprine maintenance. All but 2 patients 
(n=35) were on CNI based immunotherapy the time of the study with prednisolone (n=31) 
and an antiproliferative agent (n=21). 2 patients had their CNI therapy withdrawn and were on 
dual therapy with prednisolone and an antiproliferative agent.  
Patients were divided into 2 categories for analysis. Those with stable kidney function (n=20) 
and those with CAI (n=17) defined based upon KDIGO guidelines as eGFR <40ml/min or 
proteinuria >500mg/day (Kidney Disease: Improving Global Outcomes Transplant Work, 
2009) or those with biopsy proven chronic allograft rejection (interstitial fibrosis, glomerular 
sclerosis, tubular atrophy). Patients in the CAI group did not have evidence of CNI toxicity 
(defined as either biopsy evidence of CNI damage or 2 consecutive levels out of target range 
in the previous 3 months) or any other cause of CAI such as viral infections or circulating 
DSAs. The control group included 17 healthy subjects with 12 women and 5 men aged 26 to 
59 years, mean 37.2 years.   
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Table 4.2. Patient demographics for the 37 patients used to study cell surface markers in 
Renal Transplant Recipients 
!a!indicates(significance(by(student’s(t(test,(b!indicates(significance(by(MannOWhitney(U(test,(c!
indicates(significance(by(ChiOsquared(test.(N/A(not(applicable,(NS(not(significant.((
 Stable graft function Chronic Allograft Injury P-value 
Number of patients 20 17  N/A 
Recipient age: mean ± SD 
(range) 
47.4 ± 12.7 (19-67) 51.4 ± 10.9 (31-70) NS 
Recipient sex M: F (% male) 13:7 (65%) 13:4 (76.5%) NS 
CMV status (%)    
D-/R- 40 29.4 NS 
D+/R- 15 29.4 NS 
D-/R+ 15 17.6 NS 
D+/R+ 30 23.6 NS 
Time (yrs.) since transplantation: 
mean ± SD (range) 
8.5 ± 7.2 (2-25.3) 12.9 ± 9.9 (3.5-40.1) NS 
Recipient Creatinine: mean ± SD 
(range) 
128 ± 43.7 (65-198) 232.4 ± 79.8 (10.2- 375) 0.02 a 
Recipient ACR: mean ± SD 
(range) 
5.6 ± 8.5 (0-29.3) 83.4 ± 139.7 (0.3-51.8) 0.017 b 
Recipient eGFR: mean ± SD 
(range) 
53.6 ± 20.9 (27-90) 25.6 ± 12 (11-63) 0.005 a 
Immunosuppression regimen    
    Steroids 17/20 15/17 NS c 
    CNI                                                            
(tacrolimus/ciclosporin) 
19/20 16/17 NS c 
    Antiproliferative        
(MMF/azathioprine) 
18/20 10/17 NS c 
CAI diagnosis    
    Creatinine >150µmol/L N/A 16/17 N/A 
    ACR >30 N/A 8/17 N/A 
    Biopsy proven N/A 10/17 N/A 
Previous episodes of acute 
rejection 
7/20 7/17 NS c 
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Figure 4.7. Gating strategy used for phenotyping cell surface markers in 37 renal 
transplant recipients and 17 healthy controls. 
Lymphocytes(were(gated(on(CD4+(cells((A)(and(the(top(2.5%(CD25Hi(of(CD4+(cells((B).(T(
effector(memory(cells(were(identified(as(being(CD45RO+(and(CD127Hi((C)(and(then(identified(
as(being(either(peripheral((CCR7O)(or(central((CCR7+)((D).(
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4.5.2 CD4+CD25Hi cells in Renal Transplant Recipients 
The percentage of CD4+ T-cells after transplantation did not differ from that in healthy 
individuals (41.3% (IQR 13.8) Vs. 32.9% (IQR 16.2); p=0.06). This was in keeping with van 
De berg et al (van de Berg et al., 2012b) who showed no difference in percentages but lower 
absolute numbers at 6 month, 2 years and 5 years post transplantation with our average age of 
transplant being 10.5 years. Figure 4.8 shows the percentage of CD4+CD25Hi cells in all 4 
groups with no significant differences.   
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Figure 4.8. Box plot showing the number of CD4+CD25Hi cells within total CD4+ T-cells. 
Lymphocytes(from(the(PBMCs(of(37(RTRs(and(17(HCs(were(stained(with(cell(surface(
antibodies(and(analysed(for(various(phenotyping(cell(surface(markers(of(T(lymphoctyes(
(Figure(4.7,(page(112)(There(was(no(significant(difference(in(the(number(of(CD4+CD25Hi(cells(
within(the(CD4+(TOcell(population(as(analysed(by(a(nonOparametric(KruskalOWallis(test(
(p=0.65)(between(RTRs(and(HCs(or(within(RTRs(with(stable(function(or(features(or(CAI.(
(
(
(
( (
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4.5.3 CD4+CD25HiCD127Lo & CD4+CD25HiCD127Hi cells in Renal Transplant 
Recipients 
As shown in several studies (Codarri et al., 2007, Seddiki et al., 2006) the majority of 
CD4+CD25+ T-cells were CD45RO+CD127Lo in a representative healthy subject as shown 
from one example in Figure 4.9 (A). Only a small percentage (4.99% in this example) of 
CD4+CD25+ expressed CD127Hi.  The same analysis in a stable renal transplant recipient 
showed that the CD4+CD25+CD45RO+CD127Lo population was markedly reduced (34.5% in 
this example Figure 4.9 B) compared with a healthy control. Interestingly there was also a 
major increase (19.6%) in the proportion of CD4+CD25+CD45RO+CD127Hi population. The 
differences in these populations remained similar overall in patients with stable transplant 
function and those with CAI as shown by one example in figure 4.9 (C). %
%
The percentage of Tregs (CD4+CD25HiCD45RO+CD127Lo) within CD4+CD25Hi T-cells in 
healthy controls was significantly higher than in transplant recipients (84.8% (IQR 32.3) Vs. 
48.4% (IQR 23.4); p<0.05). There was no significant difference in the proportion of these 
cells between transplant recipients with stable function and CAI (48.1% (IQR 28.2) Vs. 
53.1% (IQR 25.6); p=0.63). Figure 4.10 shows the number of Tregs in all 4 groups. 
 
The percentage of Tems (CD4+CD25HiCD45RO+CD127Hi) within the CD4+CD25Hi T-cells in 
transplant recipients was significantly higher than in healthy controls (21.8% (IQR 24.4) Vs. 
7% (IQR 24.8); p=0.02), even when confounded for age (Pearson’s correlation). However 
there was no significant difference in the proportion of these cells between transplant 
recipients with stable function and CAI (21.2% (IQR 24.8) Vs. 24.7% (IQR 23.1); p=0.62) 
unlike what Coddari and colleagues described (Codarri et al., 2007). Figure 4.11 (page 118) 
shows the number of Tems in all 4 groups.  
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Figure 4.9. CD4+CD25+ flow cytometry profiles on one healthy donor (A), one stable 
renal transplant recipient (B) and one recipient with CAI (C). 
Lymphocytes(from(the(PBMCs(of(2(RTRs(and(1(HC((were(stained(with(cell(surface(
antibodies(and(analysed(for(various(phenotyping(cell(surface(markers(of(T(lymphoctyes(
(Figure(4.7,(page(112).(The(vast(majority(of(CD4+CD25+(TOcells(are(CD45RO+CD127Lo(in(
healthy(controls((A)(while(this(proportion(reduced(in(renal(transplant(recipients((B(&(C).(
CD45RO+CD127Hi(population(was(expanded(in(RTRs((B&C).((
( (
CD
45
RO
$
CD127$$
77.76%$$ 4.99%$$ 34.5%$ 19.6%$ 36.4%$ 27.3%$
A$ B$ C$
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Figure 4.10. Box plot showing the proportion of Tregs within CD4+CD25Hi cells. 
Lymphocytes(from(the(PBMCs(of(37(RTRs(and(17(HCs(were(stained(with(cell(surface(
antibodies(and(analysed(for(various(phenotyping(cell(surface(markers(of(T(lymphoctyes(
(Figure(4.7,(page(112)(There(was(a(significant(difference(in(the(proportion(of(
CD4+CD25+CD45RO+CD127Lo(population(between(HCs(and(RTRs(but(not(between(
recipients(with(stable(function(or(CAI.(Statistical(analyses(were(done(using(the(nonO
parametric(independent(t(test((MannWhitney(U(test)(between(groups.((
(
(
(
(
(
(
(( (
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Figure 4.11. Box plot showing the proportion of Tems within CD4+CD25Hi cells. 
Lymphocytes(from(the(PBMCs(of(37(RTRs(and(17(HCs(were(stained(with(cell(surface(
antibodies(and(analysed(for(various(phenotyping(cell(surface(markers(of(T(lymphoctyes(
(Figure(4.7,(page(112).(There(was(a(significant(difference(in(CD4+CD25+CD45RO+CD127Hi(
cells(between(RTRs(and(HCs(but(not(between(recipients(with(stable(function(or(CAI.(
Statistical(analyses(were(done(using(the(nonOparametric(MannOWhitney(U(test(between(
groups.%%
%
%
( (
p=0.02$
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4.5.4 CCR7 Chemokine Receptor Expression in Renal Transplant Recipients 
Sallusto and colleagues described the expression of CCR7 (a chemokine receptor that controls 
homing to secondary lymphoid organs) divides human memory T-cells into two subsets: 
1.CD4+CD25+CD45RO+CD127HiCCR7- (CCR7-Tems) 
2.CD4+CD25+CD45RO+CD127HiCCR7+(T central memory cells (Tcms)) 
 
As described earlier in this chapter, I have shown that cells making γ-interferon to non-
polymorphic HLA derived peptides are CD4+CD25+ CD127Hi CD45RO+CCR7- (Tem)-a 
phenotype that is over-expressed in renal transplant recipients compared to healthy controls. 
In the previous section I find that although CD4+CD25+ CD127Hi CD45RO+ ‘activated T cells’ 
are relatively over-expressed in renal transplant recipients, I could not find a correlation with 
the presence of chronic allograft injury.  
 
I subsequently analysed the proportion of CD4+CD25+ CD45RO+CD127Hi CCR7- (Tem) and 
CD4+CD25+ CD45RO+CD127Hi CCR7+ (Tcm) shown in Figures 4.12 and 4.13 respectively. In 
particular, the proportion of Tems is significantly increased in renal transplant recipients with 
chronic allograft injury (19.8% (IQR 21.5) vs. 9.2% (IQR 21.5); p=0.03). 
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Figure 4.12. Box plot showing an increased proportion CCR7-Tems in transplant 
recipients vs. healthy controls. 
Lymphocytes(from(the(PBMCs(of(37(RTRs(and(17(HCs(were(stained(with(cell(surface(
antibodies(and(analysed(for(various(phenotyping(cell(surface(markers(of(T(lymphoctyes(
(Figure(4.7,(page(112).(There(was(an(increased(in(this(population(in(RTRs(Vs.(HC(10.8%(
(IQR(16.9)(Vs.(4.5%((IQR(17.5)Z(p=0.23)(although(not(statistically(significant.(More(
interestingly,(this(population(was(further(expanded(in(transplant(recipients(with(chronic(
rejections(compared(to(those(with(stable(function((19.8%((IQR(21.5)(Vs.(9.2%((IQR(
13.7)Zp=0.03).%%
(
(
(
( (
p=0.03 
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Figure 4.13. Box plot showing an increased population of Tcms in transplant recipients 
vs. healthy controls.  
Lymphocytes(from(the(PBMCs(of(37(RTRs(and(17(HCs(were(stained(with(cell(surface(
antibodies(and(analysed(for(various(phenotyping(cell(surface(markers(of(T(lymphoctyes(
(Figure(4.7,(page(112).(There(was(a(significant(increase(in(CCR7+(Tcms(in(the(peripheral(
blood(of(transplant(recipients(Vs.(healthy(controls(((8.9%((IQR(9.2)(Vs.(2.6%((IQR(3.5)Z(
p=0.001)(as(reflected(by(the(higher(number(of(total(CD4+CD45RO+CD127Hi(cells(in(RTRs.(
There(was(no(significant(difference(in(this(population(as(calculated(by(Mann(Whitney(Test(
between(transplants(with(stable(function(and(those(with(CAI((8.4%((IQR(12)(Vs.(9.9%((IQR(
13.9)Z(p=1.0).(
(
%
%
( (
p=0.001 
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4.6 Correlations between surface markers and clinical markers of renal transplant 
dysfunction 
This finding was supported by a second analysis in which the relationship between the 
frequency of T effector memory cells and change in estimated GFR (ΔeGFR) from 
recruitment (that is to say the time of lymphocyte enumeration) to most recent follow-up (801 
± 80 days post recruitment) was investigated using Spearman rank order correlation. Figure 
4.15 shows in RTRs there was a weak but significant correlation between decline in renal 
function over the period following lymphocyte subset quantification (801 ± 80 days) and 
representation of this subset in peripheral blood CD4+ T lymphocytes (r=-0.35, p=0.03). This 
test was limited by the small number of samples.  There was no correlation between the 
number of T effector memory cells and urine albumin creatinine ratio (data not shown).  
 
Figure 4.14. Correlation between number of Tems and change in estimated GFR!
Relationship(between(change(in((CKDOEpi)(estimated(GFR((ΔeGFR)(from(recruitment(to(
most(recent(followOup((801(±(80(days(post(recruitment)(in(37(RTRs(and(peripheral(blood(
representation(of(CD4+CD25HiCD45RO+CD127+CCR7O(T(lymphocyte(within(the(CD4+CD25Hi(
population(Correlation(calculated(using(Spearman’s(rank(correlation(coefficient((r=O0.35,(
p=0.03)..((
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% representation of CD4+CD25HiCD45RO+CD127+CCR7- in 
CD4+CD25Hi gate (fixed at 2.5%) 
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4.7 Association between CMV serostatus and circulating T lymphocyte subsets 
Highly differentiated T-cells contribute to graft rejection (Reinke et al., 1994a, Reinke et al., 
1994b). In healthy individuals these cells are specifically observed in CMV seropositive 
individuals with the pool further expanded in transplant patients. In our cohort of 37 
transplant recipients 15 (40.5%) were CMV seropositive. Correlations between CMV 
serostatus and percentage of Tems showed a higher number of Tems in seropositive vs. 
seronegative status (31.8% ± 17.5 Vs. 19.8% ± 12.3; p= 0.019) as shown in Figure 4.15. As 
we did not have the CMV serostatus of our healthy control population, we were unable to 
conclude if our increase in Tems in RTRs was purely due to a high number of them (40.5%) 
being CMV seropositive. 
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Figure 4.15. Box plot showing an increase in percentage of 
CD4+CD25HiCD45RO+CD127Hi cells in CMV seropositive recipients vs. seronegative 
recipients.!
Lymphocytes(from(the(PBMCs(of(37(RTRs(were(stained(with(cell(surface(antibodies(and(
analysed(for(various(phenotyping(cell(surface(markers(of(T(lymphocytes((Figure(4.7,(page(
112).(Clinical(data(collected(including(the(patient’s(CMV(serostatus.(The(number(of(Tems(
(CD4+CD25HiCD45RO+CD127Hi)(was(compared(in(CMV(seropositive(and(seronegative(
individuals(and(showed(a(significant(difference,(being(higher(in(CMV(seropositive(RTRs(
(29%((IQR(20)(Vs.(19.5%((IQR(11.5)Zp=0.019).((
(
(
  
p=0.019$
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4.8 Cytokine release in response to non-polymorphic (autologous) HLA derived 
peptides in renal transplant recipients 
In(a(further(set(of(experiments,(autologous(lymphocyte(subsets(were(supplemented(back(to(
PBMC(cultures(in(the(presence(of(active(or(control(peptideO(n=6(for(Class(1(peptides(and(n=5(
for(Class(2(peptides.(PBMC’s(were(cultured(alone(or(following(the(addition(of(sorted(
autologous(CD25HiCD45RO+CD127+CCR7Hi(activated(effector(cells(or(
CD4+CD25HiCD45RO+CD127Lo(Tregs(in(duplicate.(At(24(hours,(supernatants(were(harvested(
and(frozen(and(subsequently(thawed(for(an(assay(of(cytokine(concentration.(A(panel(of(5(
cytokines((ILO10,(TNFOα,(ILO2,(ILORa(and(ILO1b)(was(measured(using(the(human(Bioplex(
Cytokine(Kit(and(analysed(on(a(BioOplexTM200(System((BioORad,(Hertfordshire,(UK).(A(
parallel(set(of(experiments(was(performed(on(healthy(controls((n=6(for(Class(1(and(n=6(for(
Class(2).(For(each(cytokine(eight(standards(ranging(from(2(to(32,000pg/ml(was(used.(The(
manufacturer(quoted(typical(lower(limit(of(assay(sensitivity(for(ILO10(corresponds(to(those(
achieved(in(these(experiments.(Outliers(from(the(standard(curve(were(automatically(removed(
using(the(Bioplex(software(manager(and(excluded(from(analysis.((
4.8.1 IL-10 
InterleukinO10(is(a(Th2(type(cytokine(shown(to(inhibit(the(development(and(function(of(Th1(
cells,(suppress(inflammation,(and(enhance(humoral(pathways(of(the(immune(response(
(Gaffen(and(Liu,(2004).(The(role(of(ILO10(in(transplant(rejection(is(uncertainZ(evidence(from(
animal(models(has(suggested(a(role(for(the(immunoregulatory(cytokine(ILO10(in(promoting(
graft(survival((Lowry(et(al.,(1995)(whilst(others(have(provided(evidence(supporting(the(role(of(
ILO10(in(rejection((Merville(et(al.,(1995,(Weimer(et(al.,(1996).(
(
Negligible(ILO10(release(was(seen(following(addition(of(any(TOcell(subset(using(the(peripheral(
blood(of(healthy(controls((median(2.6(pg/ml((IQR(2.3))(either(in(presence(of(active(or(control(
Class(1(and(Class(2(peptide.(In(transplant(patients(however,(the(addition(of(Tregs(in(the(
presence(of(active(peptide(as(opposed(to(control(peptide(showed(an(exponential(significant(
release(in(ILO10((Class(1:(26.1pg/ml((IQR(20.4)(Vs.(2.6pg/ml((IQR(9.4)Z(p=0.0087,(Class(2:(
170.6(pg/ml((IQR(122.4)(Vs.(28.9(pg/ml((IQR(25.1)Z(p=0.0079).(This(was(not(seen(with(the(
addition(of(CD25HiCD127Hi(cells(in(the(presence(of(active(peptide.(The(response(was(
consistent(among(all(6(patients(however(higher(levels(of(ILO10(concentration(was(seen(in(the(
presence(of(active(Class(2(peptides(compared(to(Class(1(peptides((median(170.6pg/ml((IQR(
122.4)(Vs.(26.05pg/ml((IQR(20.44).
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Figure 4.16. Graphs showing the average release of IL-10 when different 
CD4+CD25HiCD45RO+ subsets are added to wells in the presence of HLA Class 1 (A) 
and HLA Class 2 (B) derived peptide the patients were previously known to be 
responsive to.  
RTRs’(PBMCs(were(cultured(at(4x105(per(well(in(96Owell(flat(bottomed(plates(in(duplicate(in(
the(presence(of(‘active’(peptide((AP)((Class(2(derived:(DRE6C,(DRE3B(or(Class(1(derived:(
Tra(33)(or(control(peptide((CP)(at(11.4(μmol/L,(at(370C(and(5%CO2.(To(these(cultures(were(
added(2x103(autologous(T(lymphocyte(subsets(CD4+CD25HiCD45RO+CD127+CCR7O(
(CD25HiCD127+)(or(CD4+CD25HiCD45RO+CD127OCCR7+/O((Tregs).(Following(24(hours(of(
culture(supernatants(were(harvested(and(frozen.(The(cell(culture(supernatants(from(6(
individual(experiments(were(subsequently(thawed(and(the(concentrations(of(ILO10(assayed(
with(a(human(Bioplex(Cytokine(Kit(and(analysed(on(a(BioOplexTM200(System((BioORad,(
Hertfordshire,(UK).(The(median(concentration(and(IQR(is(shown(for(each(cell(mixing(
experiment.(There(was(an(increased(response(of(ILO10(in(RTRs(in(response(to(active(Class(1(
and(2(peptides(in(the(presence(of(Tregs:(
Class(1:(Treg(+CP(Vs(Treg(+AP((2.56pg/ml((9.4)(Vs.(26.1pg/ml((20.4)Z(p=0.0087)(
Class(2:(Treg(+CP(Vs(Treg(+AP((7.1pg/ml((25.1)(Vs.(170.6pg/ml((122.4)Z(p=0.079)
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4.8.2! TNF-α 
Tumour Necrosis Factor-alpha is a lymphocyte and macrophage derived cytokine that is 
pleiotropic in its actions. It plays an inflammatory and immunoregulatory role orchestrated by 
its two receptors TNFR1 and TNFR2. As allograft rejection is mediated by both innate and 
adaptive immune responses, it is not surprising that TNF-α is largely implicated in kidney 
allograft rejection. In rat experimental models, TNF-α mRNA expression is upregulated in 
tissue samples during acute and chronic rejection (Gasser et al., 2004, Herrero-Fresneda et al., 
2005), as it is in human renal tissue during acute rejection (Noronha et al., 1993, Oliveira et 
al., 2002). In Chronic allograft nephropathy, TNF-α is also upregulated and may be 
specifically implicated in the intimal hyperplasia of arterial walls observed in late graft failure 
(Zegarska et al., 2002).  
(
TNF-α was found in small quantities in the experiments using the peripheral blood of healthy 
controls. There was no significant variation with the addition of specific T-cell subsets or in(
the presence of active or control peptide in healthy controls. TNF-α concentrations were 
increased in the presence of active peptide (Class 1 and 2) and PBMCS compared with 
control peptide (Class 1: 29.7 pg/ml (IQR 56.8) Vs. 2.33 pg/ml (IQR 2.9); p=0.002, Class 2: 
29.8 pg/ml (IQR 20.3) Vs. 3.8 pg/mol (IQR 0.5);(p=0.0079). This concentration was further 
significantly increased with the addition of CD25HiCD127Hi cells in the presence of active 
peptide (Class 1; 703.3 pg/ml (IQR 116.8); Class 2: 779.3 pg/ml (IQR 935.6)) but reduced in 
the presence of Tregs (Class 1: 11pg/ml (IQR 29.3); Class 2: 4.6 pg/ml (IQR 2.8)). This 
suggests that Tregs inhibit(peptide specific responses in cell culture but does not define the 
specificity of the Treg response. The response to CD25HiCD127Hi cells was only seen with 
active peptide and not control peptide (Class 1: 703.3pg/ml (IQR 116.8) Vs. 43.8pg/ml (IQR 
56.2), p=0.002; Class 2: 779.3 pg/ml (IQR 935.6) Vs. 2.7pg/ml (IQR 1.9), p=0.0079). 
Cytokine concentrations did not differ in the presence of Class 1 or Class 2 peptides overall. (
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Figure 4.17. Graphs showing the average release of TNF-α when different 
CD4+CD25HiCD45RO+ subsets are added to wells in the presence of HLA Class 1 (A) and 
HLA Class 2 (B) derived peptide the patients were previously known to be responsive to.  
RTR’s(PBMCs(were(cultured(at(4x105(per(well(in(96Owell(flatObottomed(plates(in(duplicate(in(
the(presence(of(‘active’(peptide((AP)((class(2(derived:(DRE6C,(DRE3B(or(class(1(derived:(
Tra(33)(or(control(peptide((CP)(at(11.4(μmol/L,(at(370C(and(5%(CO2.(To(these(cultures(were(
added(2x103(autologous(T(lymphocyte(subsets(CD4+CD25HiCD45RO+CD127+CCR7O(
(CD25hiCD127+)(or(CD4+CD25HiCD45RO+CD127OCCR7+/O((Tregs).(Following(24(hours(of(
culture(supernatants(were(harvested(and(frozen.(The(cell(culture(supernatants(from(6(
individual(experiments(were(subsequently(thawed(and(the(concentrations(of(TNFOα(assayed(
with(a(human(Bioplex(Cytokine(Kit(and(analysed(on(a(BioOplexTM200(System((BioORad,(
Hertfordshire,(UK).(The(median(concentration(and(IQR(is(shown(for(each(cell(mixing(
experiment.(There(was(an(overall(increased(response(of(TNFOα(only(in(the(presence(of(
CD4+CD25HiCD127+CCR7O(Tems(in(response(to(active(peptides(compared(to(control(
peptides((Class(1:(703.3pg/ml((IQR(116.8)(Vs.(43.8pg/ml((IQR(56.2),(p=0.002Z(Class(2:(
779.3(pg/ml((IQR(935.6)(Vs.(2.7pg/ml((IQR(1.9),(p=0.0079).(Note(the(difference(in(yOaxis(
ranges(between(renal(transplant(recipients(and(healthy(controls(
( (
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4.8.3! IL-2 
The complexity of the cytokine system and the pleiotropic effects of each cytokine explain 
why therapeutic strategies to modulate cytokines have not been fruitful. To date, only 
blockade of IL-2R has translated into clinical utility, with the development of basiliximab and 
anti-CD25 monoclonal antibodies that target the IL-2/IL-2R pathway.  
 
IL-2 release was increased in the presence of active peptide and PBMCs compared to control 
peptide and PBMCs (Class 1: 10.8pg/ml (IQR 35.4) Vs. 2.1pg/ml (IQR 2.8), p=0.04; Class 2: 
18pg/ml (IQR 13.5) Vs. 1.9pg/ml (IQR 1.3), p=0.0079). Responses were further increased 
with the addition of CD25HiCD127Hi Tems and active peptide (Class 1: 4.4pg/ml (IQR; Class 
2: 45.5pg/ml (IQR 1938.9)). Interestingly, the concentrations of IL-2 were also significantly 
reduced by the(addition of Tregs in the presence of active peptide (Class 1: 30pg/ml; Class 2: 
13pg/ml) but not as marked as compared to TNF-α. This again was consistent with both 
classes of peptides.  
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Figure 4.18. Graphs showing the average release of IL-2 when different 
CD4+CD25HiCD45RO+ subsets are added to wells in the presence of HLA Class 1 (A) 
and HLA Class 2 (B) derived peptide the patients were previously known to be 
responsive to.  
RTR’s PBMCs were cultured at 4x105 per well in 96-well flat-bottomed plates in duplicate in 
the presence of ‘active’ peptide (AP) (class 2 derived: DRE6C, DRE3B or class 1 derived: 
Tra 33) or control peptide (CP) at 11.4 µmol/L, at 370C and 5% CO2. To these cultures were 
added 2x103 autologous T lymphocyte subsets CD4+CD25HiCD45RO+CD127+CCR7- 
(CD25hiCD127+) or CD4+CD25HiCD45RO+CD127-CCR7+/- (Tregs). Following 24 hours of 
culture supernatants were harvested and frozen. The cell culture supernatants from 6 
individual experiments were subsequently thawed and the concentrations of IL-2 assayed with 
a human Bioplex Cytokine Kit and analysed on a Bio-plexTM200 System (Bio-Rad, 
Hertfordshire, UK). The median concentration and IQR is shown for each cell mixing 
experiment. There was an overall increased response of IL-2 only in the presence of 
CD4+CD25HiCD127+CCR7- Tems in response to active peptides compared to control peptides 
(Class 1: 40.44 pg/ml (IQR 247.7) Vs. 2.48 pg/ml (IQR 2), p=0.002; Class 2: 45.7 pg/ml (IQR 
1938.9) Vs. 6 pg/ml (IQR 10.5), p=0.0079).  
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4.8.4 IL-1Ra & IL-1β 
IL-1 is an important mediator of inflammation and tissue damage in multiple organs, both in 
experimental models of disease and in human diseases. The IL-1 family consists of two 
agonists, IL-1Ra and IL-1b, two receptors- IL-1R1 and IL-1RII and a specific receptor 
antagonist IL-1Ra. A human recombinant form or IL-1Ra is used in the treatment of 
rheumatoid arthritis.  
Results for IL-1Ra production were harder to decipher any significance from. Using Class 1 
peptides there was overall a high background of IL-1Ra concentration (Median 593.4pg/ml; 
range 169.4- 2989) in all the wells using PBMCs from healthy controls. This was consistent 
amongst all 6 healthy controls and also using Class 2 peptides in healthy controls.  In contrast 
to the contrary changes in peptide specific TNF-α and IL-10 production with sorted 
autologous activated effector cells or Tregs, addition of either subset was associated with 
elevated IL1Ra concentrations in response to the active peptide.  
IL-1β concentrations reflected that of TNF-α and IL-2. Minimal levels were found in with 
PBMCs of healthy controls with either Class 1 or Class 2 peptides. In the presence of active 
peptide (Class 1 or Class 2) compared to control peptide there was an increase in IL-1β 
cytokine concentration in the presence of CD25hiCD127+ lymphocyte subset (Class 1: 96.2 
pg/ml (IQR 234) Vs. 1 pg/ml (IQR 2.9), p=0.002; Class 2: 374.9 pg/ml (IQR 468.1) Vs. 0.7 
pg/ml (IQR 3.6), p=0.0079). This was not seen with the addition of the Tregs subset.  
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Figure 4.19. Graphs showing the average release of IL-1Ra when different 
CD4+CD25HiCD45RO+ subsets are added to wells in the presence of HLA Class 1 (A) 
and HLA Class 2 (B) derived peptide the patients were previously known to be 
responsive to.  
RTR’s PBMCs were cultured at 4x105 per well in 96-well flat-bottomed plates in duplicate in 
the presence of ‘active’ peptide (AP) (Class 2 derived: DRE6C, DRE3B or Class 1 derived: 
Tra 33) or control peptide (CP) at 11.4 µmol/L, at 370C and 5% CO2. To these cultures were 
added 2x103 autologous T lymphocyte subsets CD4+CD25HiCD45RO+CD127+CCR7- 
(CD25hiCD127+) or CD4+CD25HiCD45RO+CD127-CCR7+/- (Tregs). Following 24 hours of 
culture supernatants were harvested and frozen. The cell culture supernatants from 6 
individual experiments were subsequently thawed and the concentrations of IL-1Ra assayed 
with a human Bioplex Cytokine Kit and analysed on a Bio-plexTM200 System (Bio-Rad, 
Hertfordshire, UK). The median concentration and IQR is shown for each cell mixing 
experiment. Note the difference in Y-axis ranges between the graphs.  The background 
release of IL-1Ra was high overall but more so with the Class 1 peptides experiments. There 
was no significant variation in levels between each cell mixing experiment.  
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Figure 4.20. Graphs showing the average release of IL-1β when different 
CD4+CD25HiCD45RO+ subsets are added to wells in the presence of HLA Class 1 (A) 
and HLA Class 2 (B) derived peptide the patients were previously known to be 
responsive to.  
RTR’s(PBMCs(were(cultured(at(4x105(per(well(in(96Owell(flatObottomed(plates(in(duplicate(in(
the(presence(of(‘active’(peptide((AP)((class(2(derived:(DRE6C,(DRE3B(or(class(1(derived:(
Tra(33)(or(control(peptide((CP)(at(11.4(μmol/L,(at(370C(and(5%(CO2.(To(these(cultures(were(
added(2x103(autologous(T(lymphocyte(subsets(CD4+CD25HiCD45RO+CD127+CCR7O(
(CD25hiCD127+)(or(CD4+CD25HiCD45RO+CD127OCCR7+/O((Tregs).(Following(24(hours(of(
culture(supernatants(were(harvested(and(frozen.(The(cell(culture(supernatants(from(6(
individual(experiments(were(subsequently(thawed(and(the(concentrations(of(ILO1β(assayed(
with(a(human(Bioplex(Cytokine(Kit(and(analysed(on(a(BioOplexTM200(System((BioORad,(
Hertfordshire,(UK).(The(median(concentration(and(IQR(is(shown(for(each(cell(mixing(
experiment.(There(was(an(increased(response(of(ILO1β(in(response(to(Class(1(and(2(
peptides(in(RTRs(only(in(the(presence(of(CD4+CD25HiCD127+CCR7O((Class(1:(96.2(pg/ml(
(IQR(234)(Vs.(1(pg/ml((IQR(2.9),(p=0.002Z(Class(2:(374.9(pg/ml((IQR(468.1)(Vs.(0.7(pg/ml(
(IQR(3.6),(p=0.0079).((
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4.8.5 Summary of responses 
These data using PBMC’s from renal transplant recipients suggests that autologous HLA 
derived peptides stimulate γ-interferon, TNF-α, IL-2 and IL-1β production from activated 
effector memory cells and IL-10 production in the presence of Tregs however the specificity 
of these responses is not defined.  
!
Table 4.3. Summary of median cytokine production (pg/ml) when T lymphocyte subsets 
are stimulated in culture with HLA- Class 1 derived peptides transplant patients have 
been known to be responsive to (active peptide-AP) Vs unresponsive to (control peptide-
CP) in the presence of PBMCS alone, addition of T effector memory cells 
(CD25HiCD127+) or addtion of Tregs.  
!
! PBMC!+CP! PBMC!+AP! CD25HiCD127+!+AP! Treg!+!AP!
IL610! 2.3((IQR(1.5)( 4.6((IQR(3.5)( 2.1((IQR(9.4)( 26.1((IQR(20.4)(
TNF6α! 2.3((IQR(2.9)( 29.7((IQR(56.8)( 703.3((IQR(116.8)( 11((IQR(29.3)(
IL62! 2.1((IQR(2.8)( 10.8((IQR(35.4)( 40.4((IQR(247.7)( 4.9((IQR(13.9)(
IL61Ra! 9.3((IQR(1150)( 102.7((IQR(1873)( 408.3((IQR(4688)(( 356.8((IQR(7206)(
IL61β! 1.5((IQR(2.9)( 2.7((IQR(16.9)( 96.2((IQR(234)( 4.3((IQR(18.1)(
(
Table 4.4. Summary of median cytokine production (pg/ml) when T lymphocyte subsets 
are stimulated in culture with HLA- Class 2 derived peptides transplant patients have 
been known to be responsive to (active peptide-AP) Vs unresponsive to (control peptide-
CP) in the presence of PBMCS alone, addition of T effector memory cells 
(CD25HiCD127+) or addtion of Tregs. 
 
! PBMC!+CP! PBMC!+AP! CD25HiCD127+!+AP! Treg!+!AP!
IL610! 6.4((IQR(6.1)( 5.3((IQR(12.7)( 4.6((IQR(36.1)( 170.6((IQR(122.4)(
TNF6α! 3.8((IQR(0.5)( 29.8((IQR(20.3)( 779.3((IQR(935.6)( 4.6((IQR(2.8)(
IL62! 1.9((IQR(1.3)( 18((IQR(13.4)( 45.7((IQR(1938.9)( 5((IQR(9.6)(
IL61Ra! 8.7((IQR(169.7)( 4.1((IQR(275.8)( 154.9((IQR(447.6)( 159.9((IQR(279.5)(
IL61β! 2.6((IQR(2.4)( 0.5((IQR(28.9)( 374.9((IQR(468.1)( 1.6((IQR(8.1)(
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4.9 IL-10 production is specific to T regulatory cells when stimulated by HLA 
derived peptides 
IL-10 production was seen in the supernatant of Tregs co-cultured with HLA derived 
peptides. To determine if IL-10 production was specific to T regulatory cells we performed 
the same cytokine release experiments on 2 previously responsive patients but instead blocked 
cytokine release from the cells (using Brefeldin) and stained for intracellular IL-10 in Tregs as 
described in Section 2.2.8, page 44. 
A significant number of total lymphocytes were lost due to the intracellular staining method. 
500,000 PBMCs were isolated per patient but after the experimental process only 5% of 
lymphocytes were gated compared to 60% when we used surface staining methods only. 
The majority of CD4+CD25Hi cells were CD45RO+CD127Hi however the number of 
CD45RO+CD127Lo (Tregs) cells was unusually low. Within this small number of cells any 
intracellular IL-10 production was undetectable.  
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5 Discussion 
Chronic allograft injury remains a barrier to improved long-term renal graft outcome. 
Although alloantigen-independent factors contribute to CAI sufficient data exists that 
emphasize the importance of ongoing immunological damage as a major mechanism for this 
process as is described in this thesis. The contribution of indirect allorecognition to the 
ongoing immune process is well established in several experimental models of transplantation 
(Benichou et al., 1992, Vella et al., 1999, Watschinger et al., 1994, Pettigrew et al., 1998) and 
in it has been associated with chronic rejection in clinical studies of kidney (Najafian et al., 
2002), heart (Ciubotariu et al., 1998) and lung transplantation (Reznik et al., 2001). Given the 
role of cellular immunity in transplant rejection, its quantification might be expected to 
provide valuable diagnostic and prognostic value – however development of a clinically 
relevant and widely applicable assay has proved difficult (Waanders et al., 2008, Iacomini and 
Sayegh, 2006, Sawitzki et al., 2009)- one important factor being the diversity of donor and 
recipient HLA. Additionally, the low precursor frequency of indirectly primed T cells makes 
this pathway difficult to quantify. Preliminary work in our research group on the identification 
of responses to non-polymorphic HLA derived peptides in RTRs via a γ-interferon ELISPOT 
assay has allowed us to detect low frequency indirect alloimmune responses.  
 
5.1 The use of HLA derived peptides as tools to predict CAI 
Colin Watts and colleagues have over many years studied antigen processing and amongst 
other findings have shown that antibody binding can determine the pattern of peptides 
generated during antigen processing and indeed this has varying effects on the presentation of 
specific peptide epitopes following processing of whole antigen (Watts, 2012).  
 
It is therefore possible that alloantibody binding of antigen enhances the presentation of 
otherwise cryptic self epitopes as described in animal models of transplantation ((Boisgerault 
et al., 2000, Lovegrove et al., 2001) and thus possible that the T-cell responses that we 
observe are testament to a prior alloantibody response – which of course does not have to be 
donor specific. γ-interferon production by lymphocytes incubated with autologous HLA 
derived peptides is associated with chronic renal allograft dysfunction (Smith et al., 2011) and 
chronic graft versus host disease (GVHD) following allogeneic bone marrow transplantation 
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(Smith et al., 2010). It is in this context that we further investigated responses to autologous 
HLA derived peptides in a clinical setting in a single population of RTRs recruited with 
minimal exclusion criteria suggesting our findings may be broadly relevant.  
 
The ELISPOT technique provides the most sensitive way for detection and quantification of 
antigen-specific responses of in vivo activated T-cells (Heeger et al., 1999). Unlike limiting 
dilution assays, culture times in ELIPSOT are shorter: consequently, the frequency measured 
corresponds to the true number of T-cells that have been encountered in vivo. A study by 
Zhang and colleagues in 11 different laboratories across Europe and the United States used 
the ELISPOT assay to measure antigen- specific T-cell responses to a CMV peptide (Zhang et 
al., 2009). Results produced were reproducible using identical reagents and a standardized 
protocol even in the hands of ELIPSOT inexperienced investigators (Zhang et al., 2009). Our 
own results with the optimization studies performed at two different sites yielded comparable 
results confirming the reproducibility of this assay.  
 
Our studies looked at the detection of T-cell responses to synthetic HLA Class 1 and Class 2 
derived peptides. With synthetic peptides the exact amino acid length and concentration is 
known making the assay reproducible. One disadvantage is the creation of neoepitopes by 
dissecting proteins into peptides. Peptides may be synthesized that do not occur in vivo 
because of the absence of natural splicing sites at relevant positions on the full protein 
(Waanders et al 2008). This is however unlikely in short culture periods as in an ELISPOT 
assay. 
 
In the first instance we demonstrated, as with HLA Class 1, RTR’s lymphocytes produce γ-
interferon to a number of non-polymorphic Class 2 derived peptides that were predicted to 
bind HLA-DR promiscuously. These responses were less frequent in healthy controls 
suggesting but not proving that the response is a feature of exposure to alloantigen.  
The fact that responses to HLA class 2 derived peptides correlated closely with those to HLA 
Class 1, suggests that saturation was approached with respect to identifying RTRs with the 
potential to generate such a response. This is consistent with the finding that responses to 
HLA class 1 derived peptide was associated with a clinical phenotype, since had significant 
reclassification occurred with a wider range of epitopes such an association would seem 
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unlikely, assuming that responses to HLA Class 2 derived peptides are mechanistically 
equivalent to those to Class 1.  
 
Correlation of responses between single peptides and mixes of different peptides derived from 
the α3 domain of HLA A2 (Class 1) and β2 domain of HLA-DR (Class 2) allowed us to 
significantly reduce the volume of whole blood required per test per patient.  
 
2 year follow up data on patients tested to HLA derived mixes showed low rates of graft 
failure and loss, hence any statistical survival analysis was not powered sufficiently. My data 
did not appear to show an association with single time point ELISPOT responses and 2-year 
graft function as measured by eFGR. There was a positive correlation with worse proteinuria 
at 2-years however confounding factors such as infection or recurrent disease were not 
corrected for. Serial time point analysis of ELISPOT responses with clinical outcome may 
give a better understanding of recipient risk, which was then attempted in the longitudinal 
study.  
 
In the longitudinal study responses were tested to Class 1 and 2 mixes pretransplantation and 
at 3,12, and 24 months post transplantation. An increasing number of responses were seen at 
12 months’ post transplantation however 5-9% of patients lost their positive responses at 24 
months’ post transplantation.  One potential explanation for this could be a reduction in the 
number of effector memory cells with time away from transplantation as we found this was 
the subset of CD4+ T lymphocytes, which contributed to the peptide response. No significant 
correlation was found between post-transplant ELISPOT responses and acute transplant 
rejection before or after testing. This result although disappointing may reflect previous 
studies where responses to donor derived antigens were increase during an episode of acute 
rejection in cardiac allografts but decreased after successful treatment (van Besouw et al., 
2005). Additionally, all our transplant recipients received induction therapy with basiliximab, 
which selectively depletes a subset of T-cells. Other studies showing a negative correlation of 
pre-transplant ELISPOT results and acute rejection had used similar induction therapy 
protocols to ours (Reinsmoen et al., 2008). Our small numbers of biopsy proven CAI (6% in 2 
years follow up) made it impossible to decipher any correlation to ELISPOT responses. 
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Infective episodes including CMV did not interfere with testing ELISPOT response although 
the number of CMV viraemia episodes was low in this study.  
 
5.2 The use of CD4+ T Lymphocyte surface makers as tools to predict CAI 
 
In previous studies we identified the phenotype of responding cells as CD4+CD25hi by 
intracellular γ-interferon staining. We have extended this characterisation by titrating 
increasingly defined subsets of CD4+CD25hi T-cells, back into autologous HLA peptide 
stimulated PBMC cultures. There was titration of γ-interferon producing cells only with the 
CD4+CD25HiCD45RO+CD127+CCR7- phenotype: ‘activated effector memory’ T-cells. This 
titration was also reflected in the supernatant concentrations of TNF-α. The need to add 
exogenous autologous peptide to identify these in vitro phenomena is serendipitous in that it 
allowed their original definition. The rapid expression of γ-interferon by memory cells 
following stimulation (within 6 hours in previously described flow cytometry studies), their 
consistent observation with a range of different class 1 and 2 derived peptide sequences and 
their association with a clinical phenotype, suggest that these observations are however 
unlikely to represent a purely in vitro phenomenon but reflect a biologically relevant 
alteration in transplant recipients’ immune repertoire. 
 
All lymphocyte activation inhibitors reduced the responses to peptides in the presence of T 
effector memory cells only- suggesting a pathway of action. This response was less marked 
however with sirolimus and abatacept. A small number of patients also showed reduced 
inhibition to ciclosporin at a dose of 100ng/ml, which corresponds to the lower quartile trough 
concentration in the BENEFIT study (at 1year). These findings illustrate how relatively subtle 
intra- and inter-individual variations in calcineurin inhibitor exposure could influence the 
expression of HLA peptide specific T-cell memory. In this assay, the relative resistance of 
peptide specific activated effector memory cell responses to CD28 blockade may relate 
mechanistically to the observation that, referred to CNI based therapy, such treatment is less 
effective with respect to the prevention of acute rejection whilst inhibiting pathogen specific 
primary responses to a greater degree. These findings echo those in a recent report by Xu & 
colleagues where mTOR inhibitors also have limited efficacy against this subset (Xu et al., 
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2014). My findings suggest mechanisms that may in part account for differing effects of 
maintenance immunosuppressive regime.  
 
Our findings of the phenotypic expression of CD4+ T lymphocytes reflect the literature. The 
majority of CD4+CD25+ T-cells lack CD127 expression in healthy controls but this number is 
reduced in RTRs. The increased representation of the CD4+CD25HiCD45RO+CD127+CCR7- 
subset in RTRs is consistent with the findings of others on CCR7 undifferentiated 
CD4+CD25HiCD45RO+CD127+ populations. Two groups have reported increased 
representation of the latter population in long-term RTRs in association with CAI (Alonso-
Arias et al., 2009) or chronic humoral rejection (Vallotton et al., 2011b). Another group did 
not confirm these findings, albeit with a different approach to case definition and lymphocyte 
isolation (van de Berg et al., 2012a). Our finding of a relationship between progressive CAI 
and peripheral representation of the CD4+CD25HiCD45RO+CD127+CCR7- subset is 
interesting but this analysis was not part of the original design and needs repetition in a study 
adequately powered to undertake multivariable analysis. 
 
Highly differentiated T cells contribute to graft rejection (Reinke et al., 1994a) and these cells 
are observed in CMV seropositive healthy controls and further expanded in RTRs (Reinke et 
al., 1994b). Previous work from our own group has identified expansion of CD4+CD28- cells 
predominantly of the effector-memory phenotype post transplantation in CMV seropositive 
individuals (Shabir et al., 2016). Work presented here has shown an expansion of 
CD4+CD25HiCD45RO+CD127Hi (Tems) in the peripheral blood of CMV seropositive RTRs 
when compared to healthy controls. I was unable to prove a difference in the peripheral 
population of Tems in CMV seropositive patients with stable function compared to CMV 
seropositive patients with CAI (data now shown). I am unable to conclude from this work if 
the expansion of Tems in RTRs was purely an effect of CMV serostatus, as we did not 
investigate the CMV serostatus of healthy controls.  
 
The predominant contribution of HLA derived peptides to the MHC Class 2 ligandome was 
reported more than 20 years ago (Chicz et al., 1992). These autologous peptides are therefore 
candidates for self-restricted engagement by T-cell receptors, resulting in self-tolerance 
through thymic deletion and agonist selection of natural Tregs (Hsieh et al., 2004). We 
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considered whether γ-interferon production to autologous HLA derived peptides might reflect 
alteration of a normal regulatory response to such peptides. Production of IL-10 in PBMC 
cultures following addition of both autologous HLA derived peptide and Tregs identified 
these as likely target epitopes for Tregs. This occurred with 3 different peptide sequences 
selected on the basis of predicted or demonstrated high affinity binding to a range of HLA-
DR, suggesting that these observations are likely to reflect a mechanism that involves 
conventional self restricted T-cell receptor engagement. The finding of novel Treg epitopes 
derived from HLA is reminiscent of reports by de Groot and colleagues of so called 
‘Tregitopes’ derived from the non-polymorphic regions of IgG (Cousens et al., 2013). Other 
ubiquitous cellular proteins are also candidate Treg epitopes (van Herwijnen et al., 2012, 
Cousens et al., 2013). 
  
Importantly in these experiments Treg dependent IL-10 synthesis required the addition of 
specific peptide antigen. Although it is possible that IL-10 production arose from a distinct 
PBMC population, this does not detract from the peptide specific link between the detection 
of IL-10 and the presence of Tregs. This requires further investigation beyond the current 
study however the parsimonious explanation is that Tregs synthesize IL-10 in response to 
these peptides. In an attempt to determine if IL-10 production was specific to Tregs I 
attempted intracellular staining for IL-10 in repeat cytokine release experiments. The 
intracellular staining method resulted in a low yield of lymphocytes within which the number 
of Tregs was extremely low. A number of points to consider were raised from the failure of 
this experiment. Firstly, isolating and staining a small population of 
CD4+CD25hiCD45RO+CD127lo cells proved to be ambitious in the first place. Secondly, 
Brefeldin was added 6 hours before the end of a 48-hour stimulation as suggested by previous 
studies in the literature and manufacturer recommendations. However, we did not perform a 
time comparison for the addition of Brefeldin. Early addition to the stimulation but have 
limited the release of IL-10 from cells into the supernatant. Due to time restraints we were 
unable to perform any further experiments to clarify this.  
 
In light of recent experimental evidence of phenotypic instability in CD25hiFoxp3+ Treg’s 
(Bailey-Bucktrout et al., 2013, Sharma et al., 2013, Lal et al., 2011), one possible explanation 
of these findings is that autologous HLA peptide specific, natural Tregs acquire an effector 
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phenotype in the presence of an inflammatory response. In which case observations of an 
association between γ-interferon production to autologous HLA derived peptides and a 
disease phenotype (CAI (Smith et al., 2011) or chronic GVHD (Smith et al., 2010)) could 
reflect loss of regulatory as much as acquisition of effector function. An alternative but 
related explanation is that T effector or induced Treg responses to cryptic self-epitopes arise 
from naïve T lymphocytes during the course of an inflammatory response (Drakesmith et al., 
1998). Since productive immunity may be associated with epitope spreading, then responses 
to autologous sequences could emerge from allogeneic responses, possibly influenced by 
other effector mechanisms. For example antibody binding to whole antigen has been reported 
to enhance presentation of certain peptide epitopes whilst diminishing others (Simitsek et al., 
1995, Watts, 2012); an additional perspective on the potential role of alloantibody in 
determining T-cell responses to HLA (Tambur et al., 2000). These findings may also be 
relevant to other settings characterised by acute and chronic inflammation in the presence of 
immunosuppression, such as autoimmune disease. Indeed the role of autoimmunity in 
cGVHD is well described and in this setting we have documented γ-interferon production to 
autologous HLA Class 1 derived peptides (Smith et al., 2010).  
 
Treg therapy attempts to address this balance between effector and tolerogenic phenotypes. 2 
broad possibilities for this therapy exist in humans- 1) induction of Tregs from naïve 
precursors in vivo or 2) infusion of autologous Tregs expanded from peripheral blood ex vivo 
(Issa et al., 2010). Recent evidence has demonstrated that Tregs can be expanded in vitro from 
healthy human blood and retain their suppressive function (Putnam et al., 2009). Joffre and 
colleagues showed that the administration of in vitro allo-stimulated and expanded host Tregs 
induces donor-specific tolerance to allogeneic bone marrow grafts (Joffre et al., 2008). The 
safety of using expanded Tregs in human patients is not certain. As previously mentioned 
there are some suggestions in the literature that Tregs retain the capacity to differentiate into 
effector populations (Bailey-Bucktrout et al., 2013). Our own findings of IL-10 production in 
the presence of autologous HLA peptides and Tregs may support this although a direct 
causative link cannot be confirmed. Reassuringly, the first trial of ex vivo expanded Treg 
therapy in humans for the treatment of GVHD did not report any unexpected side effects 
(Trzonkowski et al., 2013). The administration of Tregs to transplanted patients in order to 
induce tolerance and allow dose reduction in their immunosuppressive treatment is a realistic 
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target and our preliminary findings are potentially relevant to the development and safe 
application of Treg therapy. In conclusion these data identify autologous derived peptides that 
stimulate IL-10 production in the presence of Tregs. We hypothesize that this reflects a 
normal functional relationship, which in the setting of antigen driven immune activation and 
inflammation is redirected to be pro-inflammatory (Sharma et al., 2013, Bailey-Bucktrout et 
al., 2013).  
 
5.3 Limitations of this study 
Perhaps the biggest limitation of this study are the low numbers of recruits overall especially 
for the longitudinal study. Accounting for patient withdrawal, we lost several samples as 
patients were sent back to their base hospital for follow up. With low numbers the rates of 
CAI were also low to make any significant correlation difficult. Lack of protocol transplant 
biopsies was also a confounding factor to this. Due to the low numbers and high dropout rates 
in the longitudinal study we were unable to decipher any definitive correlations between 
ELISPOT responses and the course of a transplant in terms of alloimmune risk.  
 
Working with freshly- isolated cells we could not reproduce assay results using the same cell 
material. Circadian rhythms, nutrition, infection and stress will all change the cellular 
composition of peripheral blood mononuclear cells. Hence a major drawback of our study is 
that using freshly isolated material our T-cell assays were technically not fully standardized. 
Although ELISPOT technique provides the most sensitive way for detection of antigen- 
specific responses in vivo, we do not know how many patients had subclinical rejection 
leading to allosensitization.  
 
Renal failure necessitating transplantation has diverse aetiology and furthermore most RTRs 
have concomitant comorbidities giving rise to a fairly heterogeneous group of patient. Such 
variance undoubtedly impedes the development of a unified biomarker for predicting allograft 
survival. Studies across much groups of patients are thus necessary to define the contribution 
of underlying disease processes to the transplant outcome.  
 150 
5.4 Future work 
Several experimental and clinical trials are underway evaluating the therapeutic role of 
peptides in human diseases such as coeliac, diabetes, asthma and multiple sclerosis.  
The ultimate goal for renal transplant recipients would be a desensitization program where 
patients with HLA specific antibodies on the transplant waiting list would be vaccinated with 
peptides and antibody levels monitored pre and post operative to essentially induce peripheral 
tolerance by allowing substation for more specific tolerance and reduction of the current 
quadruple load immunosuppression.  
 
OUTSMART Trial 
Work from this thesis has contributed to the grant application for the OUTSMART trial. The 
general aim of this multicentre trial is to determine whether combinations of analyses of 
immune responsiveness against the transplant are better than anti-HLA antibody and 
conventional histology at identifying patients: a) with active immune responses against their 
transplant and b) at high risk of transplant dysfunction and graft loss. Blood and biopsy-based 
assays measuring donor-specific immune responsiveness in kidney transplant recipients using 
flow cytometry, ELISPOT, RT-PCR and microarrays will be used to assess whether a 
combination of these have better diagnostic, prognostic and mechanistic value than anti-HLA 
antibody and conventional histology. The data generated will inform the development of 
tailored therapeutic interventions to prevent premature graft failure. 
 
5.5 Final Conclusion 
In summary, this body of work has aimed to identify a set of immunological biomarkers that 
may facilitate the stratification of the risk of progressive CAI. We have identified a set of 
synthetic HLA derived peptide mixes that transplant recipients respond to irrespective of both 
donor and recipient HLA type. Furthermore, we have identified the subgroup of responding 
cells and have shown peripheral expansion of these cells in renal transplant recipients.  
Further work has identified γ-interferon and TNF-α production in the presence of T effector 
cells and active peptide and IL-10 in the presence of Tregs and active peptide- in short the 
balance as it were between effector cells and Tregs as determinants of chronic rejection or 
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transplant tolerance. The findings from this small study do not of course establish a cause and 
effect relationship between indirect T cell alloreactivity and the risk of progressive CAI. I 
conclude that further work in a larger multicenter study and involvement of protocol biopsies 
may allow the development of an alloimmune assay to be used pre transplantation and during 
the course of a transplant to help stratify a renal transplant recipient’s risk of developing CAI.  
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Appendix 2 Sequences of Peptides 
Table A2.1. Sequences of non-polymorphic HLA Class 1 derived Single Peptides. 
Their&sequences&were&derived&from&4&different&15&to&17&amino&acid&sequences&of&the&non8polymorphic&domain&of&the&α3&domain&of&HLA&
Class&1.&Polymorphic&residues&are&shown&in&red&italic&and&serine&substitutions&for&cysteine&in&blue.&Pegylation&with&KR&wraps&were&added&
to&some&peptides&as&shown&to&increase&their&solubility.&
&
!
Name Peptide Sequence  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15  
Tra30  192-206  H A V S D H E A T L R C W A L  
Tra31  192-206  H P I S D H E A T L R C W A L  
Tra33  192-206  H A V S D H E A T L R S W A L  
Tra34  192-206  H P I S D H E A T L R S W A L  
Tra39  202-216  R C W A L S F Y P A E I T L T  
Tra40  202-216  R C W A L G F Y P A E I T L T  
Tra41  202-216  R S W A L S F Y P A E I T L T  
Tra42  202-216  R S W A L G F Y P A E I T L T  
Tra46  268-282  K P L T L R W E L S S Q P T I  
Tra49    L T L R W E L S S Q P T I P I  
Tra02  280-294 KR P T I P I V G I I A G L V L F RK 
Tra06  280-294 KR P T I P I V G I I A G L V L L RK 
Tra08  280-294 KR P T I P I V G I I A G L A V L RK 
Tra10  280-294 KR P T V P I V G I I A G L A V L RK 
Tra14  282-296 KR I P I V G I I A G L V L F G A RK 
Tra19  282-296 KR I P I V G I I A G L V L L G A RK 
Tra24  282-296 KR I P I V G I I A G L A V L A V RK 
Tra29  282-296 KR V P I V G I I A G L A V L A V RK 
 P1   H S M R Y F F T S V S R P G R  
 P2   M R Y F F T S V S R P G R G E  
 P20   S D W R F L R G Y H Q Y A Y D  
 P21   W R F L R G Y H Q Y A Y D G K  
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Table A2 1 Sequences of non-polymorphic HLA Class 2 derived Single Peptides 
These sequences were derived from the non-polymorphic β2 domain of HLA Class 2. GRAVY (grand average hydropathy) denotes the 
solubility of the peptides. EpiMatrix raw scores are normalized with respect to a score distribution derived from a very large set of 
randomly generated peptide sequences. Any peptide scoring above 1.64 on the EpiMatrix “Z” scale (approximately the top 5% of any given 
peptide set) has a significant chance of binding to the MHC molecule for which it was predicted.www.expasy.org
Peptide  Sequence 
residues 
in 
parent MW Length 
Isoelectric 
point GRAVY 
Instability 
Index 
Hits 
(top 
10%) 
Hits 
(top 
5%) 
High 
(Top 
1%)  
Epi 
score 
DRE1 HFFNGTERVRLLERCIYNQ 45-63 2394.2 19 8.23 -0.642 S 8 7 4 10.6 
DRE1A HFFNGTERVRLLERSIYNQ 45-63 2378.22 19 8.75 -0.816 S 8 8 3 18.1 
DRE1B HFFNGTERVRLLE 45-57 1616.84 13 6.77 -0.492 S 7 6 1 5.82 
DRE1C ERVRLLERSIY 51-61 1432.82 11 8.84 -0.573 U 7 5 2 7.54 
DRE1D HFFNGTERVRLLERSIY 45-61 2136.12 17 8.75 -0.5 S 8 7 3 14.25 
DRE2 GEYRAVTELGRPD 74-86 1461.72 13 4.87 -1.085 S 8 6 0 12.5 
DRE2A EYRAVTELGRP 75-85 1289.67 11 6.24 -0.927 S 8 7 0 14.27 
DRE3 ESFTVQRRVEPKVTV 116-130 1773.97 15 8.85 -0.507 U 7 6 0 7.12 
DRE3A ESFTVQRRVHPKVTV 116-130 1781.99 15 10.84 -0.487 U 7 6 0 13.26 
DRE3B ESFTVQRRVQPKVTV 116-130 1772.99 15 10.84 -0.507 U 8 6 0 13.79 
DRE3C ESFTVQRRVYPKVTV 116-130 1772.99 15 9.99 -0.36 U 7 6 0 11.21 
DRE4 KVTVYPSKTQPLQHH 127-141 1761.95 15 9.7 -1.047 U 7 5 2 3.96 
DRE4A KVTVYPSKTQPLQ 127-139 1487.43 13 9.7 -0.715 U 7 5 2 5.74 
DRE5 SIEVRWFRNGQEEK 155-169 1776.89 14 5.95 -1.5 U 6 5 1 6.96 
DRE6 GDWTFQTLVMLETVPRSGE 180-198 2165.05 19 4.43 -0.211 S 8 8 2 16.99 
DRP6A GDWTFQTLVMLETVPRS 180-196 1978.98 17 4.37 -0.006 U 8 8 2 22.37 
DRE6B WTFQTLVMLETVPRS 182-196 1806.93 15 6 0.253 u 8 8 2 24.15 
DRE6C WTFQTLVMLETVPRSGE 182-198 1994.2 17 4.86 -0.006 S 8 8 2 18.77 
DRE6D QTLVMLETVPRSG 185-197 1429.76 13 6 0.169 U 8 7 2 16 
DRE7 SPLTVEWRARSESAQSK 211-227 1930.99 17 8.46 -1.071 U 8 5 2 5.92 
DRE8 GLFIYFRNQKGHSGLQ 245-260 1863.97 16 9.99 -0.481 S 8 8 5 25.11 
            !
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Table A2.3. HLA Class 1 and Class 2 peptide mixes composition 
Frozen'peptides'were'stored'in'aliquots'at'1mg/ml.'On'the'day'of'experiments'they'were'
mixed'with'complete'media'at'the'required'volumes'and'stored'at'4oC'for'a'further'1'week.'
' '
Peptide 
Mix 
      
Class 1       
Mix 2 Tra30 Tra39 Tra51 Tra02 Tra14  
Mix 3 Tra31 Tra40 Tra46 Tra49 Tra06 Tra19 
Mix 4 Tra31 Tra40 Tra52 Tra06 Tra19  
Mix 6 Tra33 Tra41 Tra53 Tra08aT
ra24 
  
Mix 7 Tra34 Tra42 Tra10 Tra29   
Mix 8 P1 P20 P45/46    
Mix 9 P2 P21 P45/46a    
       
Class 2       
DR Mix 
1 
DRE6c DRE2 DRE7    
DR Mix 
2 
DRE6d DRE3c     
DR Mix 
3 
DRE6e DRE4a     !
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APPENDIX 3 
PLATE PLANS 
 195 
Appendix 3 Plate Plans 
Figure A3.1. Plate Plan for non-polymorphic HLA Class 1 derived peptides 
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Figure A3.2. Plate plan for non-polymorphic HLA Class 2 derived peptides 
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Figure A3.3.  Plate Plan for HLA Class 1 and 2 peptide mixes  
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Figure A3.4. Plate plan for Peptide Stimulation assays with different subsets of CD4+CD25Hi subsets 
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Figure A3.5. Plate plan for Cytokine Assay (Luminex) Studies 
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Figure A3.6. Plate Plan used for Inhibition Assays
TEMS%
TRegs%
AP+TEMs%
AP+TRegs%
IP+TEMs%AP+TEMS+200ng/ml%CsA%
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Figure A3.7. Plate Plan used for intracellular IL-10 staining experiment 
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